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About the title and cover pages 
 
The title is a word play on the common statement “don’t take it personal”. While this 
saying may be good advice in many cases, there are distinct advantages to “take” medication 
personal. Genetic differences between individuals can affect both diseases and drug action. 
Therefore much research effort is focused on making medicine personalized, to tailor it 
better to the individual patient or situation, to increase beneficial effects and decrease side-
effects. 
The cover artwork was inspired by a quote from Jim Watson, the co-discoverer of DNA’s 
double helix structure, who told Time magazine in 1989: " We used to think our fate was in 
our stars. Now we know, in large measure, our fate is in our genes." (Quoted in Time, “The 
Gene Hunt”, by Leon Jaroff, March 20, 1989). The art on the cover was made from actual 
experimental xCELLigence data generated during this thesis while investigating the influence 
of genetic differences on G protein-coupled receptors. In the decorations on the edges, the 
xCELLigence data dissolves into a double helix as a further reference to the DNA that 
underlies the data itself. The distribution of the stars resembles the distribution of cell 
clusters, similar to how the lymphoblastoid cell lines, the cellular model system used 
throughout this thesis, look like under a microscope when grown on xCELLigence plates. The 
cover artwork also reminds of the season in which the defense of this thesis is held.  
The artwork on the chapter title pages is an abstract representation of both DNA and the 





CHAPTER 1 General introduction 8 
CHAPTER 2 Label-free technology and patient cells: from early drug 
development to precision medicine 
20 
CHAPTER 3 Whole-cell biosensor for label-free detection of GPCR-mediated 
drug responses in personal cell lines 
40 
CHAPTER 4 Getting personal: Endogenous adenosine receptor signaling in 
Lymphoblastoid Cell Lines 
62 
CHAPTER 5 Whole-cell biosensor for label-free detection of GPCR-mediated 
drug responses in personal cell lines 
82 
CHAPTER 6 Personal lymphoblastoid cell lines reveal E354Q polymorphism 
effects on GIP receptor signaling 
108 
CHAPTER 7 Conclusion and perspectives  134 
 Summary 153 
 Samenvatting 157 
 List of publications 161 
 Curriculum Vitae 162 















9 | Chapter 1 
About this thesis 
This thesis describes the study of the influences of genetic variation on a specific class of drug 
targets, the G protein-coupled receptors (GPCRs), using a combination of personal cellular 
models and novel label-free assay technology. The results obtained herein will likely assist in 
the translation of early in vitro experiments to more clinically relevant studies in the course 
of the drug discovery pipeline. Eventually, the findings in this thesis hopefully contribute to 
the development of clinically more effective drugs and advance the current ‘one-size-fits-all’ 
paradigm into the realm of precision medicine. In this first chapter, I introduce the concepts 
of precision medicine, importance of GPCRs as drug targets and prevalent sources of genetic 
variation. Moreover, I discuss the advantages and opportunities that arise from combining a 
novel label-free assay technology with personal cell lines. In the last section of this chapter, 
I specifically outline the objectives of this thesis. 
 
Precision medicine 
Historically, conventional disease treatments have been based on diagnosing a patient with 
a general disease state and providing a corresponding generalized drug treatment. However, 
while successful to a degree, such one-size-fits-all treatments may be ineffective or harbor 
dangers for the individual patient. Inter-individual variability in drug effectiveness poses a 
significant challenge for the conventional strategies. Even today’s best sold, ‘blockbuster’ 
drugs, poster children of the current treatment paradigm, work in only 35% - 75% of patients 
due to influences of genetics, lifestyle and environmental differences [1, 2]. Hence, modern 
medicine is undergoing a paradigm shift towards a more personalized, patient-customized 
treatment model, for which a large part is based on a deeper understanding at a molecular 
level [3, 4]. For this emerging concept known as personalized or precision medicine, it is 
paramount to better understand the effects of a drug not only in the overall population, but 
in the individual patient as well [5]. Customization using a sub-population or patient's 
individual characteristics, e.g. genetic information, could decrease risks of ineffective 
treatment, dosing or side-effects [2, 6, 7]. Genetic testing is already available for 
approximately 2000 clinical conditions today, most of which are in oncology. Two successful 
examples are genetic tests for HER2-positive breast cancer which serve as a predictor of 
response to the drug Herceptin, and CYP450 polymorphisms which affect the action and 
metabolism of drugs such as selective serotonin-reuptake inhibitors [6-9]. Despite the 
promise shown by these examples, most drug targets and disease mechanisms are still in 
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dire need of further research to determine whether, and how, genetic variation affects both 
pathology and drug responses.  
 
GPCRs and genetic differences 
The majority of drug targets today are GPCRs, a specific class of membrane proteins. In fact, 
30-40% of all current drugs work by influencing GPCR function [10, 11]. This is no surprise as 
approximately 800 GPCRs are encoded by the human genome. Over 300 of these are 
considered druggable, i.e. they constitute current or future drug targets [12]. Due to their 
ubiquity, GPCRs are involved in almost all aspects of human physiology from vision to 
immune response [13]. In general terms, the role of a GPCR is to translate an extracellular 
signal, which can range from photons to odorants, hormones or neurotransmitters, into a 
cellular response. Depending on the nature of ligand and receptor, the cellular effect can 
vary from changes in morphology to proliferation, differentiation and survival (Figure 1).  
Due to their physiological importance, it is highly interesting to decipher the influence of 
genetic variation in GPCR-mediated drug responses in the context of personalized medicine 
[5, 14]. Several studies have already linked GPCR polymorphisms to diseases and drug 
response variation [14-18], including for instance serotonin [15], dopamine [14, 16, 19-21], 
adenosine [22-24], purinergic [25, 26] and cannabinoid [17, 18] receptors, and many other 
commonly targeted GPCRs [14].  
 
Single Nucleotide Polymorphisms 
One prevalent source of genetic differences which can lead to an alteration in the drug target 
are Single Nucleotide Polymorphisms (SNPs). SNPs make up 84 to 95% of the total human 
genetic variation and are defined as single-base variations with a presence in at least one 
percent of the population. Consequently, SNPs are quite common, with on average around 
one SNP per 300 bases [27]. These variations can cause a multitude of differences in the end-
product of genes, depending on their location and nucleotide difference. For example, a SNP 
can cause a new start- or stopcodon to appear, cause the transcript to be removed or even 
change the encoded amino acid with a different one, i.e. a so called missense SNP. SNPs that 
somehow change the amino acid sequence of the resulting protein are known as non-
synonymous SNPs. It is believed that such changes are the most prevalent source of 
differences in GPCR response to drugs (Figure 2). 
A common example is the association between SNPs on the chemokine 2 and 5  
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Figure 1: GPCR signaling and in vitro assays. When a ligand binds to and activates a GPCR, the receptor 
in turn activates the G protein. The trimeric G protein dissociates and can activate various secondary 
messenger pathways, leading via a cascade of reactions to an eventual cellular response. Traditional 
drug development programs are often target-focused, i.e. relying on in vitro assays which use reporter 
systems for the investigated target. Such reporter systems include for instance the use of radioactive 
labels or fluorescent dyes for ligand, target or effector labeling, or of more downstream reporter gene 
constructs. Such modifications, however, may influence target pharmacology. Label-free whole-cell 
assays are phenotypic assays that capture the biological cellular response in real-time, without focusing 
on merely one pathway and without requiring any such modifications, potentially providing a better 
physiological context. Image constructed using components from Servier Medical Art by Servier 
(http://www.servier.com/Powerpoint‐image‐bank).  
 
receptors (CCR2 and CCR5) and the delayed or increased onset of AIDS after HIV infection 
[28]. In another instance, a SNP-caused tryptophan to arginine change in the β3-adrenergic 
receptor has been associated with obesity [29]. A set of four SNP locations on the dopamine 
D3 receptor have been associated with schizophrenia, where the susceptibility to the disease 
is most likely caused by the combined effect of these SNPs [30]. In the GRM1 glutamate 
receptor, the presence of SNPs in the splice region between two exons causes a new splice 
variant lacking one transmembrane domain, again associated with schizophrenia symptoms 
[31]. These examples emphasize that the possible influence of SNPs on GPCRs can be quite 
 
 
General Introduction | 12  
1 
 
Figure 2: Effects on individuals of SNPs in GPCRs. GPCR polymorphisms can lead to differences in drug 
response between individuals, potentially changing drug effectiveness and risks of side-effects. 
 
profound. However, the knowledge of polymorphism effects in GPCRs is still scant as of 
today. Hence we sought to find out more on the influence SNPs have on ligand-induced GPCR 
function in this thesis. 
 
Lymphoblastoid Cell Lines 
Most evidence supporting the influence of GPCR polymorphism effects are based on statistic 
association with occurrence of a disease, or by functional characterization in artificial, 
heterologous cell lines [14, 16, 17]. Both methods lack the final, well-defined physiological 
link that would allow us to understand more precisely how a polymorphism changes GPCR 
effects in an individual patient [32, 33]. Such understanding could be provided by directly 
measuring drug responses in patient material or cells as a model system. 
An upcoming phenomenon in the past two decades are biobanks, which collect and store 
biological material to support modern medical research such as -omics approaches and 
personalized medicine. For this purpose, biobanks provide biomaterial resources including 
tissues, cells, blood, and serum from patients with specific diseases, specific populations or 
individuals with specific traits [34-36]. One type of cells used in many biobanks as a preferred 
choice for storing genetic material are lymphoblastoid cell lines (LCLs), which are derived 
from a person’s B-Lymphocytes [37, 38]. Renowned consortia with LCL libraries include the 
Centre d’Étude du Polymorphisme Humain, the International HapMap and 1000 genomes 
projects [39-43]. In most cases, however, LCLs are merely used as a source of DNA or RNA 
for genotyping, expression or methylation studies [16, 37].  
In this thesis, we set out to show that LCLs can be used as a model system to directly 
study polymorphism effects on GPCR function on a cellular level.  
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Label-free technologies 
Traditional GPCR assays are often label-based, which have definite disadvantages when 
venturing to remain as close to the physiological situation as possible. These assays rely on 
(chemical) engineering by, for instance, radioligand tagging or overexpression of the receptor 
(Figure 1). All of such alterations to the cell may influence its physiology leading to for 
instance identification of false-positive or false-negative hits [44]. Furthermore, such assays 
are mostly pathway-biased as they typically focus on only one cellular event in a specific 
signaling pathway [45]. Another drawback is that they often lack the sensitivity required for 
receptors endogenously expressed in cell lines, as this is much lower level than in specifically 
engineered cell lines. In short, such assays are not well-suited for investigating subtle 
polymorphism changes on endogenous receptors in their native environment.  
However, new assays are emerging that enable measurements in endogenous cell lines 
and hereby provide greater, more relevant biological insight. By eliminating any need for 
labels, label-free cellular biosensors have the capability of assessing endogenous receptor 
function in their native physiological settings [46]. They are more sensitive, less invasive and 
monitor drug effects on a whole cell in real-time [33, 47, 48]. Hence, label-free assays are 
also more translational towards a correlation between in vitro and in vivo findings [49, 50]. 
Moreover, the sensitivity of these label-free assays allows monitoring of standard effects 
such as GPCR activation or inhibition as well as detection of smaller changes such as biased 
signaling [33, 51], which may also be affected by polymorphisms [5]. In short, label-free 
technologies offer unique advantages for precision medicine as they offer the ability to 
monitor small changes in GPCR signaling or drug responses in the native cellular context. 
 
Objective and overview of this thesis 
Aim and set-up 
The aim of the study was to provide detailed insight in the influence of genetic variation on 
ligand-induced GPCR function within the general human population. Our selection process 
of SNP containing GPCRs to be investigated with label-free technology and LCLs is visualized 
in Figure 3. In this thesis we focused on SNPs that are likely to have a profound effect on 
GPCR signaling responses by changing the amino acid sequence, in particular the so-called 
missense SNPs. The biobank employed in this research, the Netherlands Twin Registry (NTR; 
http://www.tweelingenregister.org/en/) [39], offered genotyped LCLs of individuals with a 
family structure consisting of parents and twin siblings. We first established an overview of 
such SNPs on each druggable, non-olfactory GPCR gene within these NTR individuals, after 
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Figure 3: Flowchart of target selection. The selection was aimed at identifying all druggable GPCRs 
containing non-synonymous SNPs that were well enough expressed to allow functional characterization 
in LCLs from the NTR. For the bioinformatics, the selection was limited to non-synonymous SNPs in 
druggable GPCRs. The genotype data of the cell lines was provided by the NTR, as part of the Genomes 
of the Netherlands (GoNL) consortium [39]. A list of all druggable non-olfactory GPCRs was downloaded 
from the IUPHAR database. SNPs within each gene were extracted from the NTR data using PLINK, an 
open-source whole genome association analysis toolset, and annotated with their SNP-consequence 
types (gene data, SNP location and consequences were extracted from Ensembl). Cellular assays and 
qPCR were used to determine which GPCRs were expressed above a threshold that allowed functional 
responses to be measured using the label-free technology. 
  
which we pursued several interesting cases in GPCRs commonly used in drug research.  
Three separate cases of common polymorphisms that affect GPCR signaling and cellular 
effects were discovered, each revealing different properties including the sensitivity of 
partial versus full agonists, different chemical scaffolds and intron versus missense SNPs. 
These examples should provide the reader with insights that will hopefully lead to the 
development of clinically more effective drugs and drug treatment paradigms in the long 
term. 
 
Outline of this thesis 
The concept of using patient-derived cell lines as model systems is introduced and discussed 
in Chapter 2. This chapter furthermore highlights the advantages of label-free technology for 
assays on such cell lines. 
Chapter 3 focuses on the optimization and application of an impedance-based label-free 
assay, the xCELLigence, to suspension cells such as LCLs to allow direct measurement of 
cellular effects of GPCR signaling.  
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Chapter 4 presents the case of the Adenosine A2A receptor, in which an intron SNP is 
related to differential cellular effects of a partial agonist, but not full agonists or antagonists. 
Chapter 5 summarizes the effects on a highly common non-synonymous polymorphism on 
the Cannabinoid Receptor 2, to which different chemical scaffolds show different sensitivity. 
Chapter 6 presents the case of the Glucose-Dependent Insulinotropic Polypeptide (GIP) 
Receptor, in which a missense SNP that has often been associated with diseases changes the 
cellular effects of the endogenous ligand. 
The research presented in these chapters highlights that coding and non-coding, 
common and less common genetic variations in GPCRs can affect endogenous signaling as 
well as drug effects.  
An overall conclusion from the results described in this thesis and forthcoming 
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Abstract 
Drug development requires physiologically more appropriate model systems and assays to 
increase understanding of drug action and pathological processes in the human individual. 
Specifically patient-derived cells offer great opportunities as representative cellular model 
systems. Moreover, with novel label-free cellular assays it is often possible to investigate 
complex biological processes in their native environment. Combining these two offers 
distinct opportunities for increasing physiological relevance. 
Here, we review impedance-based label-free technologies in the context of patient 
samples, focusing on commonly used cell types including fibroblasts, blood components and 
stem cells. Applications extend as far as tissue-on-a-chip models. Thus, applying label-free 
technologies to patient samples can produce highly biorelevant data and with it unique 
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Introduction 
Two significant challenges in today’s drug development are the inter-individual variability in 
drug effectiveness, and lack of translatability of preclinical results. Simultaneously, modern 
medicine is shifting towards personalized or precision medicine, which proposes to use 
individual characteristics of a specific patient or sub-population to tailor drug prescriptions, 
hereby decreasing risks of ineffective dosing or side-effects [1]. Challenges to achieve this 
are in a generally perceived lack of understanding of the molecular details of drug action and 
of pathological processes in the human individual. This, in turn, is to a large degree brought 
about by insufficient physiological representability of model systems and assays used in drug 
research. Traditional drug research has relied on a target-focused approach by screening 
compounds in in vitro assays. Such assays traditionally use reporter systems, for instance 
radiolabeled or fluorescent probes, dyes, and reporter gene constructs, all of which are 
modifications that may influence target pharmacology (Box 1, Fig. 1). In addition, cellular  
 
BOX 1: Traditional label-based versus label-free assays. 
Traditional label-based assays follow drug effects and cellular functions by chemical attachment of 
a "label" to the drug molecule, drug target or downstream effectors. These can consist of for 
instance radiolabeled or fluorescent probes or dyes. Reporter-based assays introduce specifically 
regulated gene promoters as biomarkers for specific events. Commonly used reporter genes involve 
visually identifiable characteristics such as fluorescent and luminescent proteins. 
Label-free assays do not require any such modifications as they measure cellular changes by 




Figure 1. Traditional label-based assays. Stars highlight where effects are often measured by 
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models and cell systems are often selected based on habit and technical feasibility rather 
than disease relevance, resulting in physiologically less representative heterologous or 
recombinant cells lines. Such renewable in vitro cell sources have been essential in facilitating 
drug discovery and certainly have merits for studying target or drug action in more detail. 
However,  both assay and model systems are factors that can contribute to an eventual lack 
of clinical effectiveness and thus the issues experienced in the drug development to date, 
such as high attrition rates [2]. To fully comprehend the mechanisms underlying pathologies, 
drug response and its variation in individuals, functional characterization on a physiologically 
relevant molecular and cellular level is essential. Hence, the focus is shifting onto more 
physiologically appropriate cellular models and readout systems. Specifically patient-derived 
cells offer great opportunities when used directly as a model system. Novel label-free cellular 
assays are a new type of phenotypic assay able to acquire the molecular-level understanding 
from complex biological processes in their native environment [1, 2]. Applying them to 
human primary cells can increase physiological relevance [3-5]. In this review, we highlight 
the realm of these possibilities, by focusing on the application of one type of such label-free 
cellular assays, based on impedance, on some of the most common types of human primary 
cells derived from patient samples. 
 
Advantages of Label-free cellular assay technologies 
The two currently most used forms of label-free cellular biosensors are impedance- or optics-
based. Extensive reviews on the detection principles are provided elsewhere [6-8]. In short, 
the ECIS, xCELLigence, and CellKey systems use an electrode array biosensor to measure 
impedance changes in a cell monolayer (Fig. 2). Optical systems such as the EPIC and BIND 
use resonant waveguide grating to detect dynamic mass redistribution in cells. Both optical 
and impedance methods detect a wide spectrum of cellular changes, from cell adhesion to 
life cycle processes such as proliferation, growth and death, as well as pathogen infections 
and response, cell migration and signaling such as receptor signaling or cell-cell 
communication [6]. Hence, these label-free assays are also known as phenotypic assays.  
In this review, we focus on impedance-based assays which are applicable to a broad 
range of samples, are highly versatile and can integrate many assays into one (see also Fig. 
3). For instance, such assays record a variety of cellular parameters including proliferation, 
adhesion and cellular morphology in one combined read-out in real-time(Fig. 3A). This is a 
particular advantage over many traditional assays, which often interrogate one aspect only 
of a given pathway or a cellular response (e.g., second messenger accumulation).  
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Figure 2. Principle of impedance-based label-free cellular assays. Cell attachment to gold electrodes 
generates impedance by changing the local ionic environment at the electrode-solution interface. 
Relative changes in impedance (Z) are recorded in real-time. 1. Prior to the seeding of cells, baseline 
impedance is Z0. 2. As cells adhere to the electrodes, impedance increases proportionally. 3. Changes 
in cell number, adhesion, viability and morphology are directly reflected in the impedance profile. 
Impedance-based label-free cellular assays can detect a wide range of cellular events including cell 
proliferation, division, growth, death, migration and signaling. All these parameters can in turn be 
affected by drugs. For instance, depending on the moment of drug treatment, drugs can result in 
response A by initiating receptor signaling or drug response B by decreasing overall proliferation. 
 
Impedance-based assays offer the distinct advantage of a direct read-out of drug action 
in real-time. While there are also traditional assays which record specific functions in real-
time (e.g., Ca2+-mobilization assays) impedance measurements offer the benefits of real-time 
measurements in both acute (eg. direct receptor signalling) and chronic settings (e.g., cellular 
proliferation). Besides recording the abovementioned cellular functions, impedance-based 
label-free assays also provide some specialist applications such as electrical stimulation for 
pore formation (Fig. 3D) and co-culture without contact (Fig. 3H), though these may require 
specialized recording or plate equipment (Fig. 3B, 3E, 3H). Overall, impedance-based assays 
have already successfully been applied to an extensive list of targets, including highly 
important drug target classes such as G protein-coupled receptors (GPCRs) [6, 9], nuclear 
receptors [10] and receptor tyrosine kinases [11]. Applications extend as far as toxicity 
screens on cardiac function [12] and migration of cancer cells in 3D cultures [13] (Fig. 3B and 
3E). Furthermore, almost any cell type can be studied. Examples include standard 
recombinant cell lines, primary and stem cells, both adherent as well as suspension cell types 
[6, 9, 14] (see also Table 1). This is because in comparison to many traditional assays, label-
free technologies offer a sensitive, less invasive detection methodology that monitors drug 
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Figure 3: Typical applications of impedance-based label-free cellular assays. (A) General label-free 
cellular assay formats are capable of monitoring many cellular functions such as adherence, 
proliferation, viability and morphology. Additional specialized assay applications exist for instance to 
(B) monitor cell migration (e.g. through a porous membrane, xCELLigence), (C) measure barrier 
functionality for instance in a wound scratch assay, (D) apply electrical impulses e.g. to increase cellular 
permeability (ECIS) and (E) measure (cardio)-myocyte contractility (xCELLigence CARDIO system). (F) 
Besides adherent cells, label-free cellular assays are also applicable to suspension cells and capable of 
monitoring interactions between two cell types, for instance by (G) cytotoxicity of effector cells on 
another type of target cell, or (H) cell-cell communication without actual cellular contact (xCELLigence 
co-culture set-up). 
 
effects on a whole cell. Furthermore, without the need for tagging, labeling or recombinant 
expression, cellular functions can be studied in a more physiological context, including a vast 
amount of endogenously expressed targets and pathways. Simultaneously, sensitivity is 
often high enough to distinguish subtle changes in mechanisms of action in e.g., GPCR 
signaling bias [6, 14]. Receptors are linked to various downstream signaling pathways, 
termed signaling pluridimensionality. Ligands can be biased towards one or some particular 
downstream pathways, potentially resulting in different pharmacological effects. For 
instance, closely related agonists for the β2- adrenergic receptor induced subtly yet distinctly 
different response signatures as a consequence of such bias [15, 16].  
Hence, as a number of  reviews have already summarized, label-free technologies can 
offer distinct advantages for drug development. They capture compound action in a dynamic 
time-resolved manner, allow for identification of leads independent of prior assumptions of 
signaling pathways and enable the use of more native systems at higher through-put. As a 
cell-phenotypic screen, they can be used for target identification, compound screening, lead 
selection, investigating mechanism of action and testing drug safety and toxicity [14, 17]. In 
this review we particularly focus on applications involving patient cells. This offers 
opportunities both for drug development and precision medicine research by sensitively 
detecting an extensive variety of pharmacological effects under minimally invasive conditions 
in a clinically relevant endogenous context of primary cells, and even patient samples. 
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Nowadays, such samples are increasingly available to support research, for instance by their 
systematic collection in biobanks. 
 
Advantages of primary human cells 
Over the past decades, numerous biobanks have emerged to support medical research by 
programmed storage of biological material and corresponding data. These biomaterials 
include tissues, (stem) cells, blood, and serum, all of which have played a critical role in 
medical research. These materials are actively used from translational and personalized 
medicine research to target and drug discovery [18, 19]. For human physiology, primary 
human cells are considered a much better model system than the more traditional cellular 
models such as rodent, recombinant, or immortalized non-tissue specific human cell lines, 
and even better than in‐vivo rodent models [20-22]. While the mentioned cellular models 
certainly have merits, for instance ease-of-use or to attain initial understanding of pathways, 
their physiological relevance is questioned increasingly. In recombinant cell lines, target 
overexpression, differences in intracellular metabolic conditions and products from other 
genes could modify cellular responses [5]. Well-established cell lines derived from a patient 
with a particular disease can be more representative of that specific pathological condition. 
However, these are generally immortalized cell lines derived from one particular patient 
sample a long time ago. Prolonged cell culture frequently leads to problems such as 
contamination or genotypic and phenotypic instability. These issues unfortunately contribute 
to irreproducibility in preclinical research, which is an increasingly well-recognized problem 
[23].  
In general, primary cells express signaling pathways and retain many cellular functions 
that are seen in vivo, thus providing a more relevant context. Tissue or cell samples from 
healthy or patient volunteers are even more representative for (patho)physiology and closer 
to the situation in the clinic.  
 
Application to patient samples and primary human cells 
Many patient-related biomaterials can and have already been studied using impedance-
based label-free technologies, of which some prominent examples are discussed here. The 
sample types most commonly studied include fibroblasts and blood components, but 
applications also extend to endothelial, epithelial and stem cells (Table 1). In these examples, 
label-free impedance-based assays are employed to monitor a wide range of cellular effects, 
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Table 1. Application examples of impedance-based label-free cellular technology to patient samples and 
stem-cell related types. 
 














Antibodies xCELLigence Type I diabetes patients, type II diabetes 
patients and healthy controls 
[37] 
PBMCs  xCELLigence From healthy volunteers but tested on 
patient material 
[32, 33]  
Plasma and cells 
therein  
ECIS Healthy volunteers vs. trauma patients [35] 
ECIS Hantavirus Cardiopulmonary Syndrome 
patients 
[36] 
Monocytes ECIS Patients with peripheral vascular disease 
and abdominal aortic aneurysm 
[31] 
Neutrophils  ECIS Critically ill septic patients [34] 


















γδ T cells xCELLigence Healthy volunteers and B-lineage acute 
lymphoblastic leukemia patients 
[60] 
Glioblastoma cells xCELLigence Paired tumoral and peritumoral tissue 




xCELLigence Malignant melanoma of the ciliary body 








xCELLigence Newly established cell line from patient [56] 
Mononuclear 
cells 
xCELLigence Normal controls and breast 












xCELLigence Patient-derived primary human breast 




xCELLigence Serous ovarian cancer patient and 















xCELLigence Osteoarthritic patients [32] 
 
 











xCELLigence Benign prostatic hyperplasia patients [26] 
Dermal ECIS Scleroderma patients and normal controls [27]  
Orbital ECIS Patients with or without Graves’ disease [24] 






















ECIS Healthy human donors of varying age 
groups 
[51] 
xCELLigence Female patients undergoing liposuction, 




xCELLigence Healthy human donors or commercial from 







ECIS Age-related macular degeneration patient 







From bone marrow (three donors) and 
adipose tissue (two donors) 
[48] 
 
xCELLigence From endometrial lining of the human 
uterus of premenopausal women 
[49] 
xCELLigence Healthy human donors [50] 







s Skeletal muscle 
myoblasts and 
myotubes 
xCELLigence Chronic heart failure patients and age and 
gender-matched healthy donors 
[62, 63] 
 
cardiomyocyte beating (Fig. 3). Overall, the highlighted examples show that impedance-
based label-free technology is highly versatile with an extensive range of applications. 
 
Fibroblasts 
The earliest applications of label-free assays to fibroblasts date back to over two decades. In 
one early example, prostaglandin E2 was shown to play a significant role in Graves’ disease 
pathology by comparing morphological changes of orbital fibroblasts from patients with and 
without Graves’ disease versus dermal fibroblasts (Fig. 3A). The authors chose ECIS over 
traditional light microscopy after testing both methodologies head to head, as it offered 
insight into the subtle, rapid cellular changes, especially into the underlying kinetics [24]. 
Since then, label-free cellular assays have been applied to other types of fibroblasts. 
Fibroblasts are in fact the most common cell type in human connective tissue and can often  
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retain memory of their previous tissue context, thus giving rise to numerous fibroblast types 
(Table 1). They are also among the most commonly employed clinical and biobanked samples 
in general [25]. For instance, Nolte et al. demonstrated a potential strategy against hyper-
proliferating fibroblasts by treating fibroblasts from benign prostatic hyperplasia patients 
with small interfering RNA against the transcription factor serum response factor. Effects on 
cell proliferation and growth inhibition were detected with the xCELLigence (Fig. 3A) [26]. 
Another notable study involved dermal fibroblasts and sera from scleroderma patients, 
which is discussed later [27]. 
Finally, in a clinically relevant setting synovial fibroblasts from patients with rheumatoid 
arthritis (RA) or osteoarthritis (OA) obtained during knee surgery were investigated. In the 
most recent ones, Lowin et al. used the xCELLigence to show that the endocannabinoid 
system is involved in regulating inflammatory effects in RA [28]. This suggested a potential 
treatment for RA with synthetic cannabinoids, demonstrated in a later study [29]. Similar 
studies showed further contributors to the pathogenesis of RA that modify cellular functions 
and adhesion of synovial fibroblasts, the most recent of which are included in Table 1 [30]. 
The relevance and implications of these findings for potential treatment options are of 
translational value as the cells were obtained from patients with the disease.  
 
Blood cells 
Blood is an easily obtained patient material and is thus often biobanked [25]. Hence, various 
types of blood components or cells are used in medical research and have been investigated 
using impedance-based label-free cellular assays.  
Several studies involving monocytes have been published. Interestingly, monocytes are 
often measured indirectly by quantifying their effect on another cell type. A layer of adherent 
target cells is grown on the electrodes, after which they are exposed to the effector cells, 
here monocytes, which induce for instance cytotoxicity in the target cells (Fig. 3G). Lee et al. 
used ECIS to reveal differences between patients of peripheral vascular disease and 
abdominal aortic aneurysm to find better methods for targeted therapy. Monocytes of 
peripheral vascular disease patients induced higher endothelial barrier dysfunction [31].  
Another particularly useful type of blood cells are peripheral blood-derived mononuclear 
cells (PBMCs). Hopper et al. showed PBMCs enhanced osteoarthritic human chondrocyte 
migration, which could be the basis for a treatment strategy for OA. The PBMCs were derived 
from healthy volunteers, while chondrocytes and cartilage tissue explants were from patients 
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were measured using a specialized migration assay format of the xCELLigence (Fig. 3B) 
[32]. Later it was shown that PBMCs also enhanced migration and chondrogenic 
differentiation of multipotent mesenchymal stromal cells (MSCs) from knees of OA patients 
[33]. 
Other types of blood components have been assayed using label-free technology as well, 
although most of them again rely on an indirect measurement through effects on another 
cell type. For instance, neutrophils from critically ill septic patients were found to reduce 
endothelial barrier integrity to a greater extent than untreated normal neutrophils in an ECIS 
assay [34]. Human serum was also employed in some studies. In an early example by Huang 
et al., ECIS was used to demonstrate differences in micromotions of dermal fibroblasts from 
patients with scleroderma and normal controls, as well as the effect of sera from patients on 
fibroblast behavior [27]. Rahbar et al. measured the effects of plasma samples from healthy 
volunteers and severely injured trauma patients on human endothelial cells using ECIS. 
Material of patients with low plasma colloid osmotic pressure caused an increase in cell 
permeability [35]. In a similar manner, plasma samples of patients with Hantavirus 
Cardiopulmonary Syndrome were shown to induce loss of cell-cell adhesion in epithelial and 
endothelial cells in ECIS [36]. Finally, Jackson et al. employed xCELLigence to demonstrate 
that anti-calcium channel autoantibodies from patients with type I diabetes inhibit the 
adherence of Rat insulinoma cells, while antibodies from type II diabetes patients and healthy 
controls did not [37]. 
The reason that all these blood components are measured indirectly is twofold. On one 
hand, studying their effect on the function of other cell types provides more physiological 
context. On the other hand, many of the cell types involved are suspension cells. Label-free 
technology was long deemed incompatible with suspension cells, as the detection 
mechanism positioned at the bottom of the well requires cells to adhere [7]. However, a 
number of studies demonstrated that suspension cells are amenable to label-free 
technologies as well, with both optical and impedance-based biosensors. Interestingly, 
impedance-based assays appear less susceptible to decreased cellular adherence than 
optical biosensors [7], and hence potentially applicable to an even broader range of cell 
types. Examples include various types of blood cells, one notably involving personal cell lines. 
For instance, CellKey was used to directly measure GPCR signaling in monocytes, neutrophils 
and PBMCs, though these were not in fact patient material [38, 39]. The xCELLigence was 
applied to lymphoblastoid cell lines (LCLs) from participants of the Netherlands Twin Register 
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occasions, increased cell densities and usage of adherence-mediating agents were sufficient 
to allow measurements (Fig. 3F). LCLs are in fact used as a preferred choice for storing genetic 
material, including in biobanks of renowned consortia such as the International HapMap 
project [25, 41]. 
 
iPSC and common stem-cell types 
Stem cells carry great promise for rendering physiologically more relevant cell models, in 
particular induced pluripotent stem cells (iPSCs). By reprogramming of e.g. fibroblasts into a 
pluripotent state, iPSCs can be derived that maintain the disease genotype and phenotype 
indefinitely. These iPSCs then provide a source of models for an expansive range of adult 
differentiated cells, possibly even for each individual patient, which has the potential to 
personalize drug discovery [42]. Many of the cell types derived from such iPSCs can be 
investigated using label-free technology. For one of these, a specific type of application has 
been developed for the xCELLigence, namely a cardiomyocyte-based biosensor. Safety 
pharmacology studies that evaluate potential cardiac (side) effects of drug candidates are an 
essential part of drug development. The xCELLigence RTCA Cardio System detects the beating 
rhythm of cardiomyocytes (Fig. 3E). It has been applied to human iPSC derived 
cardiomyocytes (hiPS-CMs) on several occasions to investigate risks of drug-induced 
arrhythmia and general cardiotoxicity, of which the most recent publications are listed in 
Table 1 [12, 43-45]. Rhythmic beating is essential for cardiomyocyte function, but has 
traditionally been hard to investigate in simple in vitro assays. Phenotypic measurements of 
native cellular systems are more suited for this [46]. The xCELLigence Cardio System 
capturing cardiac beating was in fact the most sensitive of various tests for detecting 
compounds with known clinical cardiac risk [43], and can be used to evaluate potential 
clinical drug candidates [12].  
Another stem cell-based study involved iPSC-derived retinal pigment epithelium (RPE) as 
a disease-model-on-a-chip of age-related macular degeneration (AMD). In general, epithelial 
and endothelial cells are often studied using label-free technology, and some specific assay 
formats related to formation and disruption of monolayers have been developed for these 
(e.g. barrier function, Fig. 3C). Here, RPE cells from a patient with inherited AMD and an 
unaffected sibling were examined using an ECIS electrical wound healing assay. Real-time 
monitoring over a 25-day period demonstrated the establishment and maturation of RPE 
layers on the microelectrode arrays, in which a spatially controlled damage to the cell layer 
was introduced to mimic AMD. Apparently, label-free technology can be used to measure 
long-term effects, and is apparently suited for tissue-on-a-chip technology. This offers 
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translational value by enabling real-time, quantitative and reproducible patient-specific 
studies [47].  
Another stem cell type of interest are MSCs, which are attractive candidates for tissue 
engineering due to their wide mesodermal differentiation potential. Angstmann et al. 
compared ECIS and xCELLigence in search for standardized quality control assays to monitor 
differentiation and high-throughput screening that is both non-invasive and time-resolved. 
They studied MSCs isolated from two different tissues of various donors, namely bone 
marrow and adipose tissue. Impedance measurements were used to discriminate osteogenic 
from adipogenic differentiation, which showed modulating effects of extracellular matrix 
components [48]. Label-free assays were also used to establish culture conditions for 
expansion of endometrial MSC (eMSC) isolated from endometrial lining of the human uterus 
of premenopausal women [49] or to test MSC labelling by a new type of nanoparticle [50]. 
In another instance, ECIS was used to monitor proliferation and osteogenic 
differentiation of human adipose stem cells (hASC) from donor populations of different ages. 
This assay could be used to predict the osteogenic potential for patient-specific bone tissue 
engineering [51]. Finally, Berger et al. studied molecular mechanisms in human obesity in 
hASCs from liposuctions of female patients. Studying lipid uptake and adipocyte 
differentiation with the xCELLigence, the authors identified several dysregulated adipocyte-
specific genes involved in fatty acid storage or cell adhesion [52]. 
 
Other cell types 
Label-free assays are suited for virtually any cell type and have in fact been applied to 
numerous others besides the most commonly biobanked samples highlighted above. 
A further category of particular interest are cancer and related cell types. Here, 
impedance-based cellular assays are most often used to measure migratory and invasive 
properties (e.g. Fig. 3B), which are key characteristics for any (metastatic) cancer type. For 
instance, the xCELLigence was used to monitor the motility of primary human normal 
mammary cells versus patient-derived breast cancer epithelial cells [8], migration in various 
ovarian cancer patient samples [53] and proliferation and response to kinase inhibitors in 
patients' glioblastoma samples [54]. Others have evaluated (potential) treatment options on 
a patient’s malignant melanoma cells [55] and on a newly established mesenchymal 
chondrosarcoma cell line from a patient [56]. Two other publications used the xCELLigence 
for characterization of newly established cell lines from patient samples, offsetting them 
versus parental tumor tissue or traditionally used carcinoma cell lines [57, 58]. Finally, Ruiz 
et al. applied the xCELLigence to patients' own cancer cells for in vitro selection of the most 
 
 
33 | Chapter 2 
promising treatment, in this case for human carcinoma cells from malignant pleural effusions 
[59]. This is an illustrative example of possible applications in precision medicine. 
Impedance-based technologies are also suited to test potential cell-based therapies (Fig. 
3G). Seidel et al. demonstrated the therapeutic potential of γδ T cells for antibody-based 
immunotherapy in pediatric patients with B-lineage acute lymphoblastic leukemia (ALL). γδ 
T cells were derived from healthy blood donors as well as from a patient with common-ALL. 
The xCELLigence was used to measure γδ T cell lysis in a breast adenocarcinoma cell line in 
real-time, and outperformed the traditional endpoint assay [60]. In a similar manner, others 
studied the ability of mononuclear cells from normal and breast cancer patients to kill 
different breast cancer cell lines in the presence or absence of trastuzumab [61].  
Myoblasts from muscle biopsy samples are another cell type of interest. In a recent 
example, Sente et al. studied pathological mechanisms of heart failure. Using the 
xCELLigence, they observed myoblast adiponectin signaling, differentiation, proliferation and 
viability in primary myoblasts and myotubes from chronic heart failure patients and age- and 
gender-matched healthy donors [62, 63].  
 
From drug discovery to precision medicine 
Due to their versatility, label-free assays and patient cells, when combined, can be utilized at 
various stages of medicines research. As a cell-phenotypic screen, label-free assays are well 
suited for target identification, compound screening andlead selection. Likewise they allow 
the investigation of mechanisms of action and the testing of drug efficacy and safety [14, 17]. 
In this review we provided typical examples involving patient cells, which offer increased 
physiological context. As such patient samples are often in limited supply, this set-up is not 
so much used for e.g., screening drug candidates but rather for understanding disease 
mechanisms and testing potential treatments. This was done by Lowin et al. in the context 
of rheumatoid arthritis to identify drug targets, to subsequently test compounds and to 
define possible treatments [28, 41]. In a more integrated approach the combination of 
patient cells and label-free assays resulted in tissue-on-a-chip technology, as demonstrated 
by Gamal et al.[47]. It is to be expected that the advent of stem cell technology will radically 
change the availability of patient-derived materials [42, 64], which would allow a further 
integration of label-free assays. This would be an ideal starting point for the advancement of 
precision medicine, if patient-derived material can be made available readily, on demand, 
and in larger quantities. In this light the question arises whether label-free technologies can 
be developed that take the three-dimensionality of advanced cellular models and organoids 
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into account [65-67]. In drug safety and toxicity research, iPSC-derived cardiomyocytes can 
be used in a label-free setting to evaluate potential cardiac (side) effects of drug candidates 
[12, 43]. Finally, the combination of patient cells and label-free technology can be used for 
clinical compound selection, for instance by measuring patient cell responses in vitro as 
means of selecting the most promising treatment. This has been demonstrated by profiling 
drug treatment responses of patient derived malignant pleural effusions in a study by Ruiz et 
al. [59], with the aim to provide drug treatment of cancer in a personalized manner.  
 
Conclusion 
Physiologically more appropriate cellular models and readout systems are needed to 
increase representability and translational value. Patient-derived cells can provide 
pathological and physiological context, and biobanking has increased the availability of 
human primary samples for research. Label-free impedance-based assays can and have been 
applied to a wide range of such samples. These assays indeed increase physiological 
representability by omitting reporter-based modifications and measuring physiological cell 
function in real-time. Thus, combining label-free assays with human primary samples offers 
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Abstract 
Deciphering how genetic variation in drug targets such as G protein-coupled receptors 
(GPCRs) affects drug response is essential for precision medicine. GPCR signaling is 
traditionally investigated in artificial cell lines which do not provide sufficient physiological 
context. Patient-derived cell lines such as lymphoblastoid cell lines (LCLs) could represent the 
ideal cellular model system. Here we describe a novel label-free, whole-cell biosensor 
method for characterizing GPCR-mediated drug responses in LCLs. Generally, such biosensor 
technology is deemed only compatible with adherent cell lines. We optimized and applied 
the methodology to study cellular adhesion properties as well as GPCR drug responses in 
LCLs, which are suspension cells. Coating the detector surface with the extracellular matrix 
protein fibronectin resulted in cell adherence and allowed detection of cellular responses. A 
prototypical GPCR present on these cells, i.e. the cannabinoid receptor 2 (CB2R), was selected 
for pharmacological characterization. Receptor activation with the agonist JWH133, 
blockade by antagonist AM630 as well as downstream signaling inhibition by PTX could be 
monitored sensitively and receptor-specifically. Potencies and effects were comparable 
between LCLs of two genetically unrelated individuals, providing the proof-of-principle that 
this biosensor technology can be applied to LCLs, despite their suspension cell nature, in 
order to serve as an in vitro model system for the evaluation of individual genetic influences 
on GPCR-mediated drug responses.  
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Introduction 
Inter-individual variability in drug action and clinical effectiveness forms a challenge in 
today's drug treatment and development. In fact, variation in drug response that arises from 
genetic, lifestyle and environmental differences causes even blockbuster drugs to work in 
only 75% to merely 35% of all [1, 2]. Personalized medicine, or, more broadly defined, 
precision medicine proposes to personalize drug prescriptions using a sub-population or 
patient's individual characteristics, e.g. genetic information, and thereby decrease risks of 
ineffective treatment, dosing or side-effects [2-4]. In order to achieve this, it is paramount to 
determine whether, and how, genetic variation affects drug responses. Today, genetic 
testing is available for around 2000 clinical conditions, particularly in oncology [3, 5]. Two 
poster children of personalized medicine are HER2-positive breast cancer tests as a predictor 
of response to the drug herceptin and screens for CYP450 polymorphisms that are known to 
affect treatment with e.g. selective serotonin-reuptake inhibitors [3, 4]. 
The majority of therapeutic targets to date are formed by a class of membrane proteins, 
the G protein-coupled receptors (GPCRs) [6]. More than 30% of all currently marketed drugs 
exert their therapeutic effect by directly binding to and influencing GPCR function. Due to 
their ubiquity GPCRs are involved in a plethora of physiological processes. It is therefore 
highly interesting to decipher the influence of genetic variation in GPCR-mediated drug 
responses [7, 8]. While several examples have linked GPCR polymorphisms to disease and 
drug response variation, research has mostly focused on the statistics of genotype influences 
followed by functional characterization in heterologous cell lines [8-10]. Heterologous cell 
lines are, however, systems with artificial receptor expression and represent a non-
physiological, cellular context [11, 12]. To fully understand the underlying mechanism of 
polymorphism influence, functional characterization on a physiologically relevant molecular 
and cellular level is vital. An ideal setup would be to use patient-derived cell lines as a model 
system to assess polymorphism influences on drug response. 
A well-established example of such personal cell lines are lymphoblastoid cell lines 
(LCLs), which to date are a preferred choice for storing a person's genetic material [13, 14]. 
Numerous consortia have built and actively utilize LCL libraries, including the Centre d’Étude 
du Polymorphisme Humain (CEPH), the International HapMap and 1000 genomes projects 
[15-19]. However, LCLs are mainly used as a source of DNA or RNA for genotyping, expression 
or methylation studies [9, 13]. Functional cellular assays on LCLs have seldom been 
performed [13, 20, 21] with virtually none for GPCRs. Only Morag and Gurwitz et al. studied 
the influence of a few GPCR antagonists on LCL growth [20]. In fact, many traditional cellular 
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assays, especially for GPCRs, are incompatible with LCLs as they require labeling and cell or 
target engineering. Another drawback is that they generally lack the sensitivity required for 
such endogenous cell lines which often have low target expression levels. Recently 
developed label-free technologies offer a more sensitive, less invasive solution and can 
monitor drug effects on a whole cell in real-time [12, 22, 23]. The sensitivities of these label-
free assays is high enough for standard applications such as GPCR activation or inhibition 
down to detection of small changes such as biased signaling [12, 24]. It may very well be that 
receptor polymorphisms induce subtle yet important changes in drug-target binding, 
signaling bias and receptor subtype selectivity [7]. Label-free technologies are therefore ideal 
for precision medicine purposes, as they harbor the ability to pick up small changes in GPCR 
signaling or drug responses in the physiologically relevant context of endogenous cells. One 
disadvantage, however, is that the detection method of label-free assays generally requires 
cells to adhere to the detector surface at the bottom of the well [12, 23] and unfortunately, 
LCLs are by nature non-adherent suspension cells [25]. However, several reports have been 
published recently on the application of label-free technology to suspension cells, including 
various types of blood cells [26, 27]. To solve the above listed challenges we developed a 
methodology for a label-free, impedance-based whole-cell assay that allows characterization 
of GPCR signaling in LCLs despite their suspension cell nature. This enables the use of LCLs as 
an in vitro cellular model system to evaluate individual differences in GPCR-mediated drug 
responses. 
 
Material and methods 
Chemicals and reagents 
The LCLs were kindly provided within the framework of this collaboration [15]. Fibronectin 
from bovine plasma, poly-D-lysine (PDL) and unsupplemented RPMI 1640 cell culture 
medium were purchased from Sigma Aldrich (Steinheim, Germany). Collagen I from rat tail 
was purchased from Fisher Scientific (Illkirch, France). The GPCR agonist JWH133 was 
purchased from TOCRIS (Bristol, UK), ATP from Sigma Aldrich and AM630 from Cayman 
Chemicals Company (Ann Arbor, Michigan, USA). RGD peptide (GRGDTP) and RGE peptide 
(GRGESP) were purchased from AnaSpec/Tebu-bio (Heerhugowaard, the Netherlands). 
Gαi blocking pertussis toxin (PTX) was purchased from Sigma Aldrich. All other chemicals 
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Lymphoblastoid cell line generation 
The LCLs had previously been generated at the Rutgers Institute (Department of Genetics, 
Piscataway, NJ, USA) using a standard transformation protocol [15]. In short, peripheral B-
lymphocytes were exposed to Epstein–Barr Virus (EBV) by treatment with filtered medium 
from a Marmoset cell line in the presence of phytohemaglutinin (PHA) during the first week 
of culture [13, 14, 28]. Cultures were maintained for 8–12 weeks to adapt and expand the 
EBV transformed lymphocytes and subsequently cryopreserved. 
 
Cell culture 
Two LCLs from two genetically unrelated individuals were used for the experiments 
presented in this manuscript. Cryopreserved cells were thawed, resuscitated and multiple 
aliquots frozen for future use. Of note, LCLs were disposed of after culturing them for 
maximally 120 days. LCLs were grown as suspension cells in culture medium consisting of 
RPMI 1640 (25 mM HEPES and NaHCO3) supplemented with 15% Fetal Calf Serum (FCS), 
50 mg/mL streptomycin and 50 IU/mL penicillin at 37 °C and 5% CO2. Cells were subcultured 
twice a week at a ratio of 1:5 on 10 cm ø plates. 
 
Label-free whole-cell biosensor analysis (xCELLigence RTCA system) 
Detection principle 
Whole-cell assays were performed using the xCELLigence RTCA system [12], a real-time cell 
analyzer (RTCA) based on the electrical impedance generated by cells attaching to gold 
electrodes embedded on the bottom of the microelectronic E-plates. Cell attachment 
changes the local ionic environment at the electrode-solution interface, thereby generating 
impedance. Such relative changes in impedance (Z) are summarized as a dimensionless 
parameter, the so-called Cell Index (CI), and displayed in a real-time plot. In detail, a very 
weak electrical signal is applied to the sensor electrodes, where the AC excitation voltage 
level is in the lower mV range and the resulting current is in the μA range (output test signal 
is 22 mV rms ± 20% with max. 5 mV DC offset at 10, 25 and 50 kHz). The RTCA analyzer 
determines cell indeces at these three predetermined optimal midrange frequencies and the 
average speed of measurement is approximately 150–250 ms for each individual well. In 
order to increase usability and ease for the user, the RTCA system provided by the 
manufacturer has pre-set conditions for amplitude, applied potential, frequency range and 
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presented in this manuscript. The CI value at a given time point is defined by the formula 
in Eq. (1): 
 
Equation (1)   CI = (Zi-Z0) Ω /15 Ω 
 
where Zi is the impedance at each individual time point and Z0 represents the baseline 
impedance in the absence of cells, which is measured prior to the start of the experiment. 
The CI in the absence of cells is therefore defined as 0. As cells adhere to the electrodes, 
impedance and the corresponding CI increase proportionally. Impedance changes thereby 
reflect variations in cell number and degree of adhesion, as well as cellular viability and 
morphology [12, 22]. Such cellular parameters are also affected upon activation of GPCR 
signaling, thereby resulting in impedance changes and real-time monitoring of cellular 
signaling events [12]. Typically, GPCR-mediated activation would result in an increase in cell 
adhesion and overall increase in CI, while a lower CI would indicate loss of adhesion [31]. 
 
General protocol 
The wells of 16 or 96 well E-plates were coated with 50 μl of fibronectin (10 μg/ml), unless 
stated otherwise. After 30 min incubation at room temperature, the coating liquid was 
removed and all plates were air dried for at least 1 h prior to use. LCLs were harvested by re-
suspending in cell culture medium after brief treatment with EDTA and centrifuged twice at 
200g for 5 min. Background impedance (Z0) was measured after adding 45 μL, or in case of 
antagonist experiments 40 μL, of culture media to 16 or 96 well E-plates, respectively. In all 
cases, final well volumes after cell and ligand addition were 100 μL. Cells were seeded by 
adding 50 μL of cell suspension containing 50,000 cells per well, unless stated otherwise. To 
ensure accurate seeding densities, cells were counted using Trypan blue staining and a 
BioRad TC10 automated cell counter. After resting at room temperature for 30–60 min, the 
E-plate was placed into the recording station situated in a 37 °C and 5% CO2 incubator. 
Impedance was measured every 15 min overnight. Cells were stimulated by a GPCR ligand or 
vehicle control in 5 µl after 18–20 h, unless specified otherwise. To record GPCR activation, 
CI was recorded for at least 30 min with a recording schedule of 15 s intervals for 20 min, 
followed by intervals of 1 min, 5 min and finally 15 min. 
For assay optimization purposes, cells were stimulated with the purinergic P2Y receptor 
agonist ATP at a saturating concentration of 100 μM. As compound solubility of JWH133 and 
AM630 required addition of dimethylsulfoxide (DMSO), the final DMSO concentration upon 
ligand or vehicle addition was kept at 0.25% DMSO for all wells and assays. For agonist assays, 
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cells were stimulated with increasing concentrations of JWH133. For antagonist assays, cells 
were pre-incubated for 30 min with 5 μl of the antagonist AM630 at increasing 
concentrations or vehicle control. Subsequently, cells were challenged with a submaximal 
agonist concentration equal to the agonist's EC80 value (100 nM for JWH133) or vehicle 
control. 
For coating trials, wells were coated with 50 μl of varying coatings such as poly-D-lysine 
(0.1 mg/ml), collagen I (50 μg/ml), pure Fetal Calf Serum or fibronectin (0.1–50 μg/ml). Non-
coated wells were used as control condition. After removing coating liquid, only poly-D-lysine 
plates were washed with 3×100 μl PBS before use. 
To assess the specificity of LCL adherence to fibronectin, assay medium was 
supplemented with increasing concentrations of the integrin blocking RGD peptide GRGDTP 
[1 µM–1 mM] or the inactive control RGE peptide GRGESP [1 mM]. Normal assay medium 
was used as control and non-coated wells were used for reference. 
For studies on Gαi coupling, cells were seeded in assay medium containing 100 ng/ml 
Pertussis Toxin (PTX). 
 
Data analysis 
Experimental data were obtained with RTCA Software 1.2 (Roche Applied Science) and 
subsequently exported and analyzed using GraphPad Prism 5.0 (GraphPad Software Inc., San 
Diego, CA, USA). For data analysis, ligand responses were normalized to Δ cell index (Δ CI) 
after subtracting baseline (vehicle control) to correct for any agonist-independent effects. 
Overall, a threshold of 0.01 Δ CI was kept for considering responses different from baseline. 
Peak responses were defined as highest Δ CI observed within 30 min after compound 
addition. Peak values and experimental Δ CI traces were exported to Prism for further 
analysis; construction of bar graphs or dose-response curves by nonlinear regression and 
calculation of IC50, EC50 and EC80 values. All values obtained are means of at least three 
independent experiments performed in duplicate. Statistical significance was determined 
using Student's t-test for two values or two column comparison, e.g. comparing pEC50 values 
between individuals. Comparison of the means of multiple data sets, e.g. the peak Δ CI of 
ATP responses of various coating conditions, was performed by one-way ANOVA, followed 
by a Tukey's post test for comparison of all columns or a Dunnett's post test when comparing 
to vehicle or non-coated control. To get an indication of statistical assay reproducibility under 
optimized assay conditions, correlation analysis was performed for the dose–response 
curves for both the CB2R agonist as well as antagonist for each cell line. 
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Results 
Coating allows detection of GPCR responses 
At first various common coatings known to mediate cellular adherence were tested for their 
ability to allow detection of GPCR signaling in LCLs, for which ATP was chosen as a typical 
GPCR ligand. The result of a representative coating experiment is shown in Fig. 1. Following 
LCL seeding, an initial increase in impedance related to cell adhesion, growth and division 
was observed (Fig. 1A). The overall levels of impedance after 1 h and 18 h, i.e. shortly prior 
to ligand addition, are summarized in Fig. 1B and C. Impedance levels after 1 h are likely to 
reflect initial cellular adhesion, while impedance after 18 h is also influenced by cellular 
proliferation or more prolonged changes in cellular morphology. Subsequent addition of the 
agonist ATP induced changes in LCL morphology that were recorded in real-time (Fig. 1A and 
D). Typically, ATP addition resulted in an immediate dose-dependent increase of impedance 
to a peak level. Subsequently, the CI trace gradually decreased towards a plateau within a 
period of 30 min.  
Lack of coating resulted in no adherence or detection of GPCR response. Even though 
poly-D-lysine initially caused a high amount of cellular adherence equal to fibronectin  
(Fig. 1B) this declined drastically over the course of 18 h (Fig. 1C) and allowed little to no 
detection of GPCR response (Fig. 1D and E). Even though both poly-D-lysine and collagen 
coating resulted in significant impedance levels in comparison to non-coated wells just 
before ATP addition (18 h, Fig. 1C), both of them failed to allow detection of an ATP-induced 
response (Fig. 1D and E) as growth curves had dropped to or below baseline levels (CI<0). 
Fibronectin coating, on the other hand, did mediate cellular adherence over a longer time 
course resulting in a stable growth curve and sufficient window for detection of GPCR 
signaling (Fig. 1D and E). 
Of note, coating experiments performed on LCLs from a second individual, individual 2, 
gave virtually identical results (data not shown).  
Subsequently, the amount of fibronectin required for stable impedance levels and GPCR 
signal detection was further optimized. While initially all amounts of fibronectin resulted in 
impedance above non-coated levels (Fig. 2A and B), only fibronectin levels from 5 μg/ml or 
higher maintained impedance above non-coated up to 18 h (Fig. 2A and C). Significant ATP 
signaling was detected from 10 to 50 μg/ml fibronectin coating (Fig. 2D and E). In fact, 25 and 
50 μg/ml were indistinguishable in impedance level and ATP response window. 10 μg/ml 
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which were both not statistically significantly different from 25 or 50 μg/ml. Fibronectin 
concentration effects were comparable for another cell line from individual 2 (data not 





























Figure 1. Fibronectin coating mediates LCL adhesion to allow detection of GPCR response. Electrodes 
were coated with various standard coatings, i.e. fibronectin (Fb; [50 μg/ml]), collagen I (Col; [50 μg/ml]) 
poly-D-lysine (PdL; [0.1 mg/ml]) and Fetal Calf Serum (FCS). Non-coated (NC) wells were used as a 
control. Cells were stimulated with the agonist (ATP [100 μM]) after 18 h of growth. Representative 
xCELLigence traces of a full experiment (A) and a baseline-corrected ATP response (D) are given. Time 
point 0 represents the time of cell seeding (A) and agonist addition (D), respectively. Bar graphs 
summarize the differences in cell index (CI) shortly after seeding (B, 1 h) and prior to agonist addition 
(C, 18 h), both normalized to fibronectin (100%) and non-coated (0%) wells. (E) Bar graph of baseline-
corrected Δ cell index (Δ CI) of peak ATP response per coating condition, normalized to fibronectin 
(100%) and non-coated (0%) wells. Data are mean ± SEM from three separate experiments performed 
in quadruplicate (B, C) and duplicate (E) using one cell line (individual 1, 50,000 cells/well). Significance 
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LCLs specifically adhere to fibronectin 
In order to confirm the specificity of LCLs' interaction with fibronectin, inhibition of 
fibronectin adherence by small, integrin-targeting peptides containing the RGD motif was 
characterized. Addition of RGD peptide to the assay medium decreased the LCLs' attachment 
to fibronectin, as reflected by a decreased cell index (Fig. 3A and B), though not to levels as 
low as the non-coated control. This inhibition was concentration-dependent (Fig. 3B). 

















Figure 2. Titration of fibronectin coating concentration. Electrodes were coated with different amounts 
of fibronectin from 0.1–50 µg/ml. Non-coated (NC) wells were used as a control. Cells were stimulated 
with agonist (ATP [100 μM]) 18 h after seeding. Representative xCELLigence traces of a full experiment 
(A) and a baseline-corrected GPCR agonist response (D) are given. Time point 0 represents time of cell 
seeding (A) or agonist addition (D). Bar graphs indicate the cell index (CI) shortly after seeding (B, 1 h) 
and prior to agonist addition (C, 18 h), both normalized to fibronectin (100%) and non-coated (0%) 
wells. (E) Bar graphs represent the baseline-corrected Δ cell index (Δ CI) at peak ATP response, 
normalized to fibronectin (100%) and non-coated (0%) wells. Data are mean ± SEM from three separate 
experiments performed in quadruplicate (B, C) and duplicate (E) using one cell line (individual 1, 50,000 
cells/well). Significance compared to control was tested using one-way ANOVA with Dunnett's post-hoc 
test. *=p<0.05, **=p<0.01, ***=p<0.001. 
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ATP response (data not shown). Treatment with the inactive RGE peptide at a high 
concentration (1 mM) did not affect any part of the impedance readout, thereby confirming 
that LCL adherence was affected by specific inhibition of integrin–fibronectin interactions. 
Similar experiments performed on LCLs from a second individual, individual 2, gave 
comparable results (data not shown). 
 
Seeding density and stimulation time affect GPCR response 
Next to optimization of coating, assay conditions were further optimized by evaluating 
various LCL densities. The experimental results are summarized in Fig. 4. Both the height of 
the growth curves (Fig. 4A and B) and the GPCR signal (Fig. 4C and D) increased accordingly 
with the cell density.  
The cell index after 18 h (Fig. 4B) was significantly different between all seeding densities, 
except between 50,000 and 25,000 cells/well. While 25,000 and 50,000 cells/well showed 
no statistically significant difference in growth curve, they did show significant differences in 
detection of an ATP signal (Fig. 4D). 25,000 cells/well gave an insufficient window for full 
pharmacological characterization and was not statistically different from the control. 50,000 
Cells/well, however, was sufficient to allow a reliable detection of a GPCR signal. 










Figure 3. Influence of peptides blocking the fibronectin interaction. Cells were seeded on fibronectin 
coated plates (Fb; [10 µg/ml]) in assay medium containing varying concentrations of RGD peptide 
[1 mM–1 µM], inactive reference peptide RGE [1 mM] or normal medium. Non-coated (NC) wells were 
used as reference. Cells were stimulated by agonist addition (ATP [100 μM]) after 18 h growth. (A) 
Representative full xCELLigence traces, where time point 0 represents the time of cell seeding. (B) Bar 
graphs indicate cell index (CI) 1 h after seeding, normalized to fibronectin (100%) and non-coated (0%) 
wells. Data derived from six separate experiments performed in quadruplicate using LCLs of one 
individual (individual 1, 50,000 cells/well). Statistical significance versus control RGE peptide was 
determined using one-way ANOVA with Dunnett's post-hoc test. *=p<0.05, **=p<0.01, ***=p<0.001. 
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100,000 cells/well. Irrespective of specific statistical significances, both the basal level of 
impedance as reflected in the growth curve and the ATP response increase in height along 
with the seeding density. As 50,000 cells/well was the lowest cell density that allowed reliable 
measurements of GPCR activation, this cell density was chosen for all further experiments. 
Similar experiments performed on LCLs from a second individual, individual 2, gave 
comparable results (data not shown). 
Additionally, as the LCL's growth curve appeared to reach a stable plateau much earlier 

























Figure 4. Seeding density influences growth curve and window of GPCR response. Cells were seeded in 
four different densities (25,000–200,000 cells/well). Cells were stimulated with the agonist (ATP 
[100 μM]) after 18 h of growth. Representative xCELLigence trace of a full experiment (A) and a 
baseline-corrected ATP response (C). Time point 0 represents the time of cell seeding (A) or agonist 
addition (C). Bar graphs indicate the cell index (CI) shortly prior to agonist addition normalized to CI=0 
(B, 18 h) and baseline-corrected Δ cell index (Δ CI) at peak ATP response, normalized to vehicle control 
(D). Data are mean ± SEM from three separate experiments performed in quadruplicate (B) and 
duplicate (D) using one cell line (individual 1). Statistical significance was determined using one-way 
ANOVA with Tukey post-hoc test to compare all columns to each other (B) and Dunnett's post-hoc test 
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Figure 5. Influence of growth phase duration. Two cell lines were stimulated with the GPCR agonist ATP 
[100 μM] immediately after reaching growth plateau at 5 h or after a longer duration of growth at 20 h. 
Representative xCELLigence traces of a full experiment (A) and a baseline-corrected ATP response (B). 
Time point 0 represents the time of cell seeding (A) or agonist addition (B). (C) Bar graphs indicate the 
baseline-corrected Δ cell index (Δ CI) at peak ATP response, normalized to vehicle control. Data 
represents means of four separate experiments performed in duplicate using the LCLs of one individual 
(individual 1, 50,000 cells/well). Statistical significance was determined using Student's t-test. 
*=p<0.05, **=p<0.01, ***=p<0.001. 
 
20 h gave a significantly higher response than stimulation after 5 h, despite the fact that the 
growth curve plateau had been reached after 5 h (Fig. 5B and C). Comparable effects were 
observed on LCLs from a second individual (individual 2, data not shown). 
 
Detailed pharmacological characterization of GPCR signaling in LCLs is possible 
After completing assay optimization, the resulting protocol was applied for full 
pharmacological characterization of an example GPCR. For this purpose, a GPCR with well 
characterized pharmacology and known to be expressed in LCLs was chosen, i.e. the 
cannabinoid receptor 2 (CB2R; Ensembl gene: ENSG00000188822). A result of a 
representative experiment along with concentration-effect curves is provided in Fig. 6. 
Responses from two cell lines from two unrelated individuals were recorded and compared. 
Addition of a CB2R selective agonist JWH133 resulted in an immediate and 
concentration- dependent increase of impedance (Fig. 6A and B), which was similar in shape 
to the recorded ATP responses (Fig. 1, Fig. 2 and Fig. 3). The impedance increase was 
concentration-dependently reduced by pretreatment with the CB2R selective antagonist  
 
 
































Figure 6. Characterization of Cannabinoid receptor 2 responses in two genetically unrelated LCLs. Cell 
lines were stimulated with a CB2R selective agonist JWH133 18 h after seeding (50,000 cells/well). (A) 
Representative example of a baseline-corrected JWH133 response [1 μM–100 pM]. (B) Dose-response 
curves of JWH133 derived from peak Δ cell index (Δ CI) within 30 min after agonist 
addition. pEC50 values of JWH133 were 7.82±0.07 (individual 1) and 7.71±0.04 (individual 2). (C) Cell 
lines were pre-incubated for 30 min with increasing concentrations of AM630 [10 μM–100 pM] before 
stimulation with JWH133 [EC80: 100 nM]. Dose-response curves of AM630 were derived from peak 
Δ CI within 30 min after agonist addition. pIC50values for AM630 were 6.77±0.06 (individual 1) and 
6.85±0.04 (individual 2). To test coupling to Gαiproteins, cells were seeded and grown in assay medium 
with or without PTX [100 ng/ml] and stimulated with JWH133 [EC80: 100 nM]. (D) Representative 
example of baseline-corrected JWH133 response in the absence and presence of PTX. (E) Bar graphs 
show the PTX effect on peak Δ cell index (Δ CI) of JWH133 response, normalized to vehicle control. Data 
represents the means of four separate experiments performed in duplicate. Statistical significance was 
calculated by Student's t-test. ns=not significant (p>0.05), *=p<0.05, **=p<0.01, 
***=p<0.001. pEC50 and pIC50 values did not differ significantly between the two individuals. 
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AM630 (Fig. 6C). Concentration-effect curves were obtained by peak analysis of 
corresponding agonist-induced CI changes. Potencies of JWH133, given as pEC50 values, were 
7.82±0.07 (15 nM) and 7.71±0.04 (20 nM) on individual 1 and individual 2, respectively. 
Antagonist IC50 values for AM630 were obtained by stimulating cells with a submaximal (EC80) 
concentration of JWH133 following antagonist pre-incubation. The pIC50 values for AM630 
were 6.77±0.06 (169 nM) and 6.85±0.04 (141 nM) on individual 1 and individual 2, 
respectively. Both agonist pEC50 and antagonist pIC50 values did not differ significantly 
between the two individuals. In order to get an indication of overall assay reproducibility 
under these optimized conditions, correlation analysis was performed for the dose–response 
curves for both the CB2R agonist as well as antagonist. Experiments were reproducible with 
a coefficient of correlation (Pearson's r) of minimum 0.95 (p<0.05) for both individuals and 
at all concentrations of the agonist and 0.85 for the antagonist (p<0.01). 
The influence of blocking the Gαi-coupled pathway upon CB2R activation was examined 
for both cell lines, as shown in Fig. 6D and E. Addition of PTX to the assay medium effectively 
diminished the CB2R response to agonist JWH133 (Fig. 6D) in a similar manner for both cell 
lines (Fig. 6E). This confirmed that the LCLs' response to the selective CB2R agonist was 
dependent on the Gαi pathway. 
 
Discussion 
Personal cell lines, such as LCLs that are commonly used for storing an individual's genetic 
material [13], can offer a model system to investigate individual differences in drug response 
in a physiologically relevant, cellular context. The introduction of highly sensitive, label-free 
technologies that allow cellular assays with minimal modifications makes harvesting this 
potential possible. In the present study, we have setup and optimized a label-free 
methodology for investigating GPCR-mediated drug responses in LCLs and characterized a 
prototypical GPCR for proof-of-principle. 
As P2Y receptors (Ensembl family: ENSFM00760001715026) are abundantly present on 
virtually all cell types, including LCLs [32, 33], ATP was chosen as initial ligand for the 
methodological setup. In fact, P2Y receptors represent one of the few examples with 
functional characterization in LCLs. Lee et al. investigated ATP-induced P2Y receptor 
responses in LCLs using a single-cell fluorescent microscopy technique. While this traditional, 
label-based technique measured little response at an ATP concentration of 100 μM, the 
label-free assay used in our study was able to measure a clear response at the same 
concentration (Fig. 1, Fig. 2,Fig. 3, Fig. 4 and Fig. 5). This emphasizes the advantage and 
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opportunity of using label-free techniques to measure GPCR signaling in LCLs over traditional, 
label-based methodologies, as they offer highly increased sensitivity and lower detection 
limits. 
The initial experimental setup was based on previously published protocols for adherent 
cell lines [24, 31, 34]. While label-free assays are often deemed incompatible with suspension 
cells, some application examples exist for various label-free assays based on optical or 
impedance detection. These include various types of blood cells. For instance, GPCR signaling 
was measured in primary human neutrophils and THP-1 cells, a human monocyte cell line, 
using an optics-based assay [27, 35]. The impedance-based CellKey technology was used to 
measure GPCR signaling in monocyte cell lines (THP-1 and U937), neutrophils and primary 
normal peripheral blood monocytes (PBMCs) [36, 37]. Both these technologies have the 
disadvantage of being performed in buffer and at room temperature, while xCELLigence 
assays use more physiologically relevant conditions like normal cell culture medium and a 
temperature of 37 ˚C. Application of xCELLigence technology to suspension cells has been 
reported, however not for investigating GPCR signaling. Obr et al. [38] applied the 
technology to measure the effect of histone deacetylase inhibitors on hematopoietic 
cells. Martinez-Serra et al. [26] investigated the cytotoxic effect of antineoplastic agents on 
cells from hematological malignancies, which included the leukemia lymphoblast cell line 
K562. It is well known that the cell density and distribution on the electrodes can significantly 
influence impedance and experimental readout [12, 22, 23]. In previous cases, fibronectin 
was often used to achieve cell adherence combined with increased cell densities with an 
optimal range of 60,000 to 45,000 cells/well [26, 27, 35, 38]. Accordingly, we first tested 
various standard coating conditions and optimized cell density for impedance recordings in 
LCLs and found similar conditions to be optimal for LCLs. In our hands, LCL densities of 50,000 
cells/well were sufficient for detection of a robust GPCR response (Fig. 4), a number that is 
merely 2.5-fold higher than common for adherent cells [24, 31, 34] and very comparable to 
existing suspension cell protocols described above. 
Following LCL seeding onto fibronectin-coated plates, an initial increase in impedance 
related to cell adhesion, growth and division was observed, as is similar for any adherent cell 
line [31, 34]. Fibronectin was capable of mediating LCL adherence sufficiently for the 
measurement of a GPCR response after 18 h (Fig. 1) in a concentration-dependent manner 
(Fig. 2). It has been shown that LCLs can attach to fibronectin [39] and that LCLs express the 
α4β1 and αvβ3 type integrins [40], which are known to interact with fibronectin [41, 42]. 
Most fibronectin-binding integrins interact with a RGD tripeptide active site of fibronectin 
[41-43]. Small soluble RGD peptides have been shown to compete for integrin binding [43, 
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44] and one of those partially blocked the LCL's cellular interaction with the fibronectin 
coating (Fig. 3). The inactivity of the RGE control peptide confirmed that adherence was due 
to a specific interaction of LCL's integrins with fibronectin. Interestingly, around 50% of LCL 
adherence remained even in the presence of a high concentration of the RGD peptide. This 
remaining adhesion is most likely mediated through another motif in fibronectin, the LDV 
motif, which is known to be the predominant binding site for the α4β1 integrin [42]. Poly-D-
lysine is known to mediate cellular adhesion by changing surface charges [45, 46], but failed 
to maintain LCL adherence at sufficiently high levels for detection of an ATP response despite 
an initially equally high adherence as fibronectin (Fig. 1). LCLs have been shown to attach to 
poly-L-lysine at the same concentration, however, for a shorter timeframe than the 18 h in 
our experiments, i.e. 4 h [33]. Moreover, collagen, which also mediates cellular adhesion 
through specific integrins [41], failed to promote adhesion of LCLs. Collagen-interacting 
integrins are thus likely not present in LCLs, while fibronectin-specific integrins are. 
Furthermore, the findings agree with Martinez-Serra et al. who showed that cells from 
hematological malignancies, including the leukemia lymphoblast cell line K562, attached 
more efficiently to fibronectin than to collagen, laminin or gelatin [26]. 
Following the methodological optimization, we showed that in-depth pharmacological 
characterization of GPCRs is possible in LCLs using the CB2 receptor as a prototypical example 
(Fig. 6). This receptor is well expressed in LCLs [47] and has been investigated in a 
heterologous cell line on the xCELLigence [31], but has not yet been functionally 
characterized in LCLs until now. With recombinant cell lines, it is straightforward to confirm 
that an impedance signal is receptor-specific by using the untransfected parental cell line as 
negative control [31, 34]. However, this is not possible for endogenously expressed 
receptors, as is the case for LCLs used in this study. Therefore, proof of a receptor-specific 
response was provided by the concentration-dependent receptor activation with a CB2 
receptor selective agonist, JWH133, and inhibition of that response by a CB2 receptor 
selective antagonist, AM630 [31, 48, 49]. Both JWH133 and AM630 effects were comparable 
between LCLs from two different individuals (Fig. 6), as was expected as both cell lines carried 
the same genotype for all non-synonymous variants (data not shown). Furthermore, both 
JWH133 and AM630 effects on LCLs were comparable to literature values obtained in 
heterologous cell lines. Scandroglio et al. determined the potency of JWH133 and AM630 in 
traditional and label-free assays using a for GPCR investigations typical heterologous cell 
system, a recombinant CHO cell line. Agonist JWH133 had a comparable potency in both 
impedance and traditional cAMP assays of 29.9±20.5 nM and 30±7.3 nM, respectively, 
showing that label-free assays yield values equal to traditional techniques. Similarly, 
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JWH133's potency determined in the present study on LCLs (pEC50: 7.82±0.07 (15 nM) for 
individual 1, 7.71±0.04 (20 nM) for individual 2) were very comparable to Scandroglio et al.'s 
values on the CHO-cells. Furthermore, these authors showed that AM630 was able to 
antagonize JWH133's effects, however they did not report an IC50 value for this inhibition. 
Literature values for AM630 include an IC50 of 128.6±40.6 nM in a traditional cAMP assay on 
a recombinant CHO cell line [48]. On LCLs, AM630 readily antagonized JWH133 effects with 
a very comparable potency (pIC50: 6.77±0.06 (169 nM) for individual 1, 6.85±0.04 (141 nM) 
for individual 2). 
Besides for measuring cellular effects on GPCR signaling by agonists or antagonists, the 
label-free xCELLigence system is also well suited to monitor inhibition of downstream 
pathways [31, 50]. The CB2 receptor is known to predominantly couple to the Gαi-pathway 
and it was previously shown that JWH133 signaling on CHO cells could be inhibited by Gαi-
blocker PTX [31, 51]. Similarly, PTX effectively diminished the CB2R response to JWH133 in 
LCLs of both individuals (Fig. 6), which thereby confirmed that the LCLs' response to the 
agonist was indeed dependent on the Gαi-pathway. Taken together, the effects of JWH133 
in LCLs are mediated by the CB2 receptor. While the effects and potencies of the CB2R ligands 
were comparable between the endogenous LCLs and the recombinant CHO cells, LCLs 
represent a more relevant physiological context as they are cell lines with specific individual 
genetic material. 
LCLs already form a large resource for personalized medicine research, as they are 
commonly used to investigate association of genetic variation to disease or drug response 
[9, 13, 21]. Moreover, large libraries of LCLs have already been built and are actively utilized 
in numerous consortia [15-19]. Investigation of GPCR drug responses in LCLs may further 
help the advancement of precision medicine. Examples linking GPCR polymorphisms to drug 
response to date are sparse and focus on statistic associations followed by validating 
polymorphism influences by generating these variants in heterologous cell lines [10]. 
Heterologous cell lines, however, are labor intensive to make and represent a different, non-
physiological cellular context than cells of an individual [11, 12]. Receptor overexpression, 
differences in intracellular metabolic conditions as well as products from other genes could 
modify cellular responses. Therefore, screening receptor responses in LCLs from persons 
with potentially interesting polymorphisms may offer a more direct way of validation. 
Expression studies indicate that LCLs express a wide range of druggable GPCRs that are of 
interest for drug research, besides the CB2 and P2Y receptors investigated in this study [47]. 
Next to investigation of GPCRs, label-free technology offers a wide range of other 
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applications and has similarly been applied to other important classes of drug targets, such 
as receptor tyrosine kinases [52, 53]. 
 
Conclusion 
In conclusion, the current paper shows that direct characterization of GPCR activity in LCLs is 
possible with a highly sensitive label-free technology, the xCELLigence. Despite that such 
biosensor technology is deemed only compatible with adherent cell lines, we were able to 
optimize the assay for the suspension cell LCLs. Using the CB2R as a prototypical GPCR, we 
were able to show that receptor activation by an agonist, blockade by an antagonist, as well 
as inhibition of downstream signaling could be monitored sensitively and receptor-
specifically. The resemblance of cellular responses between LCLs from two unrelated 
individuals confirms that the methodology is robust and applicable to LCLs in general. This 
offers the ability to use LCLs not just as a mere source of DNA for genetic studies, but also as 
a functional, physiologically more relevant cellular model system for detailed investigation of 
GPCR pharmacology in vitro. Ultimately, a mechanistic link may be made between 
polymorphisms and drug response variation in individuals. Thus combining the resolution 
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Abstract 
Genetic differences between individuals that affect drug action form a challenge in drug 
therapy. Many drugs target G protein-coupled receptors (GPCRs), and a number of receptor 
variants have been noted to impact drug efficacy. This, however, has never been addressed 
in a systematic way, and, hence, we studied real-life genetic variation of receptor function in 
personalized cell lines. As a showcase we studied adenosine A2A receptor (A2AR) signaling in 
lymphoblastoid cell lines (LCLs) derived from a family of four from the Netherlands Twin 
Register (NTR), using a non-invasive label-free cellular assay. The potency of a partial agonist 
differed significantly for one individual. Genotype comparison revealed differences in two 
intron SNPs including rs2236624, which has been associated with caffeine-induced sleep 
disorders. While further validation is needed to confirm genotype-specific effects, this set-
up clearly demonstrated that LCLs are a suitable model system to study genetic influences 
on A2AR response in particular and GPCR responses in general.  
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Introduction 
The majority of therapeutic drug targets to date are within the G protein-coupled receptor 
(GPCR) superfamily, a class of membrane-bound proteins [1, 2]. As such, GPCRs have been 
widely and intensively studied for the development of new therapeutics. Among the most 
well-studied members of this group are the adenosine receptors, a family comprising of 4 
different subtypes: A1, A2A, A2B and A3 [3]. The various subtypes have been implied in a broad 
range of diseases and (patho)-physiological conditions, such as a variety of respiratory and 
inflammatory conditions for the A2A or cardiovascular disorders for the A1 [4]. Likewise, a 
wide variety of compounds selectively activating, inhibiting or modulating these receptors 
are available to date [3, 4]. Some of these have even been or are currently in clinical trials [3, 
4]. Adenosine itself has been long approved for treatment of supraventricular tachycardia [3] 
and one A2AR antagonist, istradefylline, has made it to the market as adjuvant drug therapy 
for Parkinson’s disease in Japan [5]. 
In the emerging era of personalized medicine, it is paramount for drug development to 
better understand the effects of a drug not only in the overall population, but in the individual 
patient as well [6]. Genetic differences between individuals can affect drug action. 
Accordingly, several examples linking GPCR polymorphisms to diseases and drug response 
variation already exist [7-11], which include many commonly targeted GPCRs [11] such as 
purinergic [12, 13], cannabinoid [9, 10] and adenosine [14-16] receptors. Specifically for the 
adenosine A2A receptor, Single Nucleotide Polymorphisms (SNPs) have been associated with 
for instance anxiety [17, 18], caffeine intake [17], or vigilance and sleep [14]. Despite these 
examples of statistical association of genotype and condition, as well as extensive mutational 
characterization of the adenosine receptors, little is known about the direct functional effect 
of receptor polymorphisms or SNPs. Therefore, an ideal set-up would be to use patient-
derived material as a model system to study the influence of polymorphisms on receptor 
response. 
Lymphoblastoid cell lines (LCLs) are one of the most common choices for storing a 
person’s genetic material [19, 20] and can be used to study GPCR function as has been shown 
in Chapter 3. For example, Morag, Kirchheiner [21] studied the influence of a few GPCR 
antagonists on LCL growth. We recently published an even more direct way of measuring 
receptor function, including agonist and antagonist concentration-effect curves (Chapter 3). 
Using a newly developed, highly sensitive label-free cellular assay technology [22, 23], we 
have shown in Chapter 3 that it is possible to measure an individual’s GPCR response in LCLs 
using the cannabinoid receptor 2 as example . In such label-free assays one can monitor drug 
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effects on an intact cell in real-time, rather than being limited to a static, one-molecule-
detection of ligand binding or second messenger accumulation, as is usually employed in 
GPCR and adenosine receptor research [3, 22-24]. 
In the current study we have applied this label-free methodology to assess personal 
adenosine A2A receptor function in LCLs. We characterized A2AR signaling with various types 
of ligands including endogenous and synthetic agonists, partial agonist and antagonists, 
among which istradefylline. To allow conclusions about genotype in relation to receptor 
response, we compared responses between the individuals of a family of four from the 
Netherlands Twin Register [25]. This family consisted of two genetically unrelated individuals, 
the parents, as well as their children, which were monozygotic twins. Confirming the 
comparability of monozygotic twins’ responses is one of the standard ways to control for 
genotype-unrelated effects, and thereby assess a system’s suitability for genetic studies [25, 
26]. 
 
Material and methods 
Chemicals and reagents 
Fibronectin from bovine plasma, Roswell Park Memorial Institute (RPMI) 1640 cell culture 
medium (25 mM HEPES and NaHCO3), NECA, adenosine and ATP were purchased from Sigma 
Aldrich (Zwijndrecht, The Netherlands). CGS21680, ZM241385 and CCPA were purchased 
from Abcam Biochemicals (Cambridge, United Kingdom), Cl-IB-MECA from Tocris Bioscience 
(Bristol, United Kingdom) and istradefylline from Axon Medchem (Groningen, The 
Netherlands). BAY60-6583 was synthesized in-house. LUF compounds were synthesized as 
described by van Tilburg, von Frijtag Drabbe Kunzel [27] for LUF5448 and LUF5631, van 
Tilburg, Gremmen [28] for LUF5549 and LUF5550 and Beukers, Chang [29] for LUF5834. All 
other chemicals and reagents were of analytical grade and obtained from commercial 
sources, unless stated otherwise. 
 
Lymphoblastoid cell line generation 
The lymphoblastoid cell lines (LCLs) were generated from participants of the Netherlands 
Twin Register (NTR, VU, Amsterdam, The Netherlands) [25]. The LCLs were generated by the 
Rutgers Institute (Department of Genetics, Piscataway, NJ, USA) using a standard 
transformation protocol [25], as previously mentioned in Chapter 3. Peripheral B-
lymphocytes were transformed with Epstein–Barr Virus (EBV) by treatment with filtered 
medium from a Marmoset cell line in the presence of phytohemaglutinin (PHA) during the 
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first week of culture [19, 20, 30]. Cultures were maintained for 8–12 weeks to expand the 
EBV transformed lymphocytes and subsequently cryopreserved. 
 
Cell culture 
LCLs from a family of four individuals, two parents (genetically unrelated; called Parent 1 and 
Parent 2) and their monozygotic twin (genetically equal; called Twin 1 and Twin 2), were used 
for the experiments presented in this manuscript. According to culture conditions described 
in Chapter 3, cryopreserved cells were thawed and resuscitated. LCLs were grown as 
suspension cells in RPMI 1640 (25 mM HEPES and NaHCO3) supplemented with 15% FCS, 50 
mg/ml streptomycin, 50 IU/ml penicillin, at 37 °C and 5% CO2 and were subcultured twice a 




RNA from LCLs was isolated using RNeasy Mini kit (QIAGEN, Venlo, The Netherlands). The 
RNA was treated with optional on column DNase digestion using DNase I (QIAGEN) and 
converted to cDNA using Superscript III (Invitrogen, Bleiswijk, The Netherlands). cDNA was 
run on custom designed 384 well qPCR plates from Lonza (Copenhagen, DK), in accordance 
with a previous publication [31]. These plates contained primers for 379 GPCRs as well as 3 
RAMPs, together with primers for Rn18s and genomic DNA (Primers are listed in Engelstoft 
et al. [31]). Genomic DNA sample was used as calibrator and the relative copy number was 
calculated as stipulated previously [31]. 
 
Label-free whole-cell analysis (xCELLigence RTCA system) 
Instrumentation principle 
Cellular assays were performed using the xCELLigence RTCA system [22] in accordance with 
previously published protocols (Chapter 3, [32]). Briefly, the real-time cell analyzer (RTCA) 
measures the whole-cell responses using a detection system based on electrical impedance. 
Impedance is generated through cell attachment to gold electrodes embedded on the 
bottom of the microelectronic E-plates, which changes the local ionic environment at the 
electrode-solution interface. Relative changes in impedance (Z) are recorded in real-time and 
summarized in the so-called Cell Index (CI), a dimensionless parameter. The CI at any given 
time point is defined as (Zi - Z0) Ω/15 Ω, where Zi is the impedance at each individual time 
point. Z0 represents the baseline impedance in the absence of cells, which is measured prior 
to the start of the experiment and defined as 0. As cells adhere to the electrodes, impedance 
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and the corresponding CI increase proportionally. Changes in cell number and degree of 
adhesion, as well as cellular viability and morphology are directly reflected in the impedance 
profile [22, 23]. Such cellular parameters are also affected upon activation of GPCR signaling, 
thereby allowing real-time monitoring of cellular signaling events [22]. 
 
General protocol 
xCELLigence assays on LCLs were performed in accordance with a protocol previously 
described in Chapter 3 with minor modifications. Briefly, cells were seeded onto fibronectin-
coated E-plates (10 μg/ml) at 80,000 cells/well. All cell counts were performed using Trypan 
blue staining and a BioRad TC10 automated cell counter. E-plates were placed into the 
recording station situated in a 37 °C and 5% CO2 incubator and impedance was measured 
overnight. After 18 h, cells were stimulated by a GPCR ligand or vehicle control in 5 μl, unless 
specified otherwise. As compound solubility required addition of dimethylsulfoxide (DMSO), 
the final DMSO concentration upon ligand or vehicle addition was kept at 0.25% DMSO for 
all wells and assays. 
For agonist screening purposes, cells were stimulated with agonist concentrations 
corresponding to 100 × Ki value for their respective receptors [4]. For the partial agonist 
screen, all partial agonists as well as reference agonist CGS21680 were tested at a 
concentration of 1 μM. 
Agonist concentration–response curves were generated by stimulating cells with 
increasing concentrations of the respective agonist. For antagonist assays, cells were pre-
incubated for 30 min with 5 μl of vehicle control or the respective antagonist at increasing 
concentrations. Subsequently, cells were challenged with a submaximal agonist 
concentration of CGS21680 that was equal to the agonist’s EC80 value (100 nM) or vehicle 
control. Generally, compound dilutions for concentration–response curves were generated 
using the digital TECAN dispenser (Tecan Group, Männedorf, Switzerland). 
 
Data analysis 
Data were analyzed as stipulated in the previous protocol in Chapter 3. Briefly, experimental 
data were obtained with RTCA Software 1.2 (Roche Applied Science). Ligand responses were 
normalized to Δ cell index (Δ CI) and exported to GraphPad Prism 6.0 (GraphPad Software 
Inc., San Diego, CA, USA) for further analysis. Vehicle control was subtracted as baseline to 
correct for any agonist-independent effects. Peak responses were defined as highest Δ CI 
(Max ΔCI) observed within 60 min after compound addition. When stipulated, area under 
the curve (AUC ΔCI) within those 60 min was used as an additional parameter to analyze 
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response height. Peak values and experimental Δ CI traces were used for construction of bar 
graphs or concentration–effect curves by nonlinear regression and calculation of IC50, EC50 
and EC80 values. Ki values for antagonists were calculated using the Cheng–Prusoff equation 
[33] using the concentration of the agonist (CGS21680, 100 nM) and EC50 value 
corresponding to each cell line. 
All values obtained are means of at least three independent experiments performed in 
duplicate, unless stated otherwise. Statistical significance was determined by comparison of 
the means of multiple data sets by a one-way ANOVA, followed by Tukey’s post hoc test for 
comparison of all columns or a Dunnett’s post hoc test when comparing to control or 
reference compound. 
 
Processing of SNPs and genetic data 
SNP data for the four individuals were obtained from the Genomes of the Netherlands 
consortium (http://www.nlgenome.nl/) of which the Netherlands Twin Register is part of and 




Label-free assays enable detection of adenosine A2A receptor signaling in LCLs 
The standard applications of label-free technologies such as the xCELLigence for GPCRs 
generally require adherent cell systems [22, 23, 32]. LCLs are suspension cells for which we 
have developed a protocol in which fibronectin coating of the plate wells allowed the LCLs to 
adhere (Chapter 3). With this approach we confirmed the presence or absence of adenosine 
receptor subtypes by testing selective agonists using LCLs of one individual as example 
(parent 2). These agonists included selective ligands such as CCPA for hA1AR, CGS21680 for 
hA2AAR, BAY60-6583 for hA2BAR, Cl-IB-MECA for hA3AR and the unselective agonist NECA. To 
ensure full receptor occupancy, we tested the compounds at concentrations corresponding 
to 100 × Ki value for their respective receptor [4]. An example of resulting xCELLigence traces 
is provided in Fig. 1. Addition of the compounds induced changes in cellular morphology that 
were recorded in real-time. Typically, agonist addition resulted in an immediate increase of 
impedance to a peak level which gradually decreased toward a plateau within 30 min. 
Responses were normalized to the subtype unselective agonist NECA for reference. Overall, 
hA2AAR selective agonist CGS21680 gave the highest response which was close to the 
response to NECA itself, as would be expected from the expression data which showed that  
 









Figure 1. Adenosine receptor agonist screen. Cells were seeded onto fibronectin-coated wells 
(10 μg/ml) at 80,000 cells/well. After 18 h of growth, cells were stimulated with AR ligands at 
concentrations corresponding to 100 × Ki value for their respective receptor [4]. CCPA (83 nM) for 
hA1AR at, CGS21680 (2.7 μM) for hA2AAR, BAY60-6583 (36 μM) for hA2BAR and Cl-IB-MECA (140 nM) 
for hA3AR were compared to the unselective hAR agonist NECA. Unselective NECA was tested a 
concentration of 14 μM which is at least 100 × Ki or more for all ARs. Representative xCELLigence traces 
of a baseline-corrected ligand response are given of one individual (parent 2), where time point 0 
represents the time of ligand addition. Data are from at least three separate experiments performed 
in duplicate. Statistical differences of compound responses to NECA were analyzed using a one-way 
ANOVA with Dunnett’s post hoc-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Response 
heights normalized to NECA (100 ± 1%) were for CCPA: 35 ± 5% , CGS21680: 67 ± 11%, BAY60-6583: 
40 ± 14%  and Cl-IB-MECA: 39 ± 10% . 
 
hA2AAR is the highest expressed in LCLs while the other three subtypes were expressed to a 
much lower extent (receptor expression family mean ± SEM was hA2AAR 21.87 ± 5.41, hA1AR 
1.35 ± 0.85, hA2BAR 0.88 ± 0.35 and hA3AR 0.40 ± 0.37, calculated using a normalization factor 
derived from all genes expressed above genomic DNA levels, in accordance with a previous 
publication by Engelstoft et al. [31]). In fact, CGS21680 was the only compound whose 
response did not differ significantly from NECA. CCPA, the hA1AR agonist, and hA3AR agonist 
CL-IB-MECA gave small responses (Fig. 1), most likely caused by a modest activation of A2AR 
at the concentrations used. While all other agonists displayed a positive impedance 
response, BAY60-6583 gave a small positive peak followed by a decline to a negative 
impedance plateau. Responses to all agonists from LCLs of a second individual, parent 1, gave 
comparable results in terms of conclusion of receptor subtype presence (data not shown). 
 
A2AR agonist and antagonist responses compare well between monozygotic twins and their 
parents 
Subsequently, the label-free methodology was applied to compare adenosine A2Areceptor 
related responses between LCLs derived from the four different individuals. We 
characterized A2AR signaling with various types of ligands, including the endogenous agonist 

























Figure 2. Characterization of full agonist responses in LCLs from a family of four from the NTR. The family 
consists of two genetically unrelated individuals, parent 1 and 2, and their children which are a 
monozygotic twin (twin 1 and twin 2). Cell lines were stimulated with endogenous agonist adenosine 
[1 nM–100 μM], synthetic agonists NECA or CGS21680 [100 pM–1 μM] 18 h after seeding 
(80,000 cells/well). Representative example of a baseline-corrected concentration-dependent 
CGS21680 response (A). Concentration–response curves for CGS21680 (B), NECA (C) and adenosine (D) 
were derived from peak Δ cell index (Δ CI) within 60 min after agonist addition (see Methods). Data in 
B–D represent the means ± SEM of at least three separate experiments performed in duplicate. 
 
CGS21680. All three agonists displayed a similar shape of and height in response, both within 
each cell line and between individuals. An example of such a response is depicted in Fig. 2A. 
The corresponding concentration–response curves are shown in Fig. 2B-D. In a similar 
manner, concentration-inhibition curves for A2AR antagonists ZM241385 and istradefylline 
were obtained. An example trace of such an agonist/antagonist experiment is in Fig. 3A while 
the concentration-inhibition curves are represented in Fig. 3B and C. AllpEC50 and 
pIC50 values for the LCLs of the four individuals are summarized in Table 1. From the 
pIC50 values we derived affinity (pKi) values for both antagonists using the Cheng–Prusoff 
equation. For ZM241385 these values were 8.29 ± 0.11, 9.00 ± 0.09, 8.88 ± 0.05 and 
9.08 ± 0.08 for parent 1, parent 2, twins 1 and 2. pKi values for istradefylline were 6.84 ± 0.17, 
7.67 ± 0.07, 7.47 ± 0.05 and 7.88 ± 0.07, respectively. 
 
A2AR partial agonist responses are measurable in LCLs 
Finally, we tested a number of partial agonists synthesized in house, all at a concentration of 
 

















Figure 3. Characterization of A2AR antagonist responses in LCLs from a family of four from the NTR. The 
family consists of two genetically unrelated individuals, parent 1 and 2, and their children which are a 
monozygotic twin (twin 1 and twin 2). For antagonist curves, cell lines were pre-incubated for 30 min 
with increasing concentrations of ZM241385 [10 pM–10 μM] before stimulation with CGS21680 [EC80: 
100 nM] 18 h after seeding (80,000 cells/well). Representative example of a baseline-corrected 
concentration-dependent response to ZM241385 (A). Concentration–response curves for ZM241385 
(B) and istradefylline (C) were derived from peak Δ cell index (Δ CI) values within 60 min after agonist 
addition. Data in B and C represent the means ± SEM of at least three separate experiments performed 
in duplicate. 
 
1 μM. An example trace of partial agonist and CGS21680 responses for LCLs of one individual 
is in Fig. 4A. Some partial agonists (LUF5549 and LUF5631) displayed high efficacy in this cell 
system, as their maximum response almost equaled that of the full agonist CGS21680 with 
112 ± 9% and 95 ± 11%, respectively. LUF5448 and LUF5550 however showed robust partial 
agonistic behavior of 64 ± 5% and 40 ± 5% of maximal efficacy (Fig. 4A). Partial agonist 
LUF5834 gave a different shape of response, which was marked by a negative peak followed 
by a negative impedance plateau, which differed significantly from any other partial agonist 
or reference full agonist CGS21680 (Fig. 4A). Its maximum response was therefore at 
17 ± 8%. 
 
A2A partial agonist response differs between individuals 
In order to further demonstrate the sensitivity of the label-free technology combined with 
LCLs, one partial agonist was chosen to obtain concentration–response curves. LUF5448 was  
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chosen as a suitable candidate as it displayed robust partial agonistic behavior with a 
maximum effect of approx. 50% of the reference full agonist CGS21680. An example 
xCELLigence trace is provided in Fig. 4B while the corresponding concentration–response 
curves for the four individuals are summarized in Fig. 4C. Interestingly, while three of the 
individuals gave very comparable curves and pEC50 values, one of the parents differed 
significantly from all (Table 1), with an approx. tenfold higher potency (pEC50 value). LUF5448 
behaved as a typical partial agonist on all cell lines with a % Max ΔCI of CGS21680 of 66 ± 7% 
for parent 1, 70 ± 2% for parent 2 and 67 ± 2% and 54 ± 4% for twins 1 and 2, respectively. 
 
Figure 4. A2AR partial agonist responses in LCLs. Cells were stimulated 18 h after seeding 
(80,000 cells/well) with A2AR partial agonists as well as full agonist CGS21680 [all at 1 μM] for reference. 
(A) Representative example of a baseline-corrected response is given from one individual (parent 2). 
Maximal responses of partial agonists compared to CGS21680 were 112 ± 9% for LUF5549, 95 ± 11% 
for LUF5631, 64 ± 5%  for LUF5448, 40 ± 5%  for LUF5550 and 17 ± 8%  for LUF5834. Statistical 
differences from CGS21680 were assessed with a one-way ANOVA with Dunnett’s post hoc 
test. *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001. (B) Representative example of a baseline-
corrected response of A2AR partial agonist LUF5448 [10 pM–1 μM] for one individual (parent 2). (C) 
Concentration–response curves for all four individuals were derived from peak Δ cell index (Δ CI) within 
60 min after agonist addition, normalized to CGS21680 as reference. Data are representative examples 
or means ± SEM of at least three separate experiments performed in duplicate. 
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Table 1. Overview of the pEC50 and pIC50 values of Adenosine, NECA, CGS21680, ZM241385, istradefylline 
and LUF5448 for the tested individuals’ LCLs. Data represents the means of at least three separate 
experiments performed in duplicate. Statistical analysis was performed with one-way ANOVA with 
Tukey post-hoc test. Asterisks highlight statistical differences to the other individuals (P1 = parent 1; P2 
= parent 2; T1 = Twin 1; T2 = twin 2). * p<0.05, ** p<0.01,*** p<0.001. 
Ligand 
pEC50 / pIC50 (M) 








8.60 ± 0.02 [32] 
7.59 ± 0.33 [37] 
7.54 ± 0.07 
**T2; ***P2 
8.06 ± 0.04 
**T1; ***P1 
7.68 ± 0.04 
*T2; **P2 





8.42 ± 0.05 [32] 
8.18 ± 0.36 [38] 








7.92 a [39] 6.21 ± 0.09 
*P2; **T1; 
***T2 
6.45 ± 0.04 
*P1 
 
6.66 ± 0.02 
**P1 
 




8.62 ± 0.19 [32] 8.69 ± 0.11 
**all 
7.60 ± 0.11 
**P1 
7.69 ± 0.08  
**P1 




Table 2. SNP genotype differences within the ADORA2A gene between the four individuals included in 
this study. The heterozygous differences of parent 1 to the other individuals are underlined. Data 
obtained from the NTR and analyzed in-house. 
SNP 
Genotype 
Parent 1 Parent 2 Twins 
rs34999116 T C C C C C 
rs5751869 A G A G G G 
rs5760410 A G A G G G 
rs5751870 T G T G G G 
rs5751871 T G T G G G 
rs9624470 A G A G G G 
rs11704959 A C C C A C 
rs2298383 T C T C C C 
rs3761420 A G A G G G 
rs3761422 C T C T T T 
rs2267076 C T C T T T 
rs11704811 T C C C T C 
rs17650801 G G A G G G 
rs4822489 G T G T T T 
rs2236624 C C T C T C 
rs5751876 C T C T T T 
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Genotype differences between the four individuals 
SNP data for the four individuals were obtained from the Genomes of the Netherlands 
consortium and analyzed in-house using PLINK, an open-source whole genome association 
analysis toolset [34, 35]. SNPs within the boundaries of the ADORA2A gene as defined by 
human genome overview GRCh37 were selected. Based on GRCh37 and dbSNP information 
(http://www.ncbi.nlm.nih.gov/SNP/), SNPs were further annotated according to position 
(e.g., intron, exon) and SNP type (e.g., missense, synonymous). The genotype differences of 
the individuals used in this study are summarized in Table 2. 
 
Discussion 
It is well established that label-free technologies can be applied to investigate GPCR signaling 
in heterologous as well primary adherent cell systems [22, 23, 32]. For instance, the 
xCELLigence system has successfully been applied to study ligand effects on the cannabinoid 
receptor 2 (CB2) and the metabotropic glutamate receptor 1 (mGluR1) using recombinant 
Chinese hamster ovary (CHO) cells [40]. Similarly, A2AR signaling has been studied in 
HEK293hA2AAR cells using selective agonists as well as partial agonists [32]. While only such 
recombinant cell lines have been used to study A2AR signaling using label-free technology, 
A2AR function has been studied in some endogenous cell types using other, more traditional 
assays [38, 41, 42]. However, studying a person’s A2AR response using a personal cell line 
such as the LCLs has not been possible up until now, and is therefore a translational step 
further toward precision medicine. 
Applicability of this label-free technology to LCLs is, however, not entirely 
straightforward due to their suspension cell nature. Nonetheless, adherence levels after 
coating of the wells with fibronectin were sufficient to allow monitoring of receptor 
responses, as was demonstrated by testing adenosine receptor ligands (Fig. 1). Activation of 
A2AR receptors led to a typical increase in impedance often seen for GPCR ligands in LCLs. For 
instance, P2Y receptors (Ensembl family: ENSFM00760001715026) are abundantly present 
on many cell types, including LCLs [43, 44], which has made ATP a reference agonist for 
testing of functional LCL responses (Chapter 3). Interestingly, both adenosine receptor 
agonists and ATP display the same shape of response, which was also comparable to the 
response to cannabinoid receptor 2 (CB2) agonists as seen in earlier in Chapter 3. Herein we 
showed that LCL densities of 50,000 cells/well were sufficient for detection of a robust CB2 
as well as P2Y receptor response. In the present chapter seeding densities were increased to 
80,000 cells/well to obtain a window sufficient for A2AR partial agonist characterization. 
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It is well known that A2AR are expressed in immune cells, including lymphocytes and LCLs 
[41, 45], which was confirmed in this study by both receptor expression levels in the qPCR 
experiments and the responses to selective adenosine receptor agonists in the label-free 
assay (Fig. 1). The results from these tests indicated that A2AR are the only adenosine 
receptors highly expressed in LCLs. This was further confirmed by the comparability of the 
responses of all three full agonists tested in this paper. The endogenous ligand adenosine as 
well as subtype unselective NECA and A2AR selective CGS21680 had comparable responses 
(Fig. 2) suggesting these were all mediated through the A2AR. Similarly, antagonist responses 
were also measurable for all four different individuals (Fig. 3), strengthening the conclusion 
that responses are mediated through A2AR only. 
While it is straightforward to confirm that an impedance response is a specific receptor-
mediated effect with recombinant cell lines, namely by simply using the untransfected 
parental cell line as negative control [32, 40], this is not possible in cell lines with endogenous 
receptor expression. Therefore, for LCLs the most reliable way is to confirm overall receptor 
pharmacology with receptor subtype-selective agonists and antagonists. By showing that the 
A2AR selective antagonists ZM241385 and istradefylline competed with and blocked the 
signal of the A2AR selective agonist CGS21680 (Fig. 3), we confirmed that the impedance 
effects indeed originate from an A2AR response. 
Overall, agonist pEC50 values for agonists were within a log unit from previously reported 
literature values obtained with standard functional assays on heterologous cell lines (Table 
1). For instance, adenosine itself is within that range as it has been reported with an EC50 
value of 310 nM in a cAMP assay on hA2AAR [36]. For the antagonists, the calculated pKi 
values of ZM241385 and istradefylline were also within the range of previously published 
values. This calculation corrects for the fact that the same concentration of agonist was used 
during the assay, corresponding to the EC80 of CGS21680, while the efficacy of this agonist 
differed slightly between cell lines. 
Following this characterization of full agonists and antagonists to verify the presence and 
functional relevance of A2AR, a number of partial agonists were tested to demonstrate the 
sensitivity of the system. The set-up was well able to measure partial agonist effects on LCLs, 
quite comparable to our previous study on HEK293hA2AAR cells [32]. Interestingly, while 
most agonists induced an increase in impedance with a single peak in LCLs, there were two 
agonists which gave rise to a different shape of response. Both BAY60-6583 and the partial 
agonist LUF5834 responses were marked by a small peak followed by a negative impedance 
plateau, rather than one positive peak (Fig. 1 and Fig. 4). Interestingly, both BAY60-6583 and 
LUF5834 belong to a structurally distinct class of non-ribose agonists, as opposed to all other 
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agonists tested in this paper. Hence, it seems that non-ribose agonists, while equally able to 
activate the hA2AAR, give rise to a different cellular response than the more common ribose-
containing agonists. This was not observed in the heterologous HEK293hA2AAR cell line where 
partial agonist LUF5834 had been tested previously [32], which highlights the differences of 
using an unmodified human cell line when characterizing compound effects. In fact, 
efficacies and signaling of ligands can differ under artificial or heterologous conditions due 
to a number of factors [22, 46]. Receptor overexpression, differences in intracellular 
metabolic conditions as well as products from other genes could modify cellular responses. 
Unfortunately, most studies of receptor function involve artificially expressed receptors in 
heterologous cell systems, such as CHO or HEK cells [3, 32]. While useful for high-throughput 
screening and fundamental research, such systems are far from the real-life situation in an 
individual. To move further toward the physiological situation, it is essential to study receptor 
function in a more endogenous setting such as LCLs. This is especially true when attempting 
to understand how polymorphisms may functionally affect the receptor and therefore the 
drug response of an individual. 
Employing the LCLs, we investigated genotype effects on receptor response by 
comparing the effects of various types of A2AR ligands between the individuals of a family of 
four from the Netherlands Twin Register, which consisted of two genetically unrelated 
individuals, the parents, and their children, which were monozygotic twins. Overall, the 
results were comparable between all individuals. Analyzing and confirming the comparability 
of results obtained in monozygotic twins is one of the standard ways in genetic studies to 
control for genotype-unrelated effects, and assess a system’s suitability for genetic studies 
[25, 26]. As expected, the twins did not differ significantly from each other, with exception 
of their pEC50 values for NECA (p < 0.05; Table 1). Interestingly, NECA was also the only ligand 
for which all individuals differed significantly in their pEC50 values. As monozygotic twins are 
genetically identical, these differences could not be related to genetic effects and therefore 
precluded any further conclusion about differences between the parents. However, parent 
1 showed significant differences on two occasions, when all other three individuals, including 
the monozygotic twins, were comparable. This was the case with istradefylline as well as with 
the partial agonist LUF5448. While with istradefylline the difference was rather marginal 
within half a log unit, the potency shift (approx. tenfold higher) for LUF5448 was much more 
pronounced for parent 1. Partial agonists are deemed more sensitive to system-related 
differences in receptor function, for instance in receptor expression or downstream coupling, 
than full agonists or antagonists [28]. Therefore, the difference in potency possibly reflects 
subtle changes introduced by the genetic differences between individuals. While none of the 
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four individuals had non-synonymous SNPs in the ADORA2A gene (Table 2), there were some 
heterozygous differences present in non-coding SNPs. Two SNP differences were in line with 
the pEC50 and pIC50 changes, namely in which only parent 1 differed while parent 2 and the 
twins showed the same genotype and response. These were rs34999116 where parent 1 is 
heterozygote for the minor allele and rs2236624 where parent 1 is homozygote for the minor 
allele. Interestingly, the C-allele of rs2236624, which is located in intron 4 of the ADORA2A 
gene, has been associated with vigilance and sleep, while the CC genotype has been 
associated with anxiety in autism patients [14-16]. The TT genotype has been associated with 
pharmacotherapy-related toxicities in acute lymphoblastic leukemia [47]. Several studies 
have proposed a subtle effect on receptor expression as possible mechanism, as this intron 
SNP has intermediate regulatory potential [16, 47]. As we did not observe significant 
differences in receptor mRNA levels in our qPCR experiments, this regulation may affect the 
subsequent translation. Changes in receptor expression may affect G protein coupling 
efficiency, for which a partial agonist is more sensitive than a full agonist. 
Although this genetic variation does not provide causal evidence that response 
differences as observed in the LCLs from these individuals are directly related to these SNPs, 
the experimental results show that the chosen methodology and set-up are capable of 
picking up individual differences in receptor signaling for the A2AR. Although A2AR function 
has been studied in endogenous cell types [38, 41, 42], we made a further step toward both 
physiologically relevant conditions and personalized medicine by enabling the study of a 
person’s A2AR response using a combination of LCLs from a family of four from the NTR and 
a non-invasive label-free cellular assay. 
It is increasingly recognized that genetic differences between individuals form a large 
challenge in drug therapy indeed. In our study of real-life genetic variation of A2AR signaling, 
we found that partial agonist potency differed significantly for one individual with genotype 
differences in two intron SNPs, one of which has previously been associated with caffeine-
induced sleep disorders. While further validation is needed to confirm genotype-specific 
effects, this set-up clearly demonstrated that LCLs are a suitable model system to study 
genetic influences on A2AR and GPCR responses in general. LCLs express a wide range of other 
‘drugable’ GPCRs, besides the A2AR, CB2 and P2Y receptors investigated in this and earlier 
studies (Chapter 3, [45]). Therefore, screening receptor responses in LCLs may help to 
provide the mechanistic link between polymorphisms of various GPCRs and the individual 
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Data access 
The LCLs used in this study were kindly provided within the framework of this 
collaboration [25] and are part of the Netherlands Twin Register 
(NTR; http://www.tweelingenregister.org/en/), and part of the Center for Collaborative 
Genomic Studies on Mental Disorders (NIMH U24 MH068457-06). Data and biomaterials 
(such as cell lines) are available to qualified investigators, and may be accessed by following 
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Abstract 
The Cannabinoid Receptor 2 (CB2R) is a G protein-coupled receptor (GPCR) investigated 
intensively as therapeutic target, however no drug has reached the market yet. We 
investigated personal differences in CB2R drug responses using a label-free whole-cell assay 
(xCELLigence) combined with cell lines (Lymphoblastoid Cell Lines) from individuals with 
varying CB2R genotypes. Responses to agonists, partial agonists and antagonists of various 
chemical classes were characterized. Endogenous cannabinoids such as 2-AG induced 
cellular effects vastly different from all synthetic cannabinoids, especially in their time-
profile. 
Secondly, the Q63R polymorphism affected CB2R responses in general. Agonists and 
especially partial agonists showed higher efficacy in a Q63R minor homozygote versus other 
genotypes. Non-classical cannabinoid CP55940 showed the most pronounced personal 
effects with highly reduced potency and efficacy in this genotype. Contrarily, 
aminoalkylindole compounds showed less individual differences. 
In conclusion, a label-free whole-cell assay combined with personal cell lines is a 
promising vehicle to investigate personal differences in drug response originating from 
genetic variation in GPCRs. Such phenotypic screening allows early identification of 
compounds prone to personal differences (‘precision medicine’) or more suited as drugs for 
the general population.  
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Introduction 
The Cannabinoid Receptor 2 (CB2R) is a class A G Protein-Coupled Receptor (GPCR) which has 
been investigated intensively, for instance as therapeutic target for novel 
immunomodulators [1]. The Cannabinoid receptor family consists of CB1R, CB2R and as of 
late, the former orphan receptors GPR55 and GPR18. Together with their endogenous 
ligands, they form part of the endocannabinoid system which is involved in many 
physiological processes. CB2R is a (predominantly) Gαi-coupled receptor which is expressed 
mainly in cells of the immune system, such as T- and B-lymphocytes, as well as the central 
and peripheral nervous system and the gastrointestinal tract [1-3]. As such, the CB2R is 
involved in a wide range of pathological conditions ranging from atherosclerosis [4], 
neuropathic pain [5], neurodegenerative diseases [6], osteoporosis [7] and autoimmune 
diseases [8] to cancer [9-11]. Hence, the CB2R has been in the focus of drug development 
efforts for over a decade. However, no selective drug targeting the CB2R has made it to the 
market as of yet. There can be several reasons as to why drugs fail in clinical trials, one of 
which is differences in individuals’ responses to the drug. In fact, even the most widely 
prescribed and sold drugs, the so-called big ‘blockbuster’ drugs, only work in 35–75% of all 
patients [12], as individual drug response varies due to differences in genetics, lifestyle and 
environment. Therefore, personalized or precision medicine aims to personalize drug 
prescriptions based on a patient’s individual characteristics, e.g. genetic information, and 
thereby decreases risks of ineffective dosing or side-effects [13, 14]. An abundant source of 
genetic variation in humans is Single Nucleotide Polymorphism (SNP), which can lead to an 
alteration in the amino acid sequence of a protein [15]. Many polymorphisms have been 
documented in the CB2R, including three that change the amino acid sequence and occur 
highly frequently in the population, namely Q63R, Q66R and H316Y [16]. Of these, both Q63R 
and H316Y have been linked to various pathological conditions. Q63R is special, as it can be 
caused by a SNP (rs2501432) as well as a dinucleotide polymorphism (rs35761398). Q63R 
has been shown to be involved in schizophrenia and depression [17-19], alcoholism [20], 
eating disorders [21], early menarche in obesity [22] and various immune system related 
disorders [23-25], while H316Y has been associated with lowered bone mineral density [26]. 
We investigated personal differences in CB2R drug responses using a sensitive in 
vitro assay, i.e. a label-free cellular assay using the xCELLigence system, in combination with 
personal cell lines. With the xCELLigence, whole-cell responses are measured non-invasively 
allowing for the investigation of drug responses in an unbiased way, i.e. without selecting 
one signaling pathway or effect. The personal cell lines used in this study were 
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Lymphoblastoid Cell Lines (LCLs) obtained from participants of the Netherlands Twin Register 
(NTR), which are derived from B-lymphocytes and thus endogenously express the CB2R [27, 
28]. Using LCLs from individuals with different CB2R genotypes, we tested a number of ligands 
ranging from agonists and partial agonists to antagonists (Fig. 1), which have potential use in 
different pathological indications. Firstly, endogenous cannabinoids are fatty acid derivatives 
such as the eicosanoids 2-AG (2-Arachidonoylglycerol), the main endogenous ligand for CB2R, 
and AEA (anandamide) [29, 30]. Synthetic cannabinoids can be divided into classical and non-
classical, such as JWH133 and CP55940, respectively. Another large class of synthetic 
cannabinoid receptor ligands are the aminoalkylindoles, of which WIN55212-2 is the most 
studied agonist and AM630 is one of the most utilized CB2R antagonists [1, 31]. Several 
classes also contain partial agonists, such as aminoalkylindole GW405833 or BAY59-3074, 
which belongs to a separate chemical class. 
In this study, we show that the xCELLigence in combination with these personal cell lines 
can be successfully applied to investigate personal differences in drug response originating 
from, for instance, genetic variation in GPCRs. We furthermore demonstrate that while 
certain classes of CB2R ligands show individual differences, others deliver consistent effects  
 












4 2-AG  






1 JWH133  
(CB2R full agonist) 
 
2 CP55940  
(CB1R, CB2R 
 full agonist) 
3 BAY59-3074  
(CB2R partial agonist) 
 
5 AEA  
(CB1R, CB2R partial agonist;  




6 AM630  
(CB2R antagonist) 
7 WIN55212-2  
(CB1R, CB2R full agonist) 
8 GW405833  
(CB2R partial agonist) 
Figure 1. Chemical structures of CB2R ligands characterized in this manuscript. 
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independent of genotype. Thus while taking personal medical effects into account, it is still 
possible to identify potential ‘blockbuster’ drugs by using such phenotypic screening 
methods with personal cell lines. 
 
Material and methods 
Chemicals and reagents 
Fibronectin from bovine plasma, Roswell Park Memorial Institute (RPMI) 1640 cell culture 
medium (25 mM HEPES and NaHCO3) and Pertussis Toxin (PTX) were purchased from Sigma 
Aldrich (Zwijndrecht, NL). CB2R ligands AM630, GW405833 and CP55940 were purchased 
from Sigma Aldrich, BAY59-3074, WIN55212-2 mesylate, JWH133 and AEA from Tocris 
Bioscience (Bristol, UK) and 2-AG from Cayman Chemicals (Ann Arbor, MI, USA). All other 
chemicals and reagents were of analytical grade and obtained from commercial sources, 
unless stated otherwise. 
 
Lymphoblastoid cell line generation 
For all participants of the Netherlands Twin Register (NTR, VU, Amsterdam, NL) [27] included 
in this study, lymphoblastoid cell lines (LCLs) were generated in accordance with Chapter 3 
and 4 by the Rutgers University Cell and DNA Repository (Department of Genetics, 
Piscataway, NJ, USA). According to a standard transformation protocol [27], peripheral B-
lymphocytes were transformed with Epstein-Barr Virus (EBV) by treatment with filtered 
medium from a Marmoset cell line in the presence of phytohemagglutinin during the first 
week of culture [32-34]. EBV transformed lymphocytes were expanded by culture for 8–
12 weeks and subsequently cryopreserved. 
 
Cell culture 
LCLs from a family of four individuals, two parents (i.e. genetically unrelated; individual 2 and 
3) and their monozygotic twin children (i.e. genetically equal; individual 4 and 5), as well as 
one other unrelated individual (individual 1) were used for the experiments presented in this 
manuscript. Individual 2 and 3 have been part of previous Chapter 3, where we investigated 
effects of JWH133, AM630 as well as PTX inhibition of JWH133. These data were 
incorporated in the current Chapter to allow direct comparison to effects of other 
compounds, individuals and genotypes. The LCLs were cultured as described 
previously (Chapter 3). In short, LCLs were cultured as suspension cells in RPMI 1640 (25 mM 
HEPES and NaHCO3) supplemented with 15% Fetal calf serum (FCS), 50 mg/ml streptomycin, 
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50 IU/ml penicillin, at 37 °C and 5% CO2. Cells were subcultured twice a week at a ratio of 
1:5 on 10 cm ø plates and disposed after maximally 120 days. 
 
qPCR 
For qPCR analysis of receptor expression, RNA of three independent samples of each cell line 
was isolated by RNeasy Plus Mini (QIAGEN, Venlo, the Netherlands) and cDNA was randomly 
primed from 500 ng of total RNA using ReverstAid H Minus First Strand cDNA synthesis Kit 
(ThermoFisher, Breda, The Netherlands). The primer list is included in Table 1. Real-time 
qPCR was performed in triplicate for each sample using SYBR Green PCR (Applied Biosystems, 
part of ThermoFisher) on a 7500 Real-Time PCR System (Applied Biosystems). qPCR data 
were collected and analyzed using SDS2.3 software (Applied Biosystems). Household gene β-
actin was used as internal control to normalize receptor expression and compare between 
individuals. Relative mRNA amounts after correction for β-actin control mRNA were 
expressed using the 2 ΔΔCtmethod. 
 
Table 1. Primers for qPCR. 
 
Gene Forward  Reverse 
β-actin ATTGCCGACAGGATGCAGAA GCTGATCCACATCTGCTGGAA 
CNR1 GAGAAGATGACTGCGGGAGA GTTGTAAAATTCTGTAATGTTCACCTG 
CNR2 CATGCTGTGCCTCATCAACT GATCTCGGGGCTTCTTCTTT 
GPR55 GGAAAGTGGAAAAATACATGTGC CAGCGGGAAGAAGACCTTG 
GPR18 AACGGGGGAGAACAGTTACA AACTTTTTCTGCGCATGCTT 
 
Label-free whole-cell analysis (xCELLigence RTCA system) 
Instrumentation principle 
Cellular assays using the xCELLigence RTCA system [35] were performed in accordance with 
previously published protocols (Chapter 3) and [36]. The real-time cell analyzer (RTCA) uses 
a detection system based on electrical impedance to measure the whole-cell responses. Cell 
attachment to gold electrodes embedded on the bottom of the microelectronic E-plates 
changes the local ionic environment at the electrode-solution interface, which generates 
impedance. Relative changes in impedance (Z) are recorded in real-time and summarized in 
the Cell Index (CI). This CI, which is a dimensionless parameter, is defined at any given time 
point as (Zi  Z0) Ω/15 Ω. Zi is the impedance at each individual time point, whereas Z0 is 
defined as 0, as it represents the baseline impedance in the absence of cells measured prior 
to the start of the experiment. Impedance and the corresponding CI increase proportionally 
as cell adhere to the electrodes. The impedance profile directly reflects any changes in 
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degree of adhesion, cell number, viability and morphology [35, 37]. As such cellular 
parameters are also affected upon activation of GPCR signaling, this allows real-time 
monitoring of cellular signaling events [35]. 
 
General protocol 
xCELLigence assays on LCLs were performed as described previously in Chapter 3 with some 
minor modifications. Briefly, cells were seeded onto fibronectin-coated E-plates (10 μg/ml) 
at 50,000 cells/well, unless stated otherwise. Cell counts were performed with Trypan blue 
staining on a BioRad TC10 automated cell counter. E-plates were clicked in the xCELLigence 
recording station in an incubator (37 °C, 5% CO2). Impedance was measured overnight for 
18 h, after which the cells were stimulated with a cannabinoid receptor agonist or vehicle 
control in 5 μl, unless specified otherwise. As compound solubility required addition of 
dimethylsulfoxide (DMSO) or acetonitrile (ACN), the final concentration upon ligand or 
vehicle addition was kept at 0.25% DMSO or respectively 1% ACN for all wells and assays. 
For agonist screening purposes, cells were stimulated with agonist concentrations 
corresponding to approximately 100 × published pKI values for hCB2R [38, 39]. Agonist or 
partial agonist concentration-effect curves were generated by stimulating cells with 
increasing concentrations of the respective compound. For antagonist assays, cells were pre-
incubated for 30 min with 5 μl of vehicle control or the respective antagonist at increasing 
concentrations. Subsequently, cells were challenged with a submaximal agonist 
concentration of reference full agonist JWH133 equal to the agonist’s EC80 concentration 
(100 nM) or vehicle control. Of note, for partial agonist curves, fibronectin coating was 
increased (50 μg/ml) and cells were seeded at a higher density of 100,000 cells/well in order 
to achieve a sufficient window. To allow comparison, full agonist JWH133 was always tested 
alongside all partial agonists under equal conditions. For endocannabinoids, addition of the 
protease inhibitor phenylmethylsulfonyl fluoride (PMSF) to prevent possible degradation was 
tested, but as this did not change the responses or time-profile it was further omitted (data 
not shown). 
For studies on Gαi coupling, cells were seeded in assay medium containing 100 ng/ml 
Pertussis Toxin (PTX) or vehicle control, and stimulated after 18 h with agonist at 
corresponding EC80 concentration or vehicle control. 
 
Data analysis 
Data were analyzed as described previously in Chapter 3. Experimental data were captured 
and processed with RTCA Software 1.2 (ACEA, San Diego, CA, USA), in which ligand responses 
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were normalized to the last time point prior to compound addition resulting in the Δ Cell 
Index (Delta Cell Index or Δ CI). Data were exported to GraphPad Prism 6.0 (GraphPad 
Software Inc., San Diego, CA, USA) for further analysis. Correction for any ligand-independent 
effects was achieved by subtracting vehicle control as baseline. Peak responses were defined 
as highest Δ CI (Max Δ CI) observed within 30 min after compound addition. For negative 
impedance responses of 2-AG, Max-Min Δ CI within 1 h was used, which is the amplitude 
between the highest and lowest Δ CI. Peak values and experimental Δ CI traces were used 
for construction of bar graphs or concentration–effect curves by nonlinear regression and 
calculation of IC50 (half maximal inhibitory concentration), EC50 (half maximal effective 
concentration) and EC80 (80% maximal effective concentration) values. Emax (maximum 
effect) values of compounds were derived from maximal responses within the analyzed 
timeframe. Agonist and partial agonist curves of all individuals as well as the derived 
Emax values were normalized to Emax of CB2R-selective agonist JWH133 response on individual 
1, first as this individual also showed the highest response for all agonists with the exception 
of CP55940, and secondly as this was also the only case of a single individual per genotype 
(only minor homozygote for Q63R, Q63). 
All values obtained are means of at least three independent experiments performed in 
duplicate, unless stated otherwise. When comparing multiple means or multiple instances of 
two means, statistical significance was calculated using a two-way analysis of variance 
(ANOVA) with Fisher’s LSD test, for example comparison of multiple EC50 values or antagonist 
inhibition of multiple compounds. Comparison of multiple means to one value was 
performed with a two-way ANOVA with Dunnett’s post hoc test, for instance comparison of 
JWH133 Peak Δ CI response after pre-incubation with various antagonists. 
 
Processing of SNPs and genetic data 
As stipulated in the previous Chapter 4, SNP data for the NTR individuals included in this study 
were obtained from the Genomes of the Netherlands consortium 
(GoNL; http://www.nlgenome.nl/) of which the NTR is part of [40] and analyzed in-house 
using PLINK, an open-source whole genome association analysis toolset (PLINK 
v1.07, http://pngu.mgh.harvard.edu.ezproxy.leidenuniv.nl:2048/purcell/plink/) [41]. All SNPs 
within the boundaries of the CNR2 gene (Ensembl gene: ENSG00000188822) as defined by 
human genome overview GRCh37 were analyzed further. Based on GRCh37 and dbSNP 
information (http://www.ncbi.nlm.nih.gov.ezproxy.leidenuniv.nl:2048/SNP/), SNPs were 
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Data access 
The LCLs used in this study were kindly provided within the framework of this 
collaboration [27] and are part of the Netherlands Twin Register 
(NTR; http://www.tweelingenregister.org/en/), and part of the Center for Collaborative 
Genomic Studies on Mental Disorders (NIMH U24 MH068457-06). Data and biomaterials 
(such as cell lines) are available to qualified investigators, and may be accessed by following 




LCLs predominantly express CB2R 
To confirm the suitability of LCLs for studies of CB2R function alone, RNA expression levels of 
the four receptors belonging to the cannabinoid family were assessed by qPCR. These results 
showed that mRNA of all four cannabinoid receptors is present in LCLs to a similar degree, 
both compared between receptors and between individuals. There were however some 
differences. For instance, GPR18 was expressed higher in many individuals, though not 
statistically significant in all. The corresponding expression data are summarized in Fig. 2. We 
used the xCELLigence to further confirm the presence or absence of the different 
cannabinoid receptor subtypes, specifically CB2R, by testing selective and non-selective 




Figure 2. Cannabinoid receptor subtype mRNA expression in LCLs. Results of real-time qPCR (three 
independent samples measured in triplicate, mean ± SEM) show mRNA expression of four cannabinoid 
receptor genes per individual (A–E for individual 1–5, respectively). Significant differences in expression 
were determined with a two-way ANOVA Fisher’s LSD test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, 
**** = p < 0.0001. Expression differences within each individual are indicated in the figure. Expression 
differences between individuals were for CNR2: # = individual 1 with *to 3,5 and ***to 4. For GPR18 
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(individual 4). To ensure full receptor occupancy, we tested the compounds at 
concentrations corresponding to approximately 100× their Ki value at the respective 
receptor [38, 39]. The agonists tested included selective CB2R agonist JWH133 as well as non-
selective agonists CP55940 and WIN55212-2, which are both known to activate CB1R as well 
as CB2R. Neither of these three compounds are GPR18 agonists [42]. These agonists were 
also chosen as they represent three distinct chemical classes (Fig. 1). Ligand-induced changes 
in impedance were recorded in real-time, of which an example of resulting xCELLigence 
traces is shown in Fig. 3. A full real-time trace of a complete experiment is shown in Fig. 3A, 
and the corresponding vehicle-corrected compound responses are summarized in Fig. 3B. 
LCL seeding resulted in an initial quick increase in impedance related to cell adhesion, after 
which cells were allowed to proliferate and adjust for 18 h (Fig. 3A). Subsequent addition of 
the agonists induced an immediate increase of impedance to a peak which gradually 
decreased towards a plateau within 30 min (Fig. 3B). The responses of all three agonists were 
highly similar both in shape and height (Fig. 3B, C), indicating that the effects were mediated 
through the same receptor. AM251, which is known to be a GPR55 full agonist, partial GPR18 
agonist and CB1R antagonist [42], gave little to no response. This indicates that the actual 
protein expression of these receptors is absent or too low to contribute to any of the 
compound responses measured here. 
Furthermore, a CB2R-selective antagonist, aminoalkylindole AM630 was tested as well 
to confirm that agonist responses were indeed CB2R-mediated. While AM630 gave little to 
no response on its own, it was able to significantly block responses of all agonists at a 
concentration of 100 × Ki. The level of blockade did not differ significantly between agonists, 
irrespective of their receptor selectivity (Fig. 3D). Furthermore, comparable AM630 effects 
were observed on LCLs from other individuals. For instance, AM630 showed strong inhibition 
with a clear concentration-effect relationship that did not differ in potency between the five 
individuals tested and ranged from 6.76 ± 0.04 to 6.90 ± 0.05 (Fig. 3E). 
Finally, the effect of pertussis toxin (PTX) pre-treatment was investigated to confirm 
downstream signaling through Gαi. PTX caused a significant decrease in cellular responses of 
all three agonists for individual 4, which was to a similar degree as AM630 (Fig. 3F). In 
addition, inhibition of the agonist JWH133 by PTX was strong in all five individuals, with some 
differences in the level of remaining effects ranging from 7.6 ± 3.6% up to 35.5 ± 8.9% 
(Fig. 3G). Taken together, the agonist, antagonist and PTX effects confirm that CB2R signaling 


























































Figure 3. Cannabinoid receptor ligand screen to determine receptor subtype expression. Representative 
real-time traces of (A) a full experiment and (B) baseline-corrected responses in a screen of cannabinoid 
agonists and antagonist. (C) Corresponding maximal responses of the screen (Max Δ Cell Index or Max 
Δ CI), normalized to response to CB2R-selective agonist JWH133. Concentrations used were JWH133 
[1 μM], WIN55212-2 [10 μM], CP55940 [1 μM], AM630 [10 μM] and GPR55 agonist AM251 [10 μM]. 
All data shown were obtained with the LCLs of individual 4. (D) Inhibition of agonist effects by CB2R 
specific antagonist AM630 in LCLs of individual 4, normalized to peak Δ CI of untreated agonist 
response. LCLs were pre-incubated with AM630 [10 μM] 30 min before stimulation with agonist at 
EC80 (JWH133 [100 nM], WIN55212-2 [10 nM], CP55940 [10 nM]). Degree of inhibition did not differ 
significantly between agonists, as determined by two-way ANOVA with Fisher’s LSD post-hoc test. (E) 
Individual AM630 concentration-effect curve obtained from peak Δ CI of the baseline-corrected 
JWH133 response antagonized by increasing concentrations of AM630. Antagonist potency values 
were 6.76 ± 0.04, 6.77 ± 0.06, 6.85 ± 0.04, 6.90 ± 0.05 and 6.77 ± 0.04 for individuals 1–5, respectively. 
No statistically significant differences between individuals were observed as determined by two-way 
ANOVA with Fisher’s LSD post-hoc test. (F) Inhibition of agonist-induced Gαi downstream signaling by 
pretreatment with PTX in LCLs of individual 4, normalized to peak Δ CI of untreated agonist response. 
LCLs were seeded in presence or absence of PTX [100 ng/ml] and treated with agonist at EC80 after 18 h 
growth. Degree of inhibition did not differ significantly between agonists, as determined by two-way 
ANOVA with Fisher’s LSD post-hoc test. (G) Individual effect of Gαi inhibition by PTX on CB2R response 
to agonist JWH133. Response in the presence of PTX versus JWH133 alone was highly significantly 
reduced within each individual (****). Statistical differences between individuals were determined by 
two-way ANOVA with Fisher’s LSD post-hoc test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, 
**** = p < 0.0001. Data represent mean ± SEM obtained from three or four (B, C, E, G) independent 
experiments of performed in duplicate. For (D, F) data represent mean ± SD from two independent 
experiments performed in duplicate from individual 4, used as representative example here, while 
results on other individuals (2, 3, 5) were comparable (data not shown). #AM630 curves and PTX 
inhibition for individuals 2 and 3 had been previously established (Chapter 3) but were incorporated to 
allow direct comparison. 
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Individual differences in CB2R synthetic agonist responses in LCLs 
Following the confirmation that cellular effects were specifically CB2R-related, agonist 
concentration-effect curves were studied on LCLs from five individuals. Individuals 2 and 3 
are the parents of individuals 4 and 5, their monozygotic twin children, while individual 1 is 
unrelated. Examining their genotypes from DNA sequence data revealed that individual 1 is 
a homozygote for the minor allele (genotype GG thus Q63) for Q63R polymorphism 
(rs35761398), while individuals 2 and 3 are heterozygotes and individuals 4 and 5 are 
homozygotes for the major allele (genotype AA thus Q63) (see also Table 2 and Table 3), 
representing the most common genotype among the human population 
(http://www.ncbi.nlm.nih.gov.ezproxy.leidenuniv.nl:2048/SNP/). First, full concentration-
response curves were made for three compounds, typically referred to as full agonists, from 
different chemical classes, JWH133, WIN55212-2 and CP55940. Example xCELLigence traces 
of the JWH133 concentration-effect relationship are given in Fig. 4A. The resulting 
concentration-effect curves are summarized in Fig. 4B–D. Corresponding pEC50 values are 
summarized in Table 2 while Emax values are given in Table 3. 
As can be observed from the curves and pEC50 values (Table 2), potencies for the three 
agonists were similar for all individuals, with a notable exception for CP55940 on individual 
1 (Fig. 4D). For this individual, who is the only minor homozygote for Q63R, CP55940 showed 
a significantly increased EC50 value of approximately 10-fold. In contrast, the efficacy of all 
three agonists was much more divergent on the different cell lines. Interestingly, WIN55212-
2 which showed no significant differences in potency, showed a significant spread in efficacy 
corresponding to genotype (Fig. 4C, Table 3). WIN55212-2 had the lowest efficacy on the two 
heterozygous individuals 2 and 3, which in fact made it a partial agonist on these cell lines in 
comparison to JWH133 (Table 3). For the other three individuals, WIN55212-2 had a similar 
efficacy to JWH133, and both compounds had the highest efficacy on the LCLs of individual 
1. The two synthetic cannabinoids JWH133 and CP55940 showed differences in efficacy that 
did not correlate with genotype. However, compared to JWH133, CP55940 had a lower 
efficacy in all individuals making it a partial agonist, with exception of individual 4. Even on 
individual 1 CP55940 was a partial agonist, where for all other tested agonists the highest 
efficacy was found. Taken together, CP55940 was the only synthetic agonist with clear 
individual differences related to genotype (i.e. a decreased potency and efficacy in presence 
of Q63), while aminoalkylindole WIN55212-2 was the least prone to individual variation. 
 
Endogenous agonist induces different cellular response than synthetic agonists 
To test whether signaling caused by endogenous agonists also showed individual differences, 
 
 























Figure 4. Individual CB2R responses to full agonists of three distinct chemical classes. Cell lines were 
stimulated with different concentrations of full agonist JWH133, WIN55212-2 or CP55940 18 h after 
seeding (50,000 cells/well). (A) Representative graph of the baseline-corrected JWH133 response 
[1 μM – 100 pM] from individual 1. Concentration-effect curves of all individuals (1–5) of (B) classical 
cannabinoid JWH133 (C) aminoalkylindole WIN55212-2 and (D) non-classical cannabinoid CP55940 
obtained from Max Δ CI, normalized to Emax of CB2R-selective agonist JWH133 response on individual 
1. Data represent mean ± SEM obtained from three or four independent experiments performed in 
duplicate. #JWH133 curves for individuals 2 and 3 have been previously established (Chapter 3) but 
were incorporated to allow direct comparison. 
 
the response induced by the two main endogenous CB2R ligands, eicosanoid 2-AG and AEA, 
known as full and partial CB2R agonists respectively, were examined. In order to allow a 
sufficient response window to characterize partial agonist AEA, conditions were optimized 
by seeding more cells (100,000 cells/well) and coating with more fibronectin (50 μg/ml). Both 
full agonist JWH133 and 2-AG were also tested under these adjusted conditions, and the 
responses of JWH133 were used as reference compound to determine the level of partial 
agonism. Interestingly, the resulting real-time trace differed significantly from all synthetic 
agonists, as shown in Fig. 5A, B. While all synthetic agonists induced an immediate positive 
impedance change, which was characterized by a fast peak and subsequent decline to 
baseline in around 30 min, the endogenous 2-AG induced a negative change in impedance 
with a much slower onset after about 20 min, and a much more prolonged response that still  
 





















































Figure 5. Individual CB2R responses to endocannabinoids. Cell lines were stimulated with 2-AG (50,000 
cells/well, fibronectin 10 μg/ml) or AEA (100,000 cells/well, fibronectin 50 μg/ml) 18 h after seeding. 
Representative graphs of the baseline-corrected (A) 2-AG [10 μM – 3.16 nM] and (B) AEA [10 μM –
1 nM] response from individual 1. (C) Concentration-effect curves of 2-AG were obtained from Max-
Min Δ CI within 1 h of stimulation were normalized to Emax on individual 1. (D) Concentration-effect 
curves of AEA were obtained from Max Δ CI normalized to Emax of CB2R-selective agonist JWH133 
response on individual 1. Next, bar graphs show the inhibition of the 2-AG effect by (E) CB2R-selective 
antagonist AM630 [10 μM] and (F) Gαi-inhibitor PTX normalized to 2-AG’s effect at EC80 (3.16 μM). Data 
represent the means ± SEM from three or four (C, D) or means ± SD of two (E, F) independent 
experiments performed in duplicate. Significance of inhibitor effect versus 2-AG response only was 
determined with a two-way ANOVA Fisher’s LSD test * = p < 0.05, ** = p < 0.01. AM630 and PTX 
inhibition did not differ significantly between individuals 1 (Q63) and 4 (Q63) as determined using a 
two-way ANOVA with a Sidak post-hoc test. 
 
persisted after 180 min (Fig. 5A). Interestingly, AEA showed a similar time-profile as 2-AG 
with slower onset and prolonged response, but induced a positive impedance change like 
the synthetic cannabinoids, albeit with a different shape (Fig. 5B). Thus, endogenous agonist 
signaling through CB2R lead to vastly different cellular changes than any of the synthetic 
agonists. To confirm whether these effects were also CB2R -mediated, we showed that the 
2-AG response is blocked by CB2R -selective antagonist AM630, similar to the synthetic 
agonists (Fig. 5E). Moreover, downstream signaling via Gαi was inhibited by PTX pre-
treatment as well (Fig. 5F). Of note, AM630 blockade and PTX inhibition did not differ 
significantly between individuals, even with opposing Q63R genotype, as demonstrated in 
the LCLs of individuals 1 and 4 (Fig. 5E, F).  
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Furthermore, the concentration-effect relationship of 2-AG showed significant 
differences between the five individuals, which were within half a log-unit and therefore 
smaller than those observed for CP55940. However, these differences in potencies were not 
consistent with the presence of Q63R (Fig. 5C, Table 2). Interestingly, the differences in 
efficacy of 2-AG were consistent with genotype (Table 3), as the efficacy in heterozygous 
individuals 2 and 3 was significantly lower than for all other individuals. Any differences 
observed for AEA were not CB2R genotype-related (Fig. 5D, Table 2 and Table 3). In summary, 
especially signaling by the main CB2R endogenous ligand 2-AG lead to different cellular 
changes as opposed to synthetic agonists, and showed a genotype effect on efficacy as it 
appeared to be highest in the Q63 homozygote, but lowest in Q63R heterozygotes. 
 
Partial agonist responses differ between individuals 
Subsequently, two partial CB2R agonists were tested on all five individuals to investigate the 
presence of any differences in individual effects possibly linked to the Q63R genotype. Once 
again, conditions were adjusted to more cells (100,000 cells/well) and fibronectin (50 μg/ml) 
to allow a sufficient response window for these partial agonists. JWH133 was also tested 
under these adjusted conditions as reference compound to determine the level of partial 
agonism. The two partial agonists tested were aminoalkylindole GW405833 and BAY59-
3074, which belongs to a separate chemical class (Fig. 1). In all individuals, both agonists 
induced positive impedance responses like the synthetic full agonists, and demonstrated 
clear partial agonistic behavior in comparison to JWH133, irrespective of genotype 
(Fig. 6A and B). The concentration-effect curves are represented in Fig. 6C and D, while the 
resulting pEC50 and Emax values are summarized in Tables 2 and 3, respectively. GW405833 
showed significant differences in potency which were within half a log-unit and were not 
entirely consistent with genotype. However, the individual potencies for BAY59-3074 
showed a larger spread close to a full log-unit. The lowest potency was observed on individual 
1, though this statistical difference was not genotype consistent. In terms of efficacy, BAY59-
3074 had a higher efficacy than GW405833 for all individuals. Interestingly, the Emax value of 
GW405833 on the LCLs of individual 1 (i.e. presence of Q63) was significantly higher than 
that on all other individuals (Table 3), which was also observed for BAY59-3074. Taken 
together, the partial agonists showed personal differences in response, which (in part) 
appeared to be compound specific and less pronounced for the aminoalkylindole 
GW405833. 
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Figure 6. Individual CB2R responses from two partial agonists. Cell lines were stimulated with agonist 
18 h after seeding (100,000 cells/well, fibronectin 50 μg/ml). Representative graph of the baseline-
corrected response to (A) GW405833 and (B) BAY59-3074 [1 μM – 100 pM] from individual 1. Resulting 
concentration-effect curves of (C) GW405833 and (D) BAY59-3074 obtained from peak Δ CI normalized 
to JWH133 [1 μM] effect on individual 1. Data represent mean ± SEM obtained from three independent 
experiments performed in duplicate. 
 
Discussion 
CB2R is considered a potential therapeutic target for immune system related disorders such 
as multiple sclerosis and allergy [43], neuropathic pain [44], cancer and osteoporosis [1, 43]. 
As genetic differences between individuals can induce large variations in drug response, we 
studied such personal effects on a variety of CB2R ligands with a panel of personal cell lines, 
the LCLs, from individuals with varying CB2R genotypes. These included genetically unrelated 
individuals as well as monozygotic twins, who are deemed genetically identical. Hence, 
confirming the comparability of their responses is a standard way to control for genotype-
unrelated effects [27, 45]. The individuals in this study represent all possible genotypes for 
the polymorphism Q63R. Even though this polymorphism is present in roughly half of the 
population and thus is extremely common, it has also been associated with various 
pathological disorders [17-19, 22-25]. This makes characterizing the impact of this 
polymorphism on drug responses an important issue for CB2R drug discovery. 
We characterized the genotype-effect on responses of several individuals by applying 
label-free cellular assay technology, namely the impedance-based xCELLigence apparatus. 
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Such technologies allow sensitive non-invasive assays that enable the investigation of GPCRs 
in endogenous cell systems, including LCLs for which we previously established an optimized 
protocol (Chapter 3). The combination of such a non-invasive assay with a personal cell line 
offers many advantages over traditional GPCR methodologies. In general, potencies of all 
CB2R compounds tested in our research on the LCLs were within one log-unit range of 
previously published values (Table 2) [38, 39]. Notable exceptions were 2-AG and 
GW405833, which differed from published pEC50 values by up to 17-fold (pEC50 of 6.91 by 
Gonsiorek et al. [46]) and 43-fold (pEC50 of 9.19 ± 0.09 by Valenzano et al. [47]), respectively. 
This discrepancy is most likely due to differences in cell lines and assay type. Valenzano et al. 
[47] used a typical endpoint cAMP accumulation assay in combination with a CHO-K1 system 
overexpressing recombinant CB2R, while LCLs represent a more physiological cell system with 
endogenous receptor expression. Furthermore, rather than just being a human cell line with 
endogenous expression, LCLs are even one step closer to the physiological situation as they 
are directly derived from individual persons. The use of a label-free whole-cell assay is 
preferable over typical endpoint assays to minimize bias [48], especially when investigating 
a GPCR with functional selectivity such as the CB2R, in which multiple pathways can be 
activated to a different extent [49, 50].Before starting CB2R functional investigations in LCLs, 
we studied expression levels and screened functional responses to confirm receptor subtype 
presence. All cannabinoid receptors are expressed in LCLs at mRNA level (Fig. 2) with some 
differences between individuals. However, these did not correspond to the general 
differences we observed in compound potency or efficacy (Table 2 and Table 3). For example 
for CB2R, mRNA expression differed for individual 1, especially as opposed to individual 4. 
However, both individuals were among the highest responders on average for CB2R 
compounds (Table 3). Furthermore, most individuals showed high GPR18 mRNA levels, but 
AM251 which targets GPR18 and GPR55 but not CB2R, showed no response (Fig. 3) [46]. This 
indicates that functional GPR18 levels were in fact not high, if at all present in these LCLs, 
which shows that mRNA expression levels do not necessarily correlate with functional 
protein expression on the cellular membrane, a feature well appreciated in literature [51, 
52]. Taken together, the data shown in Fig. 3 prove that CB2R is in fact the major receptor 
responsible for compound responses, which is in accordance with previous literature that 
states CB2R is the highest expressed receptor in LCLs [28]. Of note, any of the full agonists 
tested in this manuscript such as WIN5512-2, JWH133, CP55940 and 2-AG are not known as 
agonists of GPR18 [42]. 
After confirming that CB2R is well expressed in LCLs and that CB2R signaling can be 
measured sensitively and specifically in LCLs (Fig. 2 and Fig. 3), we characterized responses  
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of five individuals to various CB2R ligand types and classes (Fig. 1) which revealed that certain 
chemical classes of compounds were more sensitive to genotype than others (Fig. 4, Fig. 
5 and Fig. 6, Table 2 and Table 3). All tested aminoalkylindole compounds as well as the 
classical cannabinoid JWH133 showed the least differences between individuals, in 
comparison to compounds of other chemical classes. The notion that aminoalkylindole 
compounds showed the least genotype-related effects was strengthened by testing three 
pharmacological types of ligands of this chemical class. Similar to the aminoalkylindole 
agonist, no individual differences were observed for the CB2R -selective antagonist AM630 
(Fig. 3D). Even a partial agonist of this class (GW405833) was less prone to individual 
differences than a partial agonist of another class. It has been suggested that partial agonists 
are more sensitive to system-related differences in receptor function, for instance receptor 
expression or downstream coupling, than full agonists or antagonists [53]. Consequently, 
they may be more prone to genotype-related effects. In fact, we have demonstrated in a 
previous Chapter that a partial agonist on the adenosine A2A receptor showed a clear 
genotype-related difference in LCLs, while full agonists did not (Chapter 4). The two synthetic 
partial agonists for the CB2R that we tested here exhibited similar sensitivity (Fig. 6, Table 
2 and Table 3). In efficacy, they showed the clearest genotype-related effect as it was only 
significantly elevated for the Q63 individual, as opposed to the full agonists where more 
individuals differed. 
Overall, CP55940 showed the most pronounced personal effects with highly reduced 
potency and efficacy in presence of Q63, while all other agonists and partial agonists showed 
the highest efficacy in presence of this genotype. Interestingly, Q63R has been reported to 
cause diminished WIN55212-2 efficacy in HEK293h CB2R cells while CP55940 was not 
affected [54]. Our results contradict these findings, which may be due to the difference in 
model systems used. HEK293 cells are recombinant and receptor-overexpressing, whereas 
LCLs are personal cell lines with endogenous levels of receptor expression, and therefore 
may represent a more physiologically relevant system. 
When investigating genotype effects on endogenous cannabinoid response, we noted 
that 2-AG showed vastly different cellular effects than any other ligand tested here, despite 
being clearly CB2R -mediated (Fig. 5). Another endocannabinoid, AEA, showed a similarly 
changed time-profile as 2-AG, even though the direction of impedance change was more 
similar to synthetic cannabinoids. These differences in cellular effects between endogenous 
and synthetic cannabinoids may originate from downstream signaling differences resulting 
in a different cellular response as measured by xCELLigence. For instance, Shoemaker et 
al. [49] found that 2-AG was a more potent activator of MAPK whereas synthetic ligands 
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more potently inhibited adenylyl cyclase activity. Moreover, our experiments with 2-AG do 
not suggest that Q63R influences its responses, which contrasts with previous reports of 
Carrasquer et al. [54] and Ishiguro et al. [17], where recombinant overexpressing cell 
systems, HEK293 and CHO cells, were used. However, our findings are confirmed by Sipe et 
al. [8] who used a more physiological setting of T-lymphocytes, as is the case in this study. 
Taken all of the above together, this once more highlights the importance of using primary 
or derived (i.e. endogenous immortalized) cell systems that offer more physiological 
relevance versus recombinant systems. 
There are several mechanisms by which a polymorphism may influence receptor 
signaling. Q63R in the CB2R results from a dinucleotide conversion of AA to GG that 
exchanges a glutamine for an arginine at position 63 in the intracellular loop 1, and as such 
it is not in proximity of the putative CB2R ligand binding site [54, 55]. Therefore, its position 
suggests that Q63R does not directly influence ligand binding. Rather, its effects on drug 
responses may originate from differences in downstream signaling [17, 54]. CB2R has been 
shown to signal through multiple pathways such as cAMP, β-arrestin, pERK and GIRK, to 
which various agonists may be differently biased [30, 56, 57]. Moreover, it has been well 
established that agonists can activate the various G protein-dependent and –independent 
pathways modulated by CB2R to a different extent [49, 50]. In our LCLs, all CB2R agonists 
signaled strongly through Gαi coupling as was demonstrated by potent inhibition through PTX 
(Fig. 3 and Fig. 5), which on some instances showed differences in the levels of remaining 
response (Fig. 3D). While Gαi signaling therefore clearly represents the predominant 
signaling pathway for CB2R in all individuals, the varying remaining responses could indicate 
individual differences in coupling to other signaling pathways. Hence, Q63R related 
differences observed between CP55940 and other agonists may be related to their specific 
bias. Q63R could potentially affect coupling to one signaling pathway more than others, an 
effect which is then only noted for agonists that preferably and potently activate that 
pathway, in this case CP55940. Alternatively, Q63R could affect the bias of a particular ligand 
as CP55940 towards different signaling pathways. 
Another interesting genotype-related effect was that in overall efficacy  
(Table 3), Q63 homozygous individual 1 generally ranked highest. Q63R heterozygotes (ind. 
2 and 3) appeared to have the lowest efficacy for CB2R agonists, even compared 
to Q63 homozygotes (ind. 4 and 5), rather than an intermediate or mixed cellular effect. This 
was most pronounced for WIN55212-2 and 2-AG (Table 3). The effect could arise from, for 
instance, a difference in signaling pathway bias between the two receptor forms. In a 
heterozygote, where both receptor forms are present that each have different efficiencies 
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in pathway-coupling, the overall signaling and cellular effect may be lower as opposed to 
either receptor form as homozygote, that works synergistically. 
In conclusion, our results demonstrate that aminoalkylindole compounds exhibited the 
least sensitivity to genotypes while non-classical cannabinoid CP55940 showed the 
most. Q63 genotype influenced CB2R ligand effects leading to higher efficacy of agonists and 
especially partial agonists, but decreased potency and efficacy of the non-classical 
cannabinoid CP55940, which was also the most pronounced ‘personal’ effect measured here. 
The LCLs, as personal cell lines, in combination with the sensitive label-free impedance-based 
technology have the potential to represent a more physiologically relevant model system to 
investigate individual differences in drug response. Their combination provided novel 
insights into the impact of CB2R polymorphism on drug response, which demonstrates on the 
one hand the ability of this phenotypic screening method to identify ‘blockbuster’ drug 
candidates that are less prone to individual differences. On the other hand, this approach 
may advance precision medicine and stratify patient groups. Altogether, this will help in 
reducing attrition rates of drugs in clinical trials. 
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Abstract 
The glucose-dependent insulinotropic polypeptide receptor (GIPR) is a G protein-coupled 
receptor that plays an important role in whole-body metabolism. One missense Single 
Nucleotide Polymorphism (SNP) rs1800437 coding for amino acid change E354Q in the GIPR, 
has been associated with several diseases including diabetes and the risk of bone fractures. 
We investigated the functional effects of this SNP in personal cell lines from a panel of 
individuals with different genotypes for the polymorphism. Genotype effects were measured 
using a sensitive in vitro assay, i.e. a label-free cell morphology-based assay (xCELLigence), in 
combination with personal lymphoblastoid cell lines (LCLs) derived from Netherlands Twin 
Register participants. Responses to the endogenous agonist GIP showed enhanced potency 
in Q354 homozygous individuals, while heterozygotes showed mixed effects. A mutational 
study of the E354 residue in recombinant HEK293 cells expressing GIPR did not show 
differences in potency, but revealed a reduced duration of effect for Q354, which was not 
observed in LCLs. Taken together, this study provides more insight into E354Q-related 
physiological changes as they occur in the human individual, and thereby contributes to 
precision medicine for GIPR-related pathologies.  
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Introduction 
The glucose-dependent insulinotropic polypeptide receptor (GIPR) is a class B G protein-
coupled receptor (GPCR) which is part of the glucagon receptor family [1]. It plays an 
important role in whole-body metabolism, such as glucose homeostasis and particularly 
insulin secretion, lipid uptake and bone density [2-4]. In the emerging era of precision 
medicine, it is becoming apparent that genetic differences between individuals can affect 
both drug action and susceptibility to disease. Several of such examples for GPCR 
polymorphisms already exist [5-8]. For the GIPR, previous research has linked Single 
Nucleotide Polymorphisms (SNPs) to various pathological conditions including obesity and 
diabetes [9-12]. One SNP of particular interest is rs1800437, which is a missense SNP that 
changes a glutamic acid to a glutamine at amino acid 354 of the receptor (E354Q). This E354Q 
is the only frequent one of 227 known GIPR missense variants that occurs in more than 1% 
of the population, namely with a Minor Allele Frequency (MAF) of 16% [13, 14]. Interestingly, 
several studies have associated this SNP with insulin resistance, type II diabetes, 
cardiovascular disease and the risk of bone fractures [3, 12, 15, 16]. Furthermore, a number 
of functional studies have indicated roles for this polymorphism in for instance receptor 
(in)activation [17] and desensitization [3].  
This polymorphism could therefore play an important role in disease susceptibility of, as 
well as influence drug treatment. Mapping and understanding the effects of this 
polymorphism not only in the overall population, but in the individual patient is therefore 
paramount [18]. However, the E354Q polymorphism has so far been the subject of either 
cohort or candidate gene studies, or of functional studies in which its effect was analyzed in 
mouse cell lines or recombinant cell systems with artificially introduced mutations [3, 12, 15, 
16, 19]. Despite their merits such cellular systems are further away from the physiological 
condition in humans. To better understand the influence of polymorphisms on receptor 
response in an individual, an ideal set-up would therefore be to use patient-derived material 
as a model system. 
One example of such are lymphoblastoid cell lines (LCLs), which are commonly used to 
store a person's genetic material, as is done by many large scale genetic consortia such as 
the International HapMap and 1000 genomes projects [20-24]. We recently published a 
methodology that allows measurement of GPCR function in such LCLs, with which we were 
able to detect the effect of polymorphisms in two other GPCRs, the adenosine A2A receptor 
and cannabinoid receptor 2 (Chapter 4, 5). Responses were measured using the xCELLigence,  
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a newly developed, highly sensitive label-free cellular assay technology. This assay measures 
changes in cell morphology in real-time as opposed to techniques traditionally employed in 
GPCR research such as ligand binding or second messenger accumulation assays, which use 
static, one-molecule-detection [25-28]. 
In the current study we have applied this real-time morphological assay to assess effects 
of the GIPR polymorphism E354Q in LCLs. We characterized GIPR responses in a selection of 
individuals from the Netherlands Twin Register (NTR) [29].  Subsequently, we performed an 
E354 mutational study in HEK293 cells using the same cellular assay technology as a 
functional read-out to provide a direct comparison to the effects observed in the LCLs. 
 
Material and methods 
Chemicals and reagents 
Fibronectin from bovine plasma, ATP, unsupplemented Roswell Park Memorial Institute 
(RPMI) 1640 cell culture medium (25 mM HEPES and NaHCO3) and Dulbecco’s Modified 
Eagles Medium – high glucose (DMEM) were purchased from Sigma Aldrich (Zwijndrecht, 
The Netherlands). Fetal calf serum (FCS) was obtained from Thermo Fisher Scientific (Breda, 
The Netherlands). GIP was purchased from Tebu-Bio (Heerhugowaard, The Netherlands), 
while (Pro3)GIP was obtained from American Peptide Company Inc (Sunnyvale, CA, USA). All 
other chemicals and reagents were of analytical grade and obtained from commercial 
sources, unless stated otherwise. 
 
Lymphoblastoid cell line generation 
For all 78 individuals of the Netherlands Twin Register (NTR, VU, Amsterdam, NL) [29] 
included in this study, lymphoblastoid cell lines (LCLs) were generated in accordance with 
previous Chapters (eg. Chapter 3) by the Rutgers Institute (Department of Genetics, 
Piscataway, NJ, USA). Briefly, peripheral B-lymphocytes were transformed with Epstein-Barr 
Virus (EBV) using a standard transformation protocol [29] and subsequently cryopreserved.  
 
Cell culture 
LCLs were cultured as suspension cells in RPMI 1640 (25 mM HEPES and NaHCO3) 
supplemented with 15% FCS, 50 mg/mL streptomycin, 50 IU/mL penicillin, at 37°C in a 
humidified 5% CO2 incubator, as described previously (Chapter 3). Cells were subcultured 
twice a week at a ratio of 1:5 on 10 cm ø plates and disposed after maximally 120 days. 
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10% FCS, 50 mg/mL streptomycin and 50 IU/mL penicillin at 37°C in a humidified 7% CO2 
incubator. Cells were subcultured twice a week at a ratio of 1:10 to 1:30 on 10 cm ø plates. 
 
DNA constructs and mutant generation 
cDNA encoding the human GIPR (ORF: NM_000164) with an N-terminal FLAG-tag cloned into 
the pcDNA3.1(+) vector was purchased from GenScript (Hong Kong, China). Primers to 
generate the E354Q mutant were designed using the online QuickChange Primer Design tool 
[30] and produced by Eurogentec (Maastricht, The Netherlands). Primer sequences were 
forward: GCTGGGTGTCCACCAGGTGGTGTTTGC, and reverse: 
GCAAACACCACCTGGTGGACACCCAGC (5’–3’). The GIPR mutant was generated based on the 
QuikChange site-directed mutagenesis method (Agilent Technologies, La Jolla, CA, USA) [31] 
using pfu polymerase (Promega, Madison, WI, USA) in an 18-cycle mutagenic PCR. 
Subsequently, template DNA was digested by DpnI (New England Biolabs, Ipswich, MA, USA) 
treatment. PCR products were transformed into chemically competent DH5α cells (Life 
Technologies, Carlsbad, CA, USA) and purified using a standard Qiagen Miniprep kit (QIAGEN 
Benelux B.V., Venlo, The Netherlands). DNA concentration and purity were determined by 
NanoDrop 2000 (Thermo Fisher Scientific) and mutations were confirmed through double 
stranded DNA sequencing by the Leiden Genome Technology Center (LUMC, Leiden, The 
Netherlands). 
 
HEK293 transfection  
hGIPR constructs were transiently transfected into HEK293 cells. HEK293 cells were cultured 
in supplemented DMEM as stipulated above as a monolayer on 10-cm ø culture plates to 80–
90% confluency. Transfections were performed using Lipofectamine 2000 (Thermo Fisher 
Scientific) and 8 µg of plasmid per 10-cm ø culture plate, in accordance with the 
manufacturer’s instructions. As per these instructions, both plasmid and lipofectamine were 
diluted in unsupplemented OptiMEM (Thermo Fisher Scientific), subsequently mixed and 
incubated for 20 min at room temperature. Medium of HEK293 cells was exchanged to 
unsupplemented OptiMEM, after which the plasmid-lipofectamine mixture was deposited 
on the cells. After 6 hours of incubation with this mixture, cells were used for experiments.  
 
Label-free whole-cell analysis (xCELLigence RTCA system) 
Instrumentation principle 
Cellular assays using the xCELLigence RTCA system [25] were performed in accordance with  
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previously published protocols (Chapter 3, 4) [32]. The detection principle of this real-time 
cell analyzer (RTCA) is based on electrical impedance. Gold electrodes are embedded on the 
bottom of the microelectronic E-plates. When cells attach to these, they alter the local ionic 
environment at the electrode-solution interface, thereby generating impedance. Relative 
changes in impedance (Z) are recorded in real-time and summarized in the dimensionless 
parameter Cell Index (CI). The CI at any given time point is defined as (Zi-Z0) Ω /15 Ω, where 
Zi is the impedance at each individual time point. Z0 is defined as 0, as it represents the 
baseline impedance in the absence of cells. The resulting time-resolved impedance profile 
directly reflects any changes in degree of adhesion, cell number, viability and morphology, 
which are also the typical cellular parameters that are affected by GPCR signaling [25, 26].  
 
General protocol 
Prior to any experiment, background impedance (Z0) was measured after adding 45 μL, or in 
case of antagonist experiments 40 μL, of the respective culture media to the E-plate wells. 
Subsequently, cells were harvested, centrifuged at 200g for 5min and resuspended in their 
corresponding fresh medium. xCELLigence assays on LCLs were performed as described 
previously (Chapter 3) with some minor modifications. Briefly, LCLs were harvested  and 
seeded onto fibronectin-coated glass-bottom E-plates (50 µg/ml) at 100,000 cells/well. 
Transiently transfected HEK293 cells were harvested 4-6 hours following transfection by 
trypsinization, spun down once and seeded onto uncoated PET E-plates at 80,000 cells/well. 
Cell counts were performed with Trypan blue staining on a BioRad TC10 automated cell 
counter. After cell seeding, E-plates were clicked in the xCELLigence recording station in an 
incubator (37°C, 5% CO2). Impedance was measured overnight for 18 hours, after which the 
cells were stimulated with a GPCR agonist or vehicle control in (5 µl), unless specified 
otherwise. For GIP concentration-response curves in LCLs, ATP [100 µM] was taken along to 
provide a receptor-independent reference of response height. As GIP and (Pro3)GIP were 
stored as aliquots in Phosphate Buffered Saline (PBS), as per vendor instructions, PBS was 
used as vehicle control. The final PBS concentration upon ligand or vehicle addition was kept 
constant at 0.5 % PBS for all wells and assays. Agonist concentration-response curves were 
generated by stimulating cells with increasing concentrations of GIP. For the (Pro3)GIP assay, 
cells were pre-incubated for 30 minutes with 5 µl of vehicle control or a high concentration 
of (Pro3)GIP [1 µM]. Subsequently, cells were challenged with vehicle control or a submaximal 
agonist concentration of GIP corresponding to its EC80 value (concentration causing 80% of 
maximal effect) of E354 and Q354, respectively (31.6 nM and 3.16 nM). All compound 
responses were recorded for at least 3 hours following agonist or vehicle addition. 
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ELISA 
HEK293 cells were transiently transfected with the hGIPR E354, Q354 variant or mock as 
described above. Flat-bottom sterile 96 wells plates were coated with 50 µl poly-D-lysine (20 
mg/L) (Sigma Aldrich) for 10 minutes. Cells were harvested, counted and seeded at 80,000 
cells/well as described under the xCELLigence protocol, and medium was exchanged to 
normal culture medium. Cells were grown overnight at 37°C and 7% CO2. Twenty-four hours 
post transfection, cells were washed once with PBS, fixed with 3,7% formaldehyde for 10 
minutes and incubated in Tris-buffered saline (TBS) with 2% bovine serum albumin (BSA) for 
30 minutes at room temperature. Cells were then incubated with 1:1000 anti-Q1-FLAG 
monoclonal antibody (Sigma Aldrich) and 1:1250 goat-anti-mouse HRP conjugated IgG 
antibody (Thermo Fisher Scientific) subsequently. Immunoreactivity was visualized by 
addition of 3,3’,5,5’-tetramethylbenzidine (Sigma Aldrich). After 5 minutes the reaction was 
stopped by addition of 0.2M H2SO4. Absorbance was measured at 450 nm using a Victor plate 
reader (Perkin Elmer, Groningen, The Netherlands).  
 
qPCR 
qPCR on LCLs was performed as described previously (Chapter 5). Briefly, for each cell line 
RNA of three independent samples was isolated with RNeasy Plus Mini (QIAGEN, Venlo, the 
Netherlands). cDNA was randomly primed from 500 ng of total RNA using ReverstAid H Minus 
First Strand cDNA synthesis Kit (ThermoFisher, Breda, The Netherlands). The primers for GIPR 
were CGTCTGCTGGGACTATGCTG forward and TCTCCAAAGTCCCCATTGGC reverse. 
Household gene β-actin was used as internal control to enable comparison between 
individuals, and the primers for this were ATTGCCGACAGGATGCAGAA forward and 
GCTGATCCACATCTGCTGGAA reverse. Real-time qPCR was performed in triplicate for each 
sample using SYBR Green PCR (Applied Biosystems, part of ThermoFisher) on a 7500 Real-
Time PCR System (Applied Biosystems). qPCR data were collected and analyzed using SDS2.3 
software (Applied Biosystems). The 2 ΔΔCt method was used to express relative mRNA 




xCELLigence data were analyzed as described previously (Chapter 3). Experimental data were 
captured with RTCA Software 1.2 (ACEA, San Diego, CA, USA). Ligand responses were 
normalized to the last time point prior to compound addition resulting in a Normalized Cell 
Index (NCI). For HEK293, this was done directly in the RTCA program, while for the LCLs the 
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NCI was calculated in GraphPad Prism as the small (and sometimes negative) growth curves 
of LCLs hindered this calculation in the RTCA program. The NCI corrects for non-receptor-
related variations that could for instance arise from a slight difference in seeding density, 
individual differences in proliferation rate and well-plate ‘edge effects’. Data were exported 
to GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA) for further analysis. The 
lowest concentration of GIP was subtracted as baseline to correct for ligand-independent 
effects. Responses after compound addition were analyzed using AUC within 30 minutes for 
GIP and 60 minutes for ATP in LCLs, and 4 hours for GIP in HEK293hGIPR, due to the 
differences in duration of response. For analysis of the duration of response in HEK293hGIPR, 
responses were defined as highest NCI (Max NCI) observed at specific time points after 
compound addition. Peak values, AUC and experimental ΔCI or NCI traces were used for 
construction of bar graphs or concentration–effect curves by nonlinear regression and 
calculation of EC50 (concentration causing half maximal effect) and EC80 (concentration 
causing 80% of maximal effect) values. Emax (maximum effect) values of compounds were 
derived from maximal responses within the analyzed timeframe. All Emax values were 
normalized to the E354 variant (individual E4 for LCLs).  
 
Statistics 
All values obtained are means of at least three independent experiments performed in 
duplicate on the same cell line, unless stated otherwise. When comparing multiple means or 
multiple instances of two means, statistical significance was calculated using a one-way 
analysis of variance (ANOVA) with Fisher’s least significant difference (LSD) test, for example 
comparison of multiple pEC50 values for LCLs or percentage of response at certain time points 
for HEK293 cells. Comparison of two values was done with Student’s t-test, for instance pEC50 
values of HEK293 cells. 
 
Processing of SNPs and genetic data 
As described in previous Chapter 4, the SNP data of the individuals included in the current 
study were obtained from the Genomes of the Netherlands consortium (GoNL, 
http://www.nlgenome.nl/) [33], in which the NTR takes part. The SNP data were analyzed in-
house using PLINK, an open-source whole genome association analysis toolset [34, 35]. For 
the current study, SNPs within the boundaries of the GIPR gene (Ensembl gene: 
ENSG00000010310) as defined by the human genome overview GRCh37 
(http://grch37.ensembl.org/index.html) were extracted. Subsequently, SNPs were annotated 
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according to position (e.g. coding sequence, exon) and SNP type (e.g. missense) based on 
GRCh37 and dbSNP (http://www.ncbi.nlm.nih.gov/SNP/).  
 
Results 
Genotypes and NTR study 
To study the effect of GIPR polymorphisms using LCLs of the NTR, we first determined the 
GIPR genotypes in the NTR population. This constituted a selection of in total related and 
unrelated 78 individuals of the NTR for whom both genetic information and corresponding 
LCLs were available. Table 1 provides an overview of the SNPs present in the GIPR gene of 
this NTR population. We found a total of 23 SNPs with varying location, type and frequency. 
None were rare as all occurred in more than 10% of this NTR population, but two SNPs were 
extremely frequent as they were found in more than 40% of the NTR individuals (i.e. SNPs 
no. 22 and 23, rs9749225 and rs2238689, respectively). Of note, frequencies of most SNPs 
within this population were similar to the global MAF, with some exceptions that were found 
more frequently (e.g. SNP 22, rs9749225) or less frequently (e.g. SNP no. 14, rs35568293). 
Most commonly, SNPs were located within introns, with the exception of three. Two of those 
were located in other non-coding regions, namely the 3’-UTR. Finally, there was only one 
missense variant, rs1800437, which is in fact the polymorphism causing E354Q by changing 
a codon from GAG to CAG. Approximately 21% of the NTR individuals carried the minor allele 
of this SNP (i.e. CAG), which therefore provided sufficient individuals to perform a study on 
the effect of this polymorphism.  
The preference for any genetic study is to include multiple unrelated individuals of each 
genotype, and if possible of both genders. Here, we also used the unique family set-up of the 
NTR for selecting individuals for inclusion into our study. The individuals from NTR included 
in GoNL comprised of  trio’s, with two genetically unrelated individuals, the parents, and an 
offspring. In a small number of families, two children, which were monozygotic or dizygotic 
twins, were included. As summarized in Table 2, we selected individuals to include: 1) one 
family with two monozygotic twins (family 1), whose comparability of response is a basic 
requirement to allow any conclusions from the experiments presented here in association 
with genotype; 2) one family in which the parents were opposing homozygotes and their 
offspring thus a heterozygote (family 2), where this special genetic relationship allowed 
further conclusions on genotype-related effects, and 3) three additional individuals to be 
able to study several unrelated individuals of each genotype. Of note, the maximum number 
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Table 2. Selected set of NTR individuals studied for the E354Q GIPR polymorphism. 
Identity E354Q 
Group Individual Gender Code Genotype Amino acid 
Family 1 
Father 1 Male E1 GG E 
Mother 1 Female E2 GG E 
Twin 1A Female E3 GG E 
Twin 1B Female E4 GG E 
Family 2 
Father 2 Male E5 GG E 
Mother 2 Female Q1 CC Q 
Twin 2A Male EQ1 CG E/Q 
Additional  
Additional 1 Female EQ2 CG E/Q 
Additional 2 Female EQ3 CG E/Q 
Additional 3 Male Q2 CC Q 
 
of Q354 individuals was investigated, as only two of such were available in the NTR 
population. Moreover, both genders were represented in each group. Thus in total, we 
studied responses of LCLs of 10 individuals (Table 2). 
 
GIPR signaling can be measured sensitively in LCLs using xCELLigence 
To confirm the suitability of LCLs for studying GIPR effects, we first performed an initial qPCR 
as well as a response screen on the xCELLigence. The qPCR on a set of E354 and Q354 
homozygous individuals revealed that mRNA of the GIPR was present in all individuals  
(Fig. 1F). mRNA levels were not consequently linked to genotype as significant differences 
were observed between individuals both with the same or different genotypes, and even 
between monozygotic twins E3 and E4.  
Subsequently, we assessed GIPR responses on the xCELLigence in comparison with 
responses to ATP. The latter was used as a reference ligand as it is known to target GPCRs 
that are highly expressed and activation of these leads to cellular responses in LCLs  
(Chapter 3) [36, 37]. In Fig. 1A an exemplary experiment on the LCLs is presented, where 
cellular growth and responses were recorded in real-time. LCL seeding resulted in an initial 
increase in impedance related to cell adhesion, growth and division. Subsequent addition of 
a GPCR agonist such as ATP or GIP induced an immediate increase of impedance to a peak 
level of similar height, which gradually decreased towards a plateau. However, the duration  
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Figure 1. Characterization of GIPR response in LCLs with varying E354Q genotypes. (A) Representative 
example of a full real-time impedance plot and baseline-corrected responses of LCLs from one 
individual (E3) to GIP [1 µM] and ATP [100 µM]. Representative examples of baseline-corrected real-
time impedance plot for one E354 (E3, B) and one Q354 (Q2, C) homozygous individual as a function of 
different concentrations of the endogenous agonist GIP ranging from 1 µM to 10 pM. (D) GIP 
concentration-response curves derived from AUC of NCI within 30 minutes after agonist addition, 
normalized to E354 (E3). pEC50 and Emax values are summarized in Table 3. (E) Inhibitory effect of 
(Pro3)GIP [1 µM] on response to a submaximal dose of GIP ([3.16 nM] for Q354 and [31.6 nM] for E354). 
(F) Results of real-time qPCR show mRNA expression of GIPR in 6 selected individuals with E354 or Q354 
genotype. Statistic differences were determined by one-way ANOVA with Fisher’s LSD test. *p≤0.05, 
**p≤0.01, ***p≤0.001, ****p≤0.0001. For F, differences to β-actin are indicated with asterisk. 
Expression differences between individuals were # =  E1 **** to E2, *** to E4 and Q2, ** to Q1. § = E3 
** to E2 and Q2, * to E4. In figures A, B and C, representative traces are shown. In figures D, E and F 
means ± SEM of three or more separate experiments performed in duplicate (D and E) or triplicate (F) 
are shown.  
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of response caused by ATP or GIP differed. For GIP, the response returned to baseline levels 
within a period of 30 minutes, where ATP induced cellular changes lasting over 60 minutes. 
This showed that LCL responses to GPCR agonists are receptor specific with regard to shape 
and duration as measured using the xCELLigence technology. 
Finally, we tested inhibition of GIP signaling effects in LCLs using the only commercially 
available GIPR selective antagonist, (Pro3)GIP, which did not elicit a response on its own upon 
addition to the LCLs (Supplemental Fig. S1). As shown in Fig. 1E, (Pro3)GIP was able to (partly) 
diminish GIP responses.  
Together, these results show that GIPR signaling in LCLs can be measured sensitively and 
specifically using the xCELLigence methodology. 
 
E534Q alters endogenous agonist potency of GIPR in personal cell lines 
Subsequently, LCL responses of the selection of E354Q individuals by the endogenous agonist 
GIP were determined. The resulting concentration-effect curves are summarized in  
Fig. 1B-D. GIP efficacy and potency values for the entire set of 10 individuals are summarized 
in Table 3. Responses between the monozygotic twins E3 and E4 were highly comparable, 
confirming that the LCLs are a suitable model system to study genetic effects on the GIPR.  
Shown in Fig. 1B and 1C are representative examples of the real-time baseline-corrected 
responses of two unrelated individuals representing the two possible E354Q homozygous 
genotypes, i.e. one E354 and one Q354 homozygous individual, respectively. Irrespective of 
genotype, these LCLs showed similar responses to GIP which did not differ significantly in 
overall shape or duration. However, differences in GIP effects were observed, especially in 
potency as can be seen in Fig. 1D where the concentration-response curves of these two 
individuals are given. Furthermore, both E354 and Q354 homozygous individuals showed 
highly similar effects in potency within their respective group of individuals with the same 
genotype, but these groups differed significantly from each other. Specifically, pEC50 values 
of GIP on E354 individuals ranged from 7.90 ± 0.07 (E4) to 8.34 ± 0.08 (E2), while the same 
values on LCLs of Q354 individuals were 8.96 ± 0.25 (Q1) and 9.12 ± 0.08 (Q2). Therefore, 
GIP potency was significantly higher (i.e. 4-17-fold) in LCLs from Q354 homozygous 
individuals (Q1 and Q2), as opposed to the E354 homozygotes. Interestingly, the LCLs of 
heterozygotes showed mixed effects, as their potency values showed a large spread with a 
range of 7.91 ± 0.11 (EQ2) to 9.32 ± 0.14 (EQ1). Heterozygotes thus also differed significantly 
from each other by 4- to 26-fold, which was similar to the difference between Q354 and E354 
homozygous individuals. In general, heterozygotes were closer in potency to Q354  
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(EQ1, EQ3) than to E354 individuals (EQ2 only). This was irrespective of gender, and not 
smaller between related family members. In fact, in family 2 who encompassed a E354 father 
and Q354 mother, GIP potency in LCLs of their child was not in between the two but instead 
much closer to Q354. 
Besides potency, we also assessed GIP efficacy for which we did not observe a genotype-
related trend, despite a wide range of efficacies with many significant differences (Table 3). 
The individuals with the highest efficacy were three E354 homozygotes, followed by two 
heterozygotes. Both Q354 individuals showed lower efficacy, with Q1 the lowest of all. The 
trend was however not consistent, as other E354 homozygotes such as E2 showed efficacies 
lower than some Q354. Furthermore, the monozygotic twin pair E3 and E4 differed largely 
in efficacy. Thus, GIP efficacies were not consistent with genotype. Of note, GIP efficacy was 
not related to gender either, as for instance for E354 the individuals with highest and lowest 
efficacy were both female. Finally, there was also no clear relationship to GIPR mRNA levels, 
as for example the two cell lines with the highest Emax, E4 and E1, differed greatly in their 
mRNA levels (Fig. 1F). 
In conclusion, the responses of the NTR individuals’ LCLs revealed that the E354Q 
polymorphism increased the potency of endogenous agonist GIP in Q354 homozygotes, 
while heterozygotes showed mixed effects with respect to GIP potency. The efficacy of GIP 
was not affected by this polymorphism. 
 
Mutational study E354 in HEK293 cells shows differences in duration of effect 
To provide a more direct comparison to our personal cell lines, we performed a mutational 
study using transiently transfected HEK293 cells and measured their responses upon GIP 
addition using the xCELLigence. An example of the real-time readout of cellular growth and 
responses to GIP for HEK293 cells transiently transfected with mock, E354 and Q354 is 
presented in Fig. 2A. Addition of GIP to mock-transfected HEK293 cells did not induce 
significant changes in impedance, while it resulted in an immediate effect in E354 or Q354 
transfected cells. In both cases, impedance increased to a peak level within 120 minutes and 
subsequently declined towards baseline, which it did not reach though, even after 240 
minutes. Thus, the GIP response dynamics of HEK293hGIPR cells are different from LCLs, 
especially in response duration. 
Fig. 2B and 2C display examples of the respective real-time traces of E354 and Q354 
HEK293hGIPR cells responses to GIP from which concentration-effect curves were 
constructed by analyzing the AUC over 4 hours of response (Fig. 2D). The overall effect of GIP 
in this time period did not differ significantly between E354 and Q354 with respect to potency  
 





















































Figure 2. Characterization for hGIPR response in HEK293 cells transiently transfected with E354 or Q354 
variant. Representative example of a full real-time impedance plot and baseline-corrected responses 
of mock, E354 and Q354 transiently transfected HEK293 cells (A) and real-time baseline-corrected 
concentration-responses curves for (B) E354 and (C) Q354 transfected HEK293 cells. (D) 
Concentration-response curves derived of AUC from NCI within 4 hours after GIP addition for E354 
and Q354 transfected HEK293 cells. pEC50 values were 10.25 ± 0.06 and 10.18 ± 0.08, while Emax 
values were 100 ± 2.9 % and 56.9 ± 6.4 %, respectively. Potency was not significantly different, while 
Emax differed by **** as determined by Student’s t-test. (E) Percentage highest baseline-corrected 
response to GIP [1 µM] of Q354 versus E354 at several time points. The overall highest response of 
E354 was set to 100%. (F) Cell-surface expression of E354 and Q354 over mock transfected HEK293 
cells as determined by FLAG-tag ELISA, which was not significantly different between the two variants. 
All data are presented as means ± SEM of three or more separate experiments performed in 
duplicate. Statistic differences were determined by two-way (E) or one-way (F) ANOVA with Fisher’s 
LSD test. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
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(pEC50 of 10.25 ± 0.06 and 10.18 ± 0.08, respectively). Efficacy, however, defined as the 
maximally achieved overall AUC, was significantly altered (Emax of 100 ± 2.9 % and 56.9 ± 6.4 
%, respectively). Thus, the overall cellular effect through Q354 was lower than through E354, 
which was mostly due to how the height of the cellular effect diverged over time (Fig. 2E). 
Specifically, at 30 minutes after agonist addition E354 and Q354 showed virtually the same 
height of response to GIP, while the effect on Q354 declined towards baseline more rapidly 
after that time. At 4 hours after GIP addition, the effect on Q354 was only 49 % of E354.   
Finally, we confirmed that any differences between E354 and Q354 receptor variants 
transiently transfected in HEK293 cells were not due to differences in cell surface expression 
by performing ELISA (Fig. 2F). In conclusion, the mutational study of E354Q in transiently 
transfected HEK293 cells showed no differences in potency. In contrast, significant 
differences were found in efficacy as the height as well as duration of response were 
decreased in Q354. 
 
Discussion 
Genetic differences between individuals can affect both drug action and susceptibility to 
diseases, as is increasingly recognized under the concept of personalized or precision 
medicine [38]. The GIPR missense SNP E354Q has been associated with diseases including 
diabetes and bone-fracture risk [12, 15, 16] and shown to have functional effects in mouse 
cell lines or recombinant cell systems [3, 16, 19]. However, results from such animal and 
recombinant cells may not be directly translatable to the human individual. Additionally, 
several of these studies yielded conflicting results. To provide a better link with the 
physiological situation we studied the effect of this SNP in personal cell lines, i.e. LCLs of a 
set of individuals from the NTR [29].  
The E354Q was present in 21% of NTR individuals, which was in accordance with its 
global MAF [14]. Most of the other SNPs in the GIPR gene (Table 1) were located in introns, 
as is common for intron-containing GPCRs due to the evolutionary conservation of the 
different regions [39, 40]. Thus for functional studies in LCLs, we selected 10 individuals 
including two or more unrelated individuals of both genders for each of the three E354Q 
genotypes (Table 2). The set of monozygotic twins used as control for genotype-unrelated 
effects [29, 41] showed highly comparable responses to the endogenous agonist GIP (Fig. 1, 
Table 3), confirming LCLs are a suitable model system. Remarkably, E354Q affected GIP 
potency consistently over all individuals, while being independent on gender and family-
relation. GIP had higher potency in all Q354 versus E354 homozygotes, while heterozygotes 
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showed a wide spread in potency, differing between each other and from both homozygotes 
(Fig. 1, Table 3). Interestingly, precisely this heterozygous variant but not the homozygous 
Q354 has been associated with cardiovascular disease [15]. Conversely, only Q354 
homozygotes were associated with reduced serum C-peptide concentrations, a parameter 
related to insulin levels [16]. Finally, Torekov et al. found minor allele carriers had lowered 
bone mineral density, but only Q354 homozygotes had increased risk for certain fractures 
[12]. The effect of E354Q heterozygosity is therefore not straightforward, and could vary 
depending on disease. Thus, investigating heterozygosity is imperative for deciphering 
E354Q pharmacology.  
In our study, the E354Q SNP showed clear (genotype-related) effects in LCLs of NTR 
individuals, mainly on the potency of the endogenous ligand GIP. For instance, GIP potency 
was highly comparable in the monozygous twins E3 and E4 (Table 3). In contrast, the efficacy 
was not genotype-related (Table 3), as for example the same monozygous twins E3 and E4 
differed greatly in their Emax. Efficacy was also not related to other characteristics such as 
gender (Table 2, Table 3) or GIPR mRNA levels (Fig. 1F). For example, E4 and E1 were the two 
cell lines with the highest Emax. Contrarily, E4 had high GIPR mRNA levels while E1 exhibited 
the lowest of all individuals. It has to be kept in mind that mRNA expression levels do not 
necessarily correlate with functional protein expression on the cellular membrane, a feature 
well-known in literature [42, 43]. Thus, it appears that neither differences in mRNA levels or 
Emax reveal any E354Q-related effects on functional GIPR expression. Notably, the maximal 
effects of both GIP and another ligand which targets a completely different set of GPCRs, 
namely ATP, showed a similar ranking of individuals (data not shown). Hence it is possible 
that the differences in maximal effects reflect each individual’s overall cell properties such 
as viability, proliferation rate and adherence to electrodes, which are not specifically GPCR-
related but are known to affect xCELLigence readout [25-28].  
Overall, the E354Q SNP showed outspoken effects in LCLs of NTR individuals. It has been 
suggested that E354, based on functionality of the same E6.48 in other class B GPCRs, has a 
potentially important role in ligand binding and receptor (in)activation [17]. It was shown 
that mutation to an alanine caused a loss of hydrogen bonding network interactions, 
resulting in a constitutively active mutant with higher GIP affinity and potency, but 
unchanged efficacy [17]. Mutation to glutamine may have similar effects by reducing 
interaction strength, thus causing increased potency yet similar efficacy for agonists, which 
is in accordance with the observations in LCLs. However, several studies examining functional 
effects of E354Q in mouse cell lines or recombinant cell systems yielded conflicting results. 
For instance, Fortin et al. noted that Q354 reduced induction of cAMP production in 
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recombinant HEK293 cells, while neither Almind et al. nor Mohammad et al. found any effect 
on cAMP formation in CHO cells or mouse adipocytes, respectively [3, 16, 19]. A similar 
discrepancy was observed for antagonism of GIPR in LCLs, which is considered a potential 
treatment for GIPR-related metabolic abnormalities such as diabetes [44]. When we tested 
(Pro3)GIP, the only commercially available GPR antagonist, in LCLs, it partly inhibited GIP 
activation (Fig. 1E) in correspondence to its reported low potency [45]. Interestingly, in our 
hands (Pro3)GIP merely acted as an antagonist (Supplemental Fig. S1), while Sparre-Ulrich et 
al. reported it to be a full or partial agonist [46]. It stands to notice that the above findings 
were established in recombinant or non-human cell systems. On the other hand, LCLs are a 
completely human system that endogenously expresses hGIPR. Lastly, all of these 
observations were obtained using typical endpoint or second messenger assays, which focus 
on one part of a cellular response only. Systems such as the xCELLigence offer the advantage 
of measuring whole-cell responses in real-time as opposed to a static, one-molecule-
detection [25-28]. Hence, such label-free whole-cell assays are preferable over typical 
endpoint assays to minimize bias [47].  
To further investigate the influence of the model system used, we measured E354Q 
mutational effects in a common recombinant system, namely transiently transfected HEK293 
cells, using the exact same xCELLigence assay to provide direct comparison. As in LCLs, E354 
and Q354 were not differentially expressed and we observed a receptor-specific impedance 
signal (Fig. 2A, F). Interestingly, HEK293hGIPR cells showed a response duration vastly 
different from LCLs (30 minutes for LCLs versus over 240 minutes for HEK293hGIPR). In 
addition, overall GIP potency was at least 5-fold higher than in LCLs. However, previously 
published potencies also span a wide range, even within the same cell type. GIP potencies 
on transiently transfected HEK293hGIPR cells expressing E354 range from 0.9 pM [19] to 490 
± 30 pM [17], and even 3.63 nM on CHO cells [16], all of which values that were determined 
in cAMP-based assays. 
Besides differences in GIP effects in general, E354Q specifically showed divergent 
pharmacological effects in HEK293hGIPR and LCLs. Specifically, E354Q did not affect potency 
in HEK293hGIPR, but had a significant influence on efficacy in terms of height and duration 
of cellular effects, which were both lower for Q354 than for E354 (Fig. 2). This is in accordance 
with findings by Mohammad et al. in the same cell type, who established that Q354 slowed 
receptor recycling to the cell surface following agonist stimulation [3]. This could lead to a 
decreased availability of receptors to mediate the cellular effects as measured by the 
xCELLigence, thus lower and declining more rapidly over time.  
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It is well-established that the behavior of GPCRs is dependent on the cellular context [48, 
49]. HEK293 cells are a prototypical recombinant system prone to receptor overexpression, 
whereas LCLs are personal cell lines with endogenous levels of receptor expression. This 
emphasizes the importance of using primary or derived (i.e. endogenous immortalized) 
human cell systems that offer more physiological relevance to confirm any effects 
established in other cell systems. 
Irrespective of the model system, it is essential to consider findings in the light of 
physiological and pathological conditions. Consumption of meals induces GIP blood 
concentrations to approx. 100 pM, which return to previous levels around 20 pM within 3 to 
4 h [3, 50-52]. It is clear that such physiological concentrations of GIP cannot reach a maximal 
effect in E354 LCLs, where potencies are around 10 nM (Table 3). However, GIP potency on 
Q534 LCLs was higher and in the pM range. This makes potency differences extremely 
relevant for physiological effects, as receptors with increased potency such as the Q354 
variant could mediate a larger response. If this variant additionally shows a shorter effect 
duration or slower recycling to the surface after GIP stimulation, as pointed at by our results 
and those of Mohammad et al. in HEK293 cells [3], the combination could contribute to 
lowered GIP sensitivity and, for instance, increasing the risk of insulin resistance. Replicating 
these findings in cell types directly involved in the physiological functions of GIP, such as 
adipocytes from patients versus healthy volunteers containing both E354Q GIPR forms, could 
offer more conclusive results.  
In conclusion, our study with personal cell lines that endogenously express E354Q shows 
that this polymorphism has a strong effect on receptor response, namely by increasing GIP 
potency, which can affect the physiological function of the receptor. Furthermore, a 
mutational study in recombinant HEK293 cells revealed a reduced effect duration for Q354, 
which was not observed in LCLs. Thus, the effects of E354Q differ depending on the model 
system used. By studying E354Q effects in personal cell lines, we aimed to increase the link 
with the real-life situation and to provide more insight into physiological changes as they 
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Studies on Mental Disorders (NIMH EQ34 MH068457-06). Data and biomaterials (such as cell 
lines) are available to qualified investigators, and may be accessed by following a set of 
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Supporting information 
Supplemental Table S1. Significant differences in endogenous agonist GIP potency and efficacy per 
individual’s LCL. Data represent pEC50 ± SEM and Emax ± SEM of at least three experiments performed 
in duplicate. Statistical analysis was performed by one-way ANOVA with Fisher’s LSD post-hoc test. For 
pEC50, a large difference between GG genotypes (E354) the CC genotype (Q354) compared to GG 
genotypes and a mixed effect for the heterozygote genotype. The Emax showed little differences that 




Summary P Value Summary P Value 
E1 vs. E2 ns 0.1670 ** 0.0027 
E1 vs. E3 ns 0.8819 * 0.0250 
E1 vs. E4 ns 0.1156 ns 0.4986 
E1 vs. E5 ns 0.9651 ns 0.7103 
E1 vs. Q1 **** <0.0001 ** 0.0015 
E1 vs. EQ1 **** <0.0001 ns 0.6019 
E1 vs. EQ2 ns 0.1278 ** 0.0067 
E1 vs. EQ3 *** 0.0002 ns 0.4815 
E1 vs. Q2 **** <0.0001 * 0.0103 
E2 vs. E3 ns 0.1278 ns 0.3722 
E2 vs. E4 ** 0.0049 *** 0.0004 
E2 vs. E5 ns 0.2149 * 0.0128 
E2 vs. Q1 *** 0.0005 ns 0.6423 
E2 vs. EQ1 **** <0.0001 * 0.0183 
E2 vs. EQ2 ** 0.0056 ns 0.7262 
E2 vs. EQ3 * 0.0100 * 0.0105 
E2 vs. Q2 **** <0.0001 ns 0.4081 
E3 vs. E4 ns 0.1518 ** 0.0048 
E3 vs. E5 ns 0.8562 ns 0.0803 
E3 vs. Q1 **** <0.0001 ns 0.2008 
E3 vs. EQ1 **** <0.0001 ns 0.1078 
E3 vs. EQ2 ns 0.1670 ns 0.5847 
E3 vs. EQ3 *** 0.0001 ns 0.0860 
E3 vs. Q2 **** <0.0001 ns 0.8790 
E4 vs. E5 ns 0.1330 ns 0.3210 
E4 vs. Q1 **** <0.0001 *** 0.0003 
E4 vs. EQ1 **** <0.0001 ns 0.2546 
E4 vs. EQ2 ns 0.9569 ** 0.0011 
E4 vs. EQ3 **** <0.0001 ns 0.1617 
E4 vs. Q2 **** <0.0001 ** 0.0015 
E5 vs. Q1 **** <0,0001 ** 0.0066 
E5 vs. EQ1 **** <0.0001 ns 0.8877 
E5 vs. EQ2 ns 0.1456 * 0.0272 
E5 vs. EQ3 *** 0.0006 ns 0.7947 
E5 vs. Q2 **** <0.0001 * 0.0447 
Q1 vs. EQ1 * 0.0406 ** 0.0094 
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Q1 vs. EQ2 **** <0.0001 ns 0.4320 
Q1 vs. EQ3 ns 0.1318 ** 0.0054 
Q1 vs. Q2 ns 0.2966 ns 0.2129 
EQ1 vs. EQ2 **** <0.0001 * 0.0381 
EQ1 vs. EQ3 *** 0.0004 ns 0.9185 
EQ1 vs. Q2 ns 0.1690 ns 0.0630 
EQ2 vs. EQ3 **** <0.0001 * 0.0251 
EQ2 vs. Q2 **** <0.0001 ns 0.6547 





















Supplemental Figure S1. (Pro3)GIP response in LCLs. Representative example of a baseline-corrected 
responses to either (Pro3)GIP [1 µM] or GIP [31.6nM] of LCLs from one E354 individual, E3. Data is 
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This thesis delves into examining the influence of genetic variation on GPCR function within 
the human individual. In this concluding chapter, insights gained from case studies at three 
different GPCRs are elaborated on, and suggestions for future investigations around 
precision medicine for GPCRs are presented. 
 
Conclusions 
Assay methodology and model systems 
GPCRs are traditionally investigated in reporter-based assays performed on heterologous cell 
lines, which offer only limited translational value [1-6]. Physiologically more appropriate 
model systems and assays are thus required (Chapter 2). LCLs, which are among the most 
frequently biobanked samples used for storing genetic material [7-13], could form a highly 
valuable resource for investigating genetic effects on drug action and receptor function. In 
addition, label-free cellular assays offer increased physiological relevance over the assays 
used traditionally in GPCR research, as discussed in Chapter 1 and 2 [4, 13-15]. Unfortunately, 
these were originally deemed incompatible with suspension cells such as LCLs due to the 
detection mechanism positioned at the bottom of the well [16]. In this thesis I present a 
methodology with increased translational value by employing personal cell lines (the LCLs) 
as a model system, in combination with a physiologically more appropriate label-free cellular 
assay (the xCELLigence) to investigate GPCR function (Chapter 3). Adaptation to suspension 
cells drastically widens the realm of application for label-free assays, while investigating GPCR 
functionality in LCLs opens up an avenue for exploring precision medicine for GPCRs.  
 
Genetic variation in GPCRs 
Genetic variants in drug targets affect pathology and drug action [17]. Despite GPCRs being 
the largest group of drug targets to-date [18], studies on their genetic variation are sporadic, 
often only statistically associative and focus on one single target. Investigations generally 
work with one consensus form of a receptor, the so-called Wild-type, hereby ignoring the 
naturally occurring genetic variation in the population. However, other receptor variants may 
be more relevant for certain diseases or drug effects. Three separate cases of common 
polymorphisms that affect GPCR signaling are presented in this thesis, each revealing 
different properties including the sensitivity to agonist type, chemical scaffold and variant 
position in the gene.  
Throughout this thesis I present examples that show genetic variations at different 
positions in GPCRs can be of influence. Logically, single nucleotide polymorphisms (SNPs) 
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most likely to have profound effects on receptor function are those that alter the amino acid 
sequence of the receptor, the so-called non-synonymous SNPs. Indeed, the variants that 
affected the Cannabinoid Receptor 2 (CB2R) and the glucose-dependent insulinotropic 
polypeptide receptor (GIPR), Q63R and E354Q respectively, both changed an amino acid 
(Chapter 5 and 6). In fact, many cases presented in the literature fall into this category [2, 19, 
20]. However, changing amino acid sequence is not the only way in which a receptor can be 
affected by polymorphisms. Chapter 4 presents the case of the Adenosine A2A receptor, in 
which responses differ between individuals in the absence of any non-synonymous SNPs. 
Genotype comparison revealed differences in two intron SNPs, one of which associated with 
caffeine-induced sleep disorders [21-23]. Such SNPs could have regulatory potential, for 
instance in affecting receptor expression which in turn may affect G protein coupling 
efficiency [23, 24].  
Interestingly, this particular A2AR SNP altered partial agonist potency, but not that of full 
agonists or antagonists (Chapter 4). In a similar manner, the partial agonists for the CB2R 
showed higher efficacy in a Q63R minor homozygote (Chapter 5). While either potency or 
efficacy of partial agonists can be affected, it overall appears that partial agonists may be 
more receptive to polymorphism-induced changes. This concurs with the theory that deems 
partial agonists more sensitive to system-related differences in receptor function, for 
instance in receptor expression or downstream coupling, than full agonists or 
antagonists [25]. The nature of the ligand thus influences its sensitivity to e.g. 
polymorphisms. In addition, the chemical scaffold of a ligand is likewise important. Chapter 
5 presents how compounds of different chemical classes show more or less modulation due 
to CB2R genetic variation. Non-classical cannabinoid CP55940 showed the most pronounced 
personal effects, while aminoalkylindole compounds showed fewer individual differences. 
Taking both ligand nature and chemical scaffold effects into account could allow early 
identification of compounds prone to personal differences (‘precision medicine’) or 
compounds that would be more suited as drugs for the general population. 
Besides affecting drug action, SNPs can also alter the physiological function of a receptor 
with potentially pathological consequences. Chapter 6 focusses on the investigation of the 
GIPR, in which E354Q influenced endogenous agonist effects, in particular with respect to 
potency in LCLs and duration of response when the receptor was expressed in recombinant 
HEK293 cells. This SNP has previously been linked with various pathologies including insulin 
resistance, diabetes and cardiovascular disease [26-29]. Interestingly, endogenous agonists 
are not necessarily more sensitive to receptor polymorphisms than synthetic ligands, as the 
study of adenosine on the A2AR and various endocannabinoids on CB2R show (Chapter 4 and 
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5). While some SNPs are of pathological consequence, others may be more relevant for drug 
effects. For instance, the A2AR SNP has been associated with caffeine effects and 
pharmacotherapy-related toxicities in acute lymphoblastic leukemia as well as pathological 
conditions including anxiety in autism [21-24]. Similarly, Q63R in the CB2R has been linked to 
various pathological disorders [5, 30-35] as well as synthetic ligand effects (Chapter 5, [36]). 
It is important to note that if a polymorphism affects an endogenous agonist, this may not 
directly leading to pathology. However it can still drastically alter a system’s sensitivity to 
drug treatment, even if the synthetic compounds are not directly affected themselves. In 
conclusion, it is undoubtedly necessary to take physiology and pathology into account when 
selecting ligands and conditions to study the influence of GPCR polymorphisms. 
Finally, it could be argued that SNPs with profound effects on receptor function are likely 
less frequent in the population due to evolutionary pressure. It is a common misconception 
that a frequent SNP has likely little effect [2]. The frequencies of the SNPs in this thesis 
however tell a different story, as the SNPs in the GIPR and CB2R with a global Minor Allele 
Frequency of approx. 35% and 16%, respectively [37-39], are in fact quite frequent, 
regardless of any functional effects. Many disease-related SNPs are quite rare, but some 
common SNPs are also known to contribute to or cause certain disease phenotypes [2, 17].  
In summary, the cases presented in this thesis demonstrate that for every GPCR, there 
appears to be at least one polymorphism candidate to affect receptor function. The 
particularities of each polymorphism can however differ, depending on the nature of the 
ligand such as endogenous vs. synthetic, partial vs. full agonist, chemical scaffold as well as 
the number of individuals potentially affected.  
 
LCLs as model system for genetic effects on GPCRs 
The examples summarized in this thesis (Chapter 3-6) demonstrate that LCLs are a suitable 
model system to study genetic effects on GPCRs, and the applied methodology facilitates 
phenotypic measurements of personal responses. LCLs thus enable direct measurement of 
polymorphism effects in a physiological environment, without having to generate and 
introduce a receptor mutant into a heterologous cell line as is generally done in the GPCR 
field. Any such alterations can affect receptor pharmacology and decrease translatability 
(Chapter 2). It is therefore unsurprising that the results presented in this thesis agree with 
previous investigations to some degree, while contradicting others. In chapter 5 for instance, 
Q63R influences on CB2R contrasted previous reports obtained in recombinant 
overexpressing cell systems, while confirming findings in a more physiological cell type [5, 
36, 40, 41]. E354Q effects on GIPR differed between LCLs and HEK293 cells even in our hands 
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(Chapter 6), and results of either cell type were both in accordance and contrast with 
previous studies [28, 29, 42]. Overall, it appears that LCLs are a well-suited system to measure 
personal polymorphism effects on GPCRs in a physiological setting, and enable explorations 
into the realm of GPCR precision medicine. While they increase translatability in comparison 
to traditional cell systems, the relevance of effects established in this thesis depends on 
further replication in e.g., more individuals for genotype effects, and/or primary cell types 
directly involved in pathology. 
 
Future perspectives 
Altogether a variety of impact factors for GPCR research including model systems, assay 
technology and genetic variation have been detailed throughout this thesis. The following 
section will discuss the future perspectives precision medicine for GPCRs involving some of 
these findings and additional aspects for further consideration. 
 
Genetic variation landscape in druggable GPCRs 
With the rise of personalized or precision medicine concepts, it is increasingly recognized 
that genetic differences between individuals can affect both drug action and susceptibility to 
diseases [17]. Examples of influential genetic variants of various types, frequencies and 
physiological consequences are accumulating. However, which variants are pathogenic, 
collateral of inconsequential is still largely undefined and subject of tremendous ongoing 
research efforts.  
When regarding any two unrelated individuals, 99% of their genomic DNA sequences are 
identical. The other 1%, however, signifies in fact 38 million different genomic variations. In 
turn, 90% of these variations are formed by SNPs, which makes these the most common 
source of genetic variation in the human population [12, 32]. On average, around one SNP 
occurs per 300 bases, meaning that each GPCRs should contain several SNPs, which occur 
more or less frequently in the population [2, 43]. During our annotation process of SNPs in 
druggable GPCRs (Chapter 1, Fig. 3), we noted several trends.  
First, the total amount of SNPs is related to gene size (Fig. 1). The largest GPCR genes, 
which belong mostly to Class C and Adhesion GPCRs, generally have the most genetic 
variation. Table 1 shows the top and bottom 5 genes with most or least SNPs. Based on these, 
SNPs of any kind occur within a GPCR gene on average around every 140 bp in the largest 
genes and every 413 bp in the shortest genes. This increased distance in shorter genes is 
unsurprising as, the shorter a gene, the larger the relative part that is coding sequence, which 
is more evolutionary conserved. 
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Figure 1. Total SNP count vs gene length for all 370 druggable GPCRs. A list of all druggable non-olfactory 
GPCRs was downloaded from the IUPHAR database. The gene length and SNP information were 
exported from Ensembl Biomart archived page (April 2013, version 71) corresponding to genome build 
GCRh37.p10. 
 
Secondly, most SNPs are located in non-coding regions and/or do not affect amino acid 
sequence in any way. Non-synonymous SNPs only represented 0.7% of all SNPs found in 
druggable GPCRs (total 152.000 SNPs on 370 GPCR genes). Synonymous SNPs which are 
located in the coding region but do not change the amino acid sequence made up 25%. 
Hence, GPCRs contain an abundance of SNPs predominantly in non-coding regions, with 
42.5% in UTR and intron regions. This is common for any intron-containing GPCR due to the 
evolutionary conservation of the different regions [43, 44]. 
Finally, SNPs with possibly profound effects on receptor function i.e. by altering the 
amino acid sequence of the receptor, are more abundantly occurring than one might expect. 
While the overall amount of SNPs increases with gene size (Fig. 1), on average each druggable 
GPCR contains at least 1-5 non-synonymous SNPs, independent of gene size (Table 1). The 
bottom line is that for each GPCR, there appear to be genetic differences which may impact 
receptor and drug functionality. Hence it is paramount not to ignore the potentially 
influential natural variation occurring in any GPCR or drug target for future pharmacological 
research.  
Although SNPs form the major source, there are other types of genetic variants present 
in the human genome. These include bi-allelic short insertions or deletions, large deletions, 
short repeats such as micro- and minisatellites, and copy number variants (CNV) which can 
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Table 1. GPCR genes with the top five most and least SNPs in total. The gene length and SNP information 
were exported from Ensembl Biomart archived page (April 2013, version 71) corresponding to genome 
build GCRh37.p10. The column labelled altering SNPs entails the number of SNPs that are either 












GRM7 Class C Metabotropic glutamate 
receptor 7 
971527 118 8216 2 
LPHN2 Adhesion Latrophilin receptor 2 686275 126 5430 5 
LPHN3 Adhesion Latrophilin receptor 3 871208 160 5430 2 
GRM8 Class C Metabotropic glutamate 
receptor 8 
814696 151 5388 5 
BAI3 Adhesion Brain-specific 
angiogenesis inhibitor 
754144 144 5248 2 
TAS2R16 Taste Type 2 taste receptor 16 995 332 3 2 
GPR32 Class A Orphan receptor 1268 423 3 1 
CHRM4 Class A Muscarinic acetylcholine 
receptor 4 
1467 489 3 0 
MC3R Class A Melanocortin receptor 3 1083 361 3 1 
FFAR1 Class A Free fatty acid receptor 1 922 461 2 1 
 
consequences, some form a pathological risk. For instance, several repeat polymorphisms in 
the Arginine vasopressin receptor 1A have been associated with altered social, sexual and 
reproductive behavior [45-47]. Also, the TAS2R receptor family that detects bitter taste of 
compounds such as caffeine contains about 25 GPCRs, but the exact number per individual 
varies due to copy number variation. Individual experiences of bitterness are altered by 
genetic variation in these receptors [48, 49]. Finally, duplication of orphan receptor GPR101 
has been shown to lead to X-linked acrogigantism [50]. Thus next to SNPs, it would be an 
important addition to study other forms of genomic variations too, as these can also account 
for a difference in GPCR response [51].  
Of note, the Netherlands Twin Registry (NTR; http://www.tweelingenregister.org/en/) 
[7] from which the collection of LCLs utilized in this study originated, has served as data 
source for many genetic studies, including SNPs as well as CNVs already [52-55]. Given the 
appropriate samples are available, utilizing the set-up of LCLs and label-free technology could 
offer additional insights into the functional influences of such other types of variants too.  
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LCLs and emerging cellular model systems for drug research 
Two of the major challenges in today’s drug development are the lack of understanding inter-
individual variability in drug effectiveness, and the translatability of preclinical results. 
Inappropriate model systems have contributed to both issues, and consequently to lack of 
reproducibility in preclinical research, lack of clinical effectiveness and high attrition rates [6, 
56].  
In this thesis I have presented a methodology utilizing LCLs from the NTR [7] as a model 
system to investigate genetic effects on GPCR functionality. Applications of LCLs are however 
by no means limited to the three exemplary GPCR cases discussed in this thesis (Chapter 4-
6), as LCLs express many more GPCRs as well as other drug targets [11, 57, 58].  
In general, renewable in vitro cell sources have been essential in facilitating drug 
discovery and pharmacogenomic studies. In fact, much of our understanding of the 
influences of genetic variation in humans is based on studies utilizing LCLs [59]. LCLs are 
already easily available in large variety as LCL repositories exist in abundance, some 
representing specific disease populations or ethnicities [7-11, 59-61]. Hence they are utilized 
in many aspects of pharmacogenomics, and examples include general genotype-phenotype 
association, many genome-wide association studies (GWAS) for drug-induced phenotypes 
and even follow-up studies of clinical findings [11, 57].  
Notwithstanding the convenience and usefulness of LCLs as a cellular model system, 
there are concerns that their immortalization and cell line maintenance could obscure 
genetic findings [59, 62-64]. Certainly, it is well known that a large number of genes are 
differentially expressed between primary cells and cell lines [59]. Opposed to this, primary 
cells express signaling pathways and retain many cellular functions that are seen in vivo, thus 
providing a more relevant context (Chapter 2). Over the past decades, numerous biobanks 
have been set up to support medical research by programmed storage of biological material 
and corresponding data. These biomaterials include LCLs as well as primary material such as 
tissues, (stem) cells and blood, all of which are actively used from translational and 
personalized medicine to target and drug discovery [65, 66]. Several approaches applying 
label-free technology to utilize patient primary cells as model system are discussed in Chapter 
2. While such cell types have increased translational value, the materials are often limited 
due to culture and sampling issues. On the other hand, LCLs are a renewable source that is 
already widely available, and offer genotypic and phenotypic information and stability that is 
absent in many other renewable sources. How appropriate either model system is depends 
largely on the application and question at hand.  
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An alternative that could incorporate renewability, primary tissue properties and patient 
origin are stem cells, which offer great potential as physiologically more relevant models. In 
particular induced pluripotent stem cells (iPSC), which can maintain the disease genotype 
and phenotype indefinitely, provide a source of models for an expansive range of adult 
differentiated cells, possibly even for each individual patient. The ability to reprogram cells 
of patients into disease-relevant cell types could provide more representative and predictive 
cellular models for both disease modelling and drug discovery [60], and has the potential to 
personalize pharmacological research [67, 68]. iPSC have already been used for drug 
screening and disease modelling, particular as neural cells, haematopoietic cell types, 
hepatocytes and cardiomyoctes [69, 70]. For some of such cell types, hiPSC-cardiomyocytes 
in particular, there are also examples of their application in label-free assays (Chapter 2, Table 
1) [71-73]. Interestingly, iPSC can be derived from a variety of cellular sources, including LCLs. 
This taps into the invaluable resources of the already available, vast collections of LCLs. iPSC 
derived from LCLs retain their disease mutation, exhibit identical characteristics as iPSC 
derived from more common sources such as fibroblasts, and can be differentiated into 
various cell types including neurons and even intestinal organoids [60, 61]. Organoids 
constitute near-physiological 3D models of an organ with realistic micro-anatomy, and as 
such enable more accurate study of many physiological processes [74]. Furthermore, iPSC 
from LCLs even recover their donor-specific gene expression signature [59, 60]. While it is 
unlikely that the lack of donor signature on gene expression in LCLs themselves would cause 
false-positive findings of genetic influence, such as the ones presented in this thesis in 
Chapter 3-6, regaining this signature in iPSC increases the ability to study inter-individual 
differences in gene expression [59].  
In summary, as these developments show, LCLs offer an enormous bioresource for both 
drug discovery and disease modelling [60, 61]. 
 
Comeback of phenotypic assays for drug research 
In addition to the need for more representative model systems, a preference is emerging for 
minimally invasive, time-resolved and thus pharmacologically more relevant assays. As 
principal criteria, new assay approaches for pharmaceutical drug discovery are to be more 
efficient and multidimensional [19]. Amongst these are label-free cellular assays. As 
discussed in Chapter 2, these assays offer a wide range of applications and have similarly 
been applied to many important classes of drug targets, which include besides GPCRs also 
receptor tyrosine kinases and nuclear receptors [75-78]. Their realm of application is large 
and constantly expanding. 
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This preference is part of a general trend back towards phenotypic screening. Phenotypic 
screens were in fact the norm for drug discovery prior to the 1980s. Following the advent of 
molecular cloning then, target-based screening became the standard approach for drug 
discovery. This strategy includes cloning and functional expression of potential drug targets 
in recombinant cell lines for study and screening of drug candidates (Fig. 2). While this 
approach has delivered many drug candidates over the years, there were relatively few new 
drugs. One reason is that this approach may work very well for monogenic diseases, however, 
most human diseases are likely multifactorial. Rather than caused by a single genetic change, 
they are complex diseases originating through an interplay of a multitude of genetic and 
environmental factors. Hence they may require engagement of multiple targets to achieve 
clinical efficacy [79-82].  
In such instances, target-agnostic approaches as utilized in phenotypic screening assays 
can offer advantages. In fact, significantly more small-molecule first-in-class drugs were 
discovered through phenotypic screening than target-based approaches [83]. Instead of 
focusing on engaging a specific target, phenotypic assays rely on finding molecules with a 
particular biological effect in cell-based or animal models (Fig. 2) [80-82]. This approach does 
however have its own hurdles to overcome, which include the need to identify a phenotypic  
 
Figure 2. Phenotypic assays versus target-based approach. Target-based drug discovery approach 
focuses on engaging a specific target, often using molecular cloning and recombinant techniques. 
Phenotypic assays identify molecules with a particular biological effect in cell-based or animal models. 
Phenotypic assays can provide context that is closer to the clinical situation. 
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endpoint appropriately associated with the disease of interest. Label-free assay technologies 
offer additional advantages here, as they do not require assumptions about molecular 
mechanisms and pathways but rather allow for a multidimensional and less biased 
investigation [80]. In summary, label-free assay technology provides phenotypic assays that 
are able to acquire molecular-level understanding of complex biological processes in their 
native environment [6, 84]. When combined with the appropriate cellular model systems, as 
discussed in this thesis in e.g. Chapter 2, the combination offers a powerful approach for 
pharmaceutical research in general and precision medicine in particular. 
 
Precision medicine prospective for GPCRs 
The human genome mapping, the resulting pharmacogenetic discoveries and the ongoing 
movement towards precision medicine have influenced drug development in general, and 
hence also for GPCRs. It is increasingly recognized among the GPCR research community that 
tailoring a drug candidate for a particular genetic variant of a GPCR could offer various 
benefits [19] (Fig. 3). There are numerous examples of genetic variants in GPCRs altering 
pharmacology or pathology. In 2001, Sadee et al. published an exemplary catalogue of 
genetic GPCR variants and possible implications for drug therapy [64]. More than a decade 
later, the tailoring of GPCR targeting drugs based on genetic variation in patients is still 
deemed to be in the early stages of feasibility [34]. To name a particular example, the α2A 
adrenergic receptor antagonist yohimibine improved insulin secretion in type II diabetes 
patients that were carriers of a particular SNP in this receptor [20]. Other forms of genetic 
variation besides SNPs have also been found to be of influence, for instance GPCR expression  
 
Figure 3. Precision medicine versus traditional treatment paradigm. Tailoring a drug (candidate) to 
patient characteristics such as genetic information can offer several benefits including decreased risks 
of ineffective treatment, of inappropriate dosing or of side effects [91-93].  
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as a biomarker for the clinical efficacy of the A3 adenosine receptor agonist IB-MECA, or the 
conversion of P2Y12 receptor prodrug Plavix being impaired by the 2C16 isoform of CYP450 
enzymes [85, 86] . 
The progress in precision medicine for GPCRs has come in large part through 
pharmacogenomic advances. Over the past two decades, the Human Genome Project, 
HapMap project and 1000 Genomes project have been instrumental in identifying human 
genetic variants contributing to common diseases [8, 79, 87]. The emergence of GWAS in 
2005 has led to a surge in the successful identification of numerous disease-associated 
genetic loci. However useful, with GWAS genetic variants are mostly associated, not 
necessarily correlated with disease, as there is no clue to the underlying mechanism [79, 88]. 
Finally, in the past couple of years, whole-exome sequencing experiments which specifically 
focus on coding regions related to proteins have become available [79]. The costs of such 
techniques are decreasing, while patient willingness to participate is on the rise [79, 89]. 
Continuing these trends, first personalized whole-genome sequencing and finally, with 
gaining the appropriate pharmacological understanding, various forms of precision medicine 
may become standard clinical practice (Fig. 3). Before this becomes clinical reality however, 
there are  hurdles to be overcome such as the existing skepticism by clinicians, mostly related 
to ethical concerns about privacy and potential discrimination of patients [79, 90]. First and 
foremost however remains the appropriate identification of disease-related genetic variants 
and corresponding implications for medical treatment. To deliver the required molecular-
level understanding of genetic influences on pathology and pharmacology, more 
representative model systems and assay techniques are becoming available. Now is the time 
to employ these tools to become more familiar with the key contributing factors, establish 
the necessary key concepts, integrate these into target discovery and drug development and 




Altogether a novel cellular approach towards studying genetic effects on GPCR function has 
been explored and detailed throughout this thesis. Several GPCRs and different types of 
genetic variations were investigated, demonstrating together that personal cell lines in 
combination with label-free technology are an appropriate tool to enable GPCR 
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representative model systems and appropriate assay technology are important factors for 
advancing GPCR drug discovery. The data presented in this thesis contributes towards the 
progress of applying precision medicine concepts to this class of drug targets. 
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Summary 
The traditional medical treatment paradigm focuses on prescribing one drug to treat all 
patients with a specific disease or condition, so called ‘one-size-fits-all’. However, it has been 
shown increasingly that differences between persons, such as in lifestyle or genes, can 
change both the course of a disease and effect of a drug. In order to adapt medical treatment 
and drug development to that, a concept know as precision medicine, it is essential to study 
which and how genetic differences, i.e. polymorphisms, affect drug response. In this thesis I 
studied of the influences of genetic variation on a specific class of drug targets, the G protein-
coupled receptors (GPCRs), by using a combination of personal cellular models and novel 
label-free assay technology.  
Chapter 1 introduces the main subjects and concepts around precision medicine, GPCRs 
and genetic variation discussed in this thesis. Chapter 2 continues with discussing the concept 
of using patient-derived cell lines as model systems and highlights the advantages of label-
free technology assays to investigate these. To better understand drug action and 
pathological processes in the human individual, physiologically more appropriate model 
systems are needed. For this, patient-derived cells can offer specific advantages. Traditional 
GPCR assays are often label-based, which has disadvantages when aiming to represent the 
physiological situation as closely as possible. Novel label-free cellular assays enable the study 
of complex biological processes in their native environment. Examples and advantages of the 
combination of these two are discussed in chapter 2.  
Chapter 3 describes the optimization and application of an impedance-based label-free 
assay methodology, the xCELLigence, to a type of personal cell line, the lymphoblastoid cell 
lines (LCLs) from individuals of the Netherlands Twin Registry (NTR), to allow direct 
measurement of cellular effects of GPCR signaling. Generally, this label-free assay technology 
was deemed only compatible with adherent cell lines, while LCLs are suspension cells. 
Therefore, the methodology was optimized and applied to study cellular properties and GPCR 
signaling in LCLs. A prototypical GPCR present on LCLs, the cannabinoid receptor 2 (CB2R), 
was selected for proof-or-principle. Effects of several compound types were studied and 
proved comparable between LCLs of two unrelated individuals with the same genotype, 
providing the first evidence that the technology and model system were well suited to 
evaluate genetic influences on GPCR-mediated drug responses. 
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Chapter 4 presents the case of another GPCR, the adenosine A2A receptor (A2AR).  The 
A2AR is a potential drug target for a variety of respiratory and inflammatory conditions, 
including Parkinson’s disease, as well as the receptor for caffeine. After identifying which 
adenosine receptor subtypes were present on LCLs, the cellular effects of various types of 
compounds targeting the A2AR were compared between LCLs derived from a family of four 
individuals, consisting of parents and their identical twin children. In the presence of a 
specific type of genetic variation, an intron Single nucleotide polymorphism (SNP) that is 
potentially linked to caffeine-induced sleep disorders, different cellular effects were found 
for a specific type of compound, a partial agonist, but not for other compounds such as full 
agonists or antagonists. Although this does not provide causal evidence that response 
differences are directly related to this genetic variation, it does show that the chosen 
methodology is capable of picking up individual differences in GPCR signaling. 
After this demonstration, genetic differences in other GPCRs were studied. The CB2R is a 
GPCR investigated intensively as therapeutic target due to its important role in the immune 
system. In chapter 5, responses to agonists, partial agonists and antagonists of various 
chemical classes were characterized in LCLs from individuals with varying CB2R genotypes. 
One of the interesting findings was that endogenous cannabinoids such as 2-AG induced 
cellular effects vastly different from all synthetic cannabinoids, especially in their time-
profile. More importantly, it was also found that compounds with different chemical 
scaffolds showed different sensitivity to a highly common amino-acid altering polymorphism 
in the CB2R, the Q63R variant. In a similar manner it may be possible to identify compounds 
prone to personal differences, so for precision medicine, or more suited as drugs for the 
general population early on in drug development. 
Genetic differences may however not only influence drug effects, but can alter a 
person’s susceptibility to disease or alter disease progression. Chapter 6 presents the case of 
the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR), in which an amino-acid 
altering SNP that has often been associated with diseases changed the cellular effects of the 
endogenous ligand. The GIPR plays an important role in whole-body metabolism, and its 
amino-acid altering SNP E354Q has been associated with several diseases including diabetes. 
When studying this receptor in a panel of LCLs of individuals with different genotypes for 
E354Q, responses to the endogenous agonist GIP showed enhanced potency in Q354 
homozygous individuals. This study hereby provides more insight into how GPCR 
polymorphisms could change physiology in the human individual. 
In summary, a novel cellular approach for studying genetic effects on GPCRs has been 
explored and detailed throughout this thesis. Several GPCRs and different types of genetic 
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variations were investigated, and the findings highlight that various kinds of genetic 
differences in GPCRs, can profoundly influence drug response. These include differing effects 
depending on compound type or chemical scaffold, as well as on endogenous signaling. The 
overall conclusion from the results described in this thesis and forthcoming opportunities for 
drug discovery and treatment are discussed in detail in chapter 7. In concert, the findings in 
this thesis may contribute to the progress of applying precision medicine concepts to the 
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Samenvatting 
Historisch gezien richt zich medische behandeling op het voorschrijven van één 
geneesmiddel om alle patiënten met een specifieke ziekte of aandoening te behandelen, ook 
bekend als 'one-size-fits-all'. Het wordt echter steeds duidelijker dat verschillen tussen 
personen, zoals in levensstijl of genen, zowel het verloop van een ziekte als het effect van 
een geneesmiddel kunnen veranderen. Om medische behandeling en medicijnontwikkeling 
hierop aan te kunnen passen, een concept bekend als ‘precision medicine’, is het essentieel 
om te identificeren hoe en welke genetische verschillen, d.w.z. polymorfismen, de 
geneesmiddelrespons beïnvloeden. Dit proefschrift richt zich op het bestuderen van 
genetische verschillen in een bepaalde klasse van doelwitten voor geneesmiddelen, de G-
eiwit gekoppelde receptoren (GPCRs), door gebruik te maken van een combinatie van een 
persoonlijk cellulair model en een recent ontwikkelde label-vrije meettechnologie. 
In hoofdstuk 1 worden de hoofonderwerpen en concepten rondom precision medicine, 
GPCRs en genetische verschillen, die in dit proefschrift aan bod komen, geïntroduceerd. 
Hoofdstuk 2 gaat verder met de discussie over het concept om persoonlijke cellulaire 
modellen te gebruiken en belicht de voordelen die de label-vrije meettechnologie biedt om 
deze te onderzoeken. Om de geneesmiddelwerking en ziekteprocessen in het menselijke 
individu beter te kunnen begrijpen, zijn meer fysiologische representatieve model systemen 
nodig. Hiervoor bieden cellulaire modellen afkomstig van patiënten specifieke voordelen. 
Traditionele GPCR bepalingsmethoden zijn vaak gebaseerd op labels, wat nadelen met zich 
meebrengt als het doel is om de fysiologische situatie zo goed mogelijk te benaderen. Recent 
ontwikkelde label-vrije cellulaire bepalingsmethoden maken het bestuderen van complexe 
biologische processen in hun natuurlijke omgeving mogelijk. Voorbeelden en voordelen van 
de combinatie van deze twee worden in hoofdstuk 2 besproken. 
Hoofdstuk 3 beschrijft de optimalisatie en toepassing van een dergelijke, op weerstand 
gebaseerde label-vrije technologie, de xCELLigence, voor een bepaald type persoonlijke 
cellijnen, de lymfoblastoïde cellijnen (LCLs) van individuen van het Nederlandse Tweelingen 
Register (NTR), voor directe meeting van de cellulaire effecten van GPCR stimulatie. Over het 
algemeen wordt deze label-vrije technologie alleen toepasbaar op hechtende cellen geacht, 
terwijl LCLs suspensie cellen zijn. Daarom werd de methodologie geoptimaliseerd en 
toegepast om zowel de cellulaire eigenschappen en GPCR activatie in LCLs te kunnen 
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bestuderen. Een GPCR die in LCLs aanwezig is, de Cannabinoïde receptor 2 (CB2R), werd 
geselecteerd als voorbeeld ter demonstratie. De effecten van verschillende typen chemische 
verbindingen werden bestudeerd en bleken vergelijkbaar tussen LCLs van twee niet 
verwante individuen met hetzelfde genotype, wat het proof-of-principle leverde dat deze 
technologie en het cellulaire model systeem goed geschikt waren om genetische invloeden 
op GPCR-gemedieerde geneesmiddelrespons te onderzoeken. 
Hoofdstuk 4 laat het voorbeeld van een andere GPCR, de Adenosine A2A receptor (A2AR) 
zien. De A2AR is een mogelijk aangrijpingspunt voor geneesmiddelen voor een breed aantal 
van ademhalings- en ontstekingsaandoeningen, waaronder de ziekte van Parkinson, en is ook 
de receptor voor cafeïne. Na het bepalen van welke subtypes van adenosinereceptoren 
aanwezig waren in LCLs, werden de cellulaire effecten van verschillende typen chemische 
verbindingen die op de A2AR aangrijpen vergeleken tussen de LCLs van een familie van vier, 
bestaande uit ouders en hun eeneiige tweelingkinderen. Bij aanwezigheid van een bepaalde 
genetische variant, een Single Nucleotide Polymorphism (SNP) in een intron die eerder in 
verband is gebracht met cafeïne-gerelateerde slaapstoornissen, werden afwijkende 
cellulaire effecten gezien voor een bepaald type verbinding, namelijk een partiële agonist,  
maar niet bij andere typen verbindingen zoals volle agonisten of antagonisten. Hoewel dit 
geen direct causaal verband aantoont tussen de verschillen in respons en de genetische 
variatie, laat het wel zien dat de gekozen methode geschikt is om individuele verschillen in 
GPCR effecten te detecteren. 
Na deze demonstratie weden genetische verschillen in andere GPCRs bestudeerd. De 
CB2R is een GPCR die intensief onderzocht wordt als mogelijk therapeutisch doelwit vanwege 
zijn belangrijke rol in het immuunsysteem. In hoofdstuk 5 werd de respons op agonisten, 
partiële agonisten en antagonisten van verschillende chemische klassen in LCLs van 
meerdere individuen met verschillend CB2R genotype gekarakteriseerd. Éen van de 
interessante bevindingen was dat endogene cannabinoïdes zoals 2-AG duidelijk andere 
cellulaire effecten induceerden dan alle synthetische cannabinoïdes, vooral in hun 
tijdsprofiel. Nog belangrijker is dat ook werd gevonden dat verbindingen van verschillende 
chemische signatuur verschillend reageerden op een veel voorkomende aminozuur-
veranderende polymorfisme in de CB2R, de Q63R variant.   
Genetische verschillen kunnen echter niet alleen de effecten van geneesmiddelen 
beïnvloeden, maar ook de vatbaarheid van een persoon voor een ziekte of het verloop van 
een ziekte veranderen. In hoofdstuk 6 wordt het geval van de Glucose-afhankelijke 
Insulinotrope Polypeptide receptor (GIPR) gepresenteerd, waarin een aminozuur-
veranderende SNP, die al vaak met ziektes geassocieerd werd, de cellulaire effecten van het 
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endogene ligand veranderde. De GIPR speelt een belangrijke rol in het metabolisme in het 
hele lichaam, en deze aminozuur-veranderende SNP, E354Q, wordt onder andere met 
diabetes geassocieerd. Tijdens het bestuderen van deze receptor in een panel van meerdere 
individuen met verschillende genotype van E354Q, werd een verhoogde potentie van de 
endogene agonist GIP op Q354 homozygote individuen aangetoond. Dit onderzoek verschaft 
hiermee meer inzicht in hoe polymorfismen in GPCRs de fysiologie in een menselijk individu 
kunnen veranderen.  
Samengevat wordt in dit proefschrift een nieuwe cellulaire aanpak voor het bestuderen 
van genetische effecten op GPCRs onderzocht en beschreven. Meerdere GPCRs en diverse 
soorten genetische verschillen werden bestudeerd, en de bevindingen tonen aan dat 
verschillende soorten van genetische variatie in GPCRs, bijvoorbeeld veel voorkomend of 
juist zelden, verscheidende effecten kunnen hebben. Deze verschillende effecten kunnen 
afhankelijk zijn van het type ligand of de chemische signatuur van een verbinding, en van 
invloed zijn op de endogene signaalverwerking. De algemene conclusie uit de resultaten van 
dit proefschrift en de daaruit ontstaande mogelijkheden voor geneesmiddelonderzoek en 
behandeling wordt uitgebreid in hoofdstuk 7 besproken en van commentaar voorzien. 
Samen kunnen de bevindingen in dit proefschrift bijdragen tot vooruitgang in de 
mogelijkheden om ‘precision medicine’ op de GPCR-klasse der geneesmiddeldoelwitten toe 
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